

CITATION REPORT

List of articles citing

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

DOI: 10.1002/art.38098

Arthritis and Rheumatism, 2013, 65, 2737-47.

Source: <https://exaly.com/paper-pdf/55089544/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2034	[Hand involvement in systemic sclerosis]. 2013 , 42, 1616-26		10
2033	Updated systemic sclerosis criteria improve disease classification. 2013 , 74, 609-609		
2032	Indagine conoscitiva sull'attività dei Laboratori italiani di autoimmunologia Anno 2012. 2014 , 10, 172-180		2
2031	Nailfold videocapillaroscopy micro-haemorrhage and giant capillary counting as an accurate approach for a steady state definition of disease activity in systemic sclerosis. 2014 , 16, 462		24
2030	Lung function and survival in systemic sclerosis interstitial lung disease. 2014 , 41, 2326-8		5
2029	Association of immunological cell profiles with specific clinical phenotypes of scleroderma disease. 2014 , 2014, 148293		12
2028	Proinflammatory effects of diesel exhaust nanoparticles on scleroderma skin cells. 2014 , 2014, 138751		32
2027	Maladies de système. 2014 , 17-54		
2026	The effect of male sex on survival in systemic sclerosis. 2014 , 41, 2193-200		40
2025	Direct and indirect pathogenic roles of autoantibodies in systemic autoimmune diseases. 2014 , 63, 515-22		7
2024	Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. 2014 , 44, 331-7		32
2023	DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. 2014 , 171, 39-47		59
2022	A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAChR3) in patients' sera. 2014 , 177, 179-89		11
2021	Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement. 2014 , 26, 646-52		39
2020	Update on scleroderma and other fibrosing syndromes. 2014 , 26, 605-6		
2019	Measuring microangiopathy abnormalities in systemic sclerosis patients: the role of capillaroscopy-based scoring models. 2014 , 348, 331-6		15
2018	The use and abuse of diagnostic/classification criteria. 2014 , 28, 921-34		31

2017	SSc and the 2013 diagnostic criteria: the case of Paul Klee's manual pathology and dysgraphia. 2014 , 33, 1671-4	2
2016	Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases. 2014 , 41, 2495-6	5
2015	Clinical and autoimmune profile of scleroderma patients from Western India. 2014 , 2014, 983781	16
2014	Association of interleukin 1 family with systemic sclerosis. 2014 , 37, 1213-20	18
2013	Diagnostic criteria of systemic sclerosis. 2014 , 48-49, 38-41	31
2012	Hope for disease-modifying treatment of systemic sclerosis/scleroderma. 2014 , 350, 480-2	
2011	Autonomic dysfunction in patients with systemic sclerosis: correlation with intrarenal arterial stiffness. 2014 , 177, 578-80	16
2010	La crise r ^h ale scl ^h odermique. 2014 , 23, 653-658	
2009	Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. 2014 , 66, 1520-7	37
2008	Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. 2014 , 66, 1967-78	120
2007	[Pulmonary arterial hypertension associated with connective tissue diseases]. 2014 , 43, 957-69	3
2006	Technical feasibility of real-time elastography to assess the peri-oral region in patients affected by systemic sclerosis. 2014 , 17, 265-9	19
2005	Molecular and cellular basis of scleroderma. 2014 , 92, 913-24	27
2004	Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity. 2014 , 76, 104-11	30
2003	Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. 2014 , 34, 663-8	46
2002	Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. 2014 , 41, 1334-43	16
2001	Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. 2014 , 16, R29	87
2000	[Nail-fold capillaroscopy in dermatology]. 2014 , 141, 429-37	4

1999	Scleroderma in the Caribbean: Characteristics in a Dominican Case Series. 2014 , 10, 373-379	
1998	[Clinical and capillaroscopic regression of CD30 anaplastic lymphoma associated with limited cutaneous systemic sclerosis following autologous bone marrow transplantation]. 2014 , 141, 446-51	4
1997	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. 2014 , 67, 706-14	40
1996	Scleroderma in the Caribbean: characteristics in a Dominican case series. 2014 , 10, 373-9	10
1995	Tight skin 2 mice exhibit a novel time line of events leading to increased extracellular matrix deposition and dermal fibrosis. 2014 , 38, 91-100	16
1994	Fructose Malabsorption in Systemic Sclerosis. 2015 , 94, e1601	14
1993	Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis. 2015 , 148, 1268-1275	31
1992	Stem cell transplantation for systemic sclerosis. 2015 ,	0
1991	2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. 2015 , 67, 2557-68	280
1990	Two-Dimensional near Infrared Spectroscopic Imaging of the Hand to Assess Microvascular Abnormalities in Systemic Sclerosis: A Pilot Study. 2015 , 23, 59-66	5
1989	Macitentan inhibits the transforming growth factor- β profibrotic action, blocking the signaling mediated by the ETR/TBI complex in systemic sclerosis dermal fibroblasts. 2015 , 17, 247	18
1988	Transforming growth factor- β increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis. 2015 , 17, 196	15
1987	Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. 2015 , 67, 3016-26	87
1986	DNA methylation similarities in genes of black South Africans with systemic lupus erythematosus and systemic sclerosis. 2015 , 22, 34	25
1985	Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. 2015 , 17, 194	30
1984	Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. 2015 , 17, 221	23
1983	CD1a+ survivin+ dendritic cell infiltration in dermal lesions of systemic sclerosis. 2015 , 17, 275	13
1982	Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. 2015 , 24, 2297-305	58

1981	Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis. 2015 , 67, 3234-44	58
1980	Serum heparanase levels: A protective marker against digital ulcers in patients with systemic sclerosis. 2015 , 42, 625-8	3
1979	Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. 2015 , 45, 1134-40	14
1978	Lessons learned from Canadian databases in RA, SLE and systemic sclerosis: highlights from the Canadian Rheumatology Association Annual Scientific Meeting. 2015 , 10, 135-137	
1977	Dr. Hoffmann-Vold replies. 2015 , 42, 2513	2
1976	Movement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the Literature. 2015 , 94, e0971	4
1975	Editorial: Scleroderma: Bringing a Disease From Black-and-White Into Technicolor. 2015 , 67, 3101-3	7
1974	A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis. 2015 , 173, 681-9	26
1973	Stem cell transplantation for systemic sclerosis: many steps forward in Poland. 2015 , 6, 297-300	
1972	Genotoxic Effect in Autoimmune Diseases Evaluated by the Micronucleus Test Assay: Our Experience and Literature Review. 2015 , 2015, 194031	17
1971	Pathogenesis of Systemic Sclerosis. 2015 , 6, 272	201
1970	The Efficacy of Nailfold Capillaroscopy in Patients with Raynaud's Phenomenon. 2015 , 22, 69	3
1969	Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGF β Signaling within Lesional Scleroderma Skin. 2015 , 10, e0134092	44
1968	Plant-Derived Chimeric Virus Particles for the Diagnosis of Primary Sjögren Syndrome. 2015 , 6, 1080	16
1967	Airway resistance and reactance are affected in systemic sclerosis. 2015 , 2, 28667	14
1966	Nailfold Capillaroscopy in Rheumatic Diseases: Which Parameters Should Be Evaluated?. 2015 , 2015, 974530	90
1965	Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis. 2015 , 2015, 147616	34
1964	Uniphasic Blanching of the Fingers, Abnormal Capillaroscopy in Nonsymptomatic Digits, and Autoantibodies: Expanding Options to Increase the Level of Suspicion of Connective Tissue Diseases beyond the Classification of Raynaud's Phenomenon. 2015 , 2015, 371960	12

1963	The frequency of pulmonary hypertension in patients with juvenile scleroderma. 2015 , 15, 30-5	5
1962	Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. 2015 , 54, 1454-8	54
1961	Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches. 2015 , 41, 399-417	15
1960	Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. 2015 , 74, 1612-20	115
1959	[New classification criteria for systemic sclerosis taking into account capillaroscopy]. 2015 , 66, 487-8	
1958	Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. 2015 , 17, 57	38
1957	Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: reports of two cases of systemic sclerosis and review of the literature. 2015 , 44, 597-601	3
1956	Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma. 2015 , 41, 419-38	31
1955	New Classification Criteria for Systemic Sclerosis (Scleroderma). 2015 , 41, 383-98	24
1954	Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts. 2015 , 42, 456-63	10
1953	Lower limb muscle strength is associated with functional performance and quality of life in patients with systemic sclerosis. 2015 , 19, 129-36	23
1952	Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. 2015 , 16, 74-80	55
1951	Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. 2015 , 74, 2175-82	109
1950	Specificity of Systemic Sclerosis Classification Criteria. 2015 , 42, 2512	3
1949	From microvasculature to fibroblasts: Contribution of anti-endothelial cell antibodies in systemic sclerosis. 2015 , 28, 93-103	11
1948	Outcome of patients with autoimmune diseases in the intensive care unit: a mixed cluster analysis. 2015 , 2, e000122	15
1947	Advances in pathogenesis and treatment of systemic sclerosis. 2015 , 15 Suppl 6, s58-63	36
1946	Important options available--from start to finish--for translating proteomics results to clinical chemistry. 2015 , 9, 235-52	8

1945	Contractile reserve in systemic sclerosis patients as a major predictor of global cardiac impairment and exercise tolerance. 2015 , 31, 529-36	10
1944	Infection and Systemic Sclerosis. 2015 , 735-744	
1943	Systemic sclerosis classification: a rose by any other name would smell as sweet?. 2015 , 42, 11-3	9
1942	Association of occupational exposure with features of systemic sclerosis. 2015 , 72, 456-64	28
1941	Decreased numbers of endothelial progenitor cells in patients in the early stages of systemic sclerosis. 2015 , 98, 82-7	17
1940	Progress in the evolution of systemic sclerosis classification criteria and recommendation for additional comparative specificity studies. 2015 , 42, 8-10	14
1939	Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?. 2015 , 54, 757-67	21
1938	QTc interval prolongation in systemic sclerosis: correlations with clinical variables. 2015 , 182, 20-2	12
1937	Microvascular abnormalities in patients with early systemic sclerosis: less severe morphological changes than in patients with definite disease. 2015 , 44, 48-55	9
1936	Epigenetics and Fibrosis. 2015 , 53-74	1
1935	Validation of the ICD-9-CM code for systemic sclerosis using updated ACR/EULAR classification criteria. 2015 , 44, 253-5	17
1934	Presence of enthesopathy demonstrated with ultrasonography in systemic sclerosis. 2015 , 25, 731-6	8
1933	Serum vaspin levels: A possible correlation with digital ulcers in patients with systemic sclerosis. 2015 , 42, 528-31	9
1932	The clinical relevance of sexual dysfunction in systemic sclerosis. 2015 , 14, 1111-5	13
1931	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. 2015 , 54, 2273-82	14
1930	Clinical peculiarities of patients with scleroderma exposed to silica: A systematic review of the literature. 2015 , 45, 294-300	18
1929	Nocardiose c [^] h [^] brale apr [^] ß autogreffe de cellules souches h [^] matopo [^] ¶ tiques chez une patiente scl [^] hodermique. 2015 , 36, A183	
1928	Psoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review. 2015 , 42, 1432-8	18

1927	Update on systemic sclerosis. 2015 , 15, 25	8
1926	High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosis. 2015 , 87, 282-9	29
1925	[Systemic sclerosis. Current classification and diagnosis of organ involvement]. 2015 , 66, 599-603	1
1924	The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. 2015 , 120, 104-11	35
1923	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. 2015 , 42, 1156-62	4
1922	The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling. 2015 , 67, 1323-34	61
1921	Nested case-control study of selected systemic autoimmune diseases in World Trade Center rescue/recovery workers. 2015 , 67, 1369-76	43
1920	The role of serological testing in idiopathic interstitial pneumonia: a rheumatologist perspective. 2015 , 4, 130-134	
1919	Regenerative Approach to Scleroderma with Fat Grafting. 2015 , 42, 353-64, viii-ix	36
1918	Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis. 2015 , 42, 64-72	31
1917	Autoantibodies in systemic sclerosis: unanswered questions. 2015 , 6, 167	61
1916	Fecal calprotectin in systemic sclerosis and review of the literature. 2015 , 14, 547-54	47
1915	In situ evidence of pulmonary endothelial activation in patients with granulomatosis with polyangiitis and systemic sclerosis. 2015 , 193, 355-9	3
1914	Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications. 2015 , 99, 92-5	19
1913	Correlation between intrarenal arterial stiffness and exercise tolerance in systemic sclerosis patients without renal and cardiopulmonary impairment: The role of the microvascular damage. 2015 , 185, 122-4	5
1912	Scleroderma: Assessment of posture, balance and pulmonary function in a cross-sectional controlled study. 2015 , 30, 438-43	8
1911	Early systemic sclerosis-opportunities for treatment. 2015 , 34, 1327-31	14
1910	Distinctions between diagnostic and classification criteria?. 2015 , 67, 891-7	268

1909	Systemic sclerosis. 2015 , 1, 15002	351
1908	Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts. 2015 , 194, 5161-73	22
1907	Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis. 2015 , 42, 461-6	11
1906	A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders. 2015 , 54, 1435-42	41
1905	New ACR EULAR guidelines for systemic sclerosis classification. 2015 , 17, 32	36
1904	High-resolution ultrasound of peripheral nerves in systemic sclerosis: a pilot study of computer-aided quantitative assessment of nerve density. 2015 , 44, 1761-7	14
1903	Overview of Myocardial T1 Mapping Applications. 2015 , 3, 1	
1902	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. 2015 , 74, 1789-98	342
1901	T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review. 2015 , 49, 347-69	27
1900	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. 2015 , 102, 19-24	11
1899	Cross-sectional study of soluble selectins, fractions of circulating microparticles and their relationship to lung and skin involvement in systemic sclerosis. 2015 , 16, 191	16
1898	Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort. 2015 , 42, 2327-31	9
1897	Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. 2015 , 67, 2205-12	86
1896	Progranulin Overproduction Due to Fli-1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor in Systemic Sclerosis. 2015 , 67, 3245-55	24
1895	Endothelial Dysfunction and Nailfold Videocapillaroscopy Pattern as Predictors of Digital Ulcers in Systemic Sclerosis: a Cohort Study and Review of the Literature. 2015 , 49, 240-52	27
1894	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor- β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 2015 , 42, 1808-16	60
1893	Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography. 2015 , 44, 389-98	44
1892	A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. 2015 , 14, 140-52	43

1891	Unexpected post-mortem diagnosis of systemic sclerosis presenting as pneumatosis intestinalis: revised diagnostic criteria and medicolegal implications. 2015 , 17, 29-33	3
1890	Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. 2015 , 67, 498-507	45
1889	Relationship between functional capacity, joint mobility and pulmonary function in patients with systemic sclerosis. 2015 , 19, 17-24	14
1888	Stem cell therapies for systemic sclerosis. 2015 , 168, 328-37	10
1887	Connective tissue diseases: New criteria improve recognition of early systemic sclerosis. 2015 , 11, 3-4	1
1886	Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). 2015 , 14, 210-3	23
1885	2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. 2015 , 67, 582-7	51
1884	Choroidal impairment and macular thinning in patients with systemic sclerosis: the acute study. 2015 , 97, 31-6	37
1883	Dystrophic calcinosis with both a huge calcified mass in the cervical spine and calcification in the chest wall in a patient with rheumatoid overlap syndrome. 2016 , 35, 1403-9	7
1882	The Assessment of Tp-e Interval and Tp-e/QT Ratio in Patients With Systemic Sclerosis. 2016 , 31, 139-144	11
1881	The Turkish Version of Multidimensional Assessment of Fatigue and Fatigue Severity Scale is Reproducible and Correlated With Other Outcome Measures in Patients With Systemic Sclerosis. 2016 , 31, 329-332	7
1880	Controversies: molecular vs. clinical systemic sclerosis classification. 2016 , 1, 277-285	11
1879	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. 2016 , 12, 828-43	5
1878	Systemic Sclerosis Trial Design Moving Forward. 2016 , 1, 177-180	34
1877	Current practice in laboratory diagnostics of autoimmune diseases in Croatia. ?Survey of the Working group for laboratory diagnostics of autoimmune diseases of the Croatian Society of Medical Biochemistry and Laboratory Medicine. 2016 , 26, 376-394	1
1876	Subsets in systemic sclerosis: one size does not fit all. 2016 , 1, 298-306	7
1875	Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases. 2016 , 3, 48	8
1874	Pneumatosis Cystoides Intestinalis in Patients with Systemic Sclerosis: A Case Report and Review of 39 Japanese Cases. 2016 , 2016, 2474515	13

1873	Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. 2016 , 1, 234-240	11
1872	Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. 2016 , 17,	53
1871	Capillaroscopy - a role in modern rheumatology. 2016 , 54, 67-72	47
1870	Classification Criteria for Sjögren Syndrome. 2016 , 47-60	2
1869	Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients. 2016 , 14, 262	8
1868	Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. 2016 , 18, 131	34
1867	Anti-U3 ribonucleoprotein antibody-positive inflammatory myopathy: a case report. 2016 , 10, 169	5
1866	miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis. 2016 , 11, e0158367	80
1865	Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus. 2016 , 11, e0160283	0
1864	Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis. 2016 , 11, e0161908	8
1863	D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts. 2016 , 11, e0162357	1
1862	Current perspectives on the immunopathogenesis of systemic sclerosis. 2016 , 5, 21-35	44
1861	Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria. 2016 , 54, 296-305	6
1860	Pros and cons of conjoint analysis of discrete choice experiments to define classification and response criteria in rheumatology. 2016 , 28, 117-21	4
1859	Chest Ultrasonography as a Screening Tool for High-Resolution Computed Tomography Referral in Patients With Systemic Sclerosis-A Future Perspective: Comment on the Article by Suliman et al. 2016 , 68, 2345-6	1
1858	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. 2016 , 43, 1672-9	163
1857	Pigmented skin patches without scleroderma as a predominant clinical symptom revealing systemic sclerosis. 2016 , 41, 379-82	4
1856	The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. 2016 , 28, 1157-65	45

1855	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. 2016 , 68, 1195-200	23
1854	Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells. 2016 , 68, 2540-9	6
1853	Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1. 2016 , 68, 473-83	17
1852	Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions. 2016 , 174, 338-47	25
1851	Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children. 2016 , 2, e000271	11
1850	Extracorporeal Shock Wave Therapy for Digital Ulcers of Systemic Sclerosis: A Phase 2 Pilot Study. 2016 , 238, 39-47	17
1849	Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. 2016 , 48, 1658-1667	35
1848	Association of a rare NOTCH4 coding variant with systemic sclerosis: a family-based whole exome sequencing study. 2016 , 17, 462	8
1847	Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. 2016 , 6, e011028	9
1846	Could nailfold videocapillaroscopy usher in a new era of preventative disease-modifying therapeutic intervention in systemic sclerosis?. 2017 , 56, 1053-1055	0
1845	Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. 2017 , 56, 451-456	4
1844	Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. 2017 , 56, 1081-1088	17
1843	Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis. 2016 , 28, 586-94	25
1842	Usefulness of nailfold videocapillaroscopy for systemic sclerosis. 2016 , 36, 5	4
1841	Serum uric acid as a marker of microvascular damage in systemic sclerosis patients. 2016 , 106, 39-43	13
1840	Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. 2016 , 46, 200-208	25
1839	Type B insulin resistance syndrome with Scleroderma successfully treated with multiple immune suppressants after eradication of Helicobacter pylori infection: a case report. 2016 , 16, 20	8
1838	Baixos n ^o de níveis séricos de vitamina D na esclerose sistêmica difusa: correlação com pior qualidade de vida e alterações capilares graves. 2016 , 56, 337-344	5

1837	Raynaud's phenomenon. 2016 , 30, 112-32	47
1836	Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series. 2016 , 46, 196-199	7
1835	Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010. 2016 , 36, 917-24	14
1834	Mixed connective tissue disease. 2016 , 30, 95-111	60
1833	Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic Sclerosis. 2016 , 14, 1502-6	61
1832	Raynaud phenomenon causing lingual pallor and dysarthria. 2016 , 188, E396	3
1831	Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study. 2016 , 35, 1733-42	15
1830	Analysis of Systemic Sclerosis-associated Genes in a Turkish Population. 2016 , 43, 1376-9	4
1829	Current and future direction in the management of scleroderma. 2016 , 308, 461-71	3
1828	Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes. 2016 , 13, 784-92	47
1827	Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension. 2016 , 133, 2413-22	111
1826	Characterization of patients with clinical overlap of morphea and systemic sclerosis: A case series. 2016 , 74, 1272-4	5
1825	Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity. 2016 , 5, 1401	6
1824	Assessment for Pulmonary Artery Hypertension Using Clinical and Echocardiographic Criteria in Patients With Systemic Sclerosis. 2016 , 352, 343-347	3
1823	Enfermedad mixta del tejido conjuntivo o s̄ndrome de Sharp. 2016 , 49, 1-13	
1822	Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. 2016 , 18, 228	19
1821	Low vitamin D serum levels in diffuse systemic sclerosis: a correlation with worst quality of life and severe capillaroscopic findings. 2016 , 56, 337-44	13
1820	Systemic sclerosis-related changes on nailfold videocapillaroscopy in genetic and metabolic myopathies. 2016 , 55, 1911-2	2

1819	Lactose malabsorption in systemic sclerosis. 2016 , 44, 1123-1133	11
1818	Orofacial manifestations of systemic sclerosis. 2016 , 221, 305-10	25
1817	The skin in autoimmune diseases-Unmet needs. 2016 , 15, 948-54	8
1816	Pulmonary involvement in systemic sclerosis. 2016 , 15, 1094-1108	42
1815	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. 2016 , 15, 983-93	76
1814	Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?. 2016 , 68, 1340-5	14
1813	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. 2016 , 68, 2527-39	92
1812	Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4?. 2016 , 55, 2066-2073	12
1811	Autoantibodies and Their Role in Scleroderma Clinical Care. 2016 , 2, 239-251	11
1810	An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. 2016 , 68, 2964-2974	56
1809	Contribution of CD8+ T cells to inflammatory cytokine production in systemic sclerosis (SSc). 2016 , 49, 532-546	7
1808	Angiotensin II Type 1 receptor (AGTR1) gene polymorphisms are associated with vascular manifestations in patients with systemic sclerosis (SSc). 2016 , 17,	4
1807	Early Endothelial Progenitor Cells (eEPCs) in systemic sclerosis (SSc) - dynamics of cellular regeneration and mesenchymal transdifferentiation. 2016 , 17, 339	6
1806	Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. 2016 , 310, G1052-60	32
1805	Tratamento da esclerose sistêmica com rituximabe: uma série de 10 casos em centro médico. 2016 , 56, 458-463	8
1804	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. 2016 , 55, 2023-2032	8
1803	An explanatory model of functional exercise capacity in patients with systemic sclerosis: considerations for rehabilitation programs. 2016 , 28, 569-75	3
1802	High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis. 2016 , 239, 297-305	23

1801	Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. 2016 , 56, 458-463	4
1800	Current Perspectives on Imaging for Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis. 2016 , 42, 711-732	2
1799	The magnitude of cytokine production by stimulated CD56 cells is associated with early stages of systemic sclerosis. 2016 , 173, 76-80	14
1798	Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies. 2016 , 9, 358-364	4
1797	Nierenmanifestation bei systemischer Sklerose. 2016 , 11, 198-204	1
1796	Imbalance of the Vanin-1 Pathway in Systemic Sclerosis. 2016 , 197, 3326-3335	14
1795	Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis. 2016 , 68, 2784-2794	24
1794	Validation of disease activity indices using the 28 joint counts in systemic sclerosis. 2016 , 55, 1849-58	10
1793	The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. 2016 , 18, 246	10
1792	Emerging drugs and therapeutics for systemic sclerosis. 2016 , 21, 421-430	6
1791	Labordiagnostik bei systemischen Autoimmunerkrankungen. 2016 , 40,	0
1790	Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. 2016 , 113, E7526-E7534	48
1789	Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis. 2016 , 68, 1504-1511	12
1788	Left Ventricular Mass and Intrarenal Arterial Stiffness as Early Diagnostic Markers in Cardiorenal Syndrome Type 5 due to Systemic Sclerosis. 2016 , 6, 135-42	2
1787	Overlap syndrome with Sjögren's syndrome and systemic sclerosis in a steel rolling mill worker: a case report. 2016 , 28, 24	5
1786	Emerging biomarkers in systemic sclerosis. 2016 , 28, 606-12	12
1785	Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. 2016 , 95, e3931	8
1784	Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. 2016 , 95, e4713	36

1783	Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren's Syndrome: Analysis of the Sjögren's International Collaborative Clinical Alliance Cohort. 2016 , 68, 1554-9	28
1782	Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. 2016 , 68, 1704-1713	15
1781	Development and Validation of the Body Concealment Scale for Scleroderma. 2016 , 68, 1158-65	8
1780	Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic. 2016 , 46, 350-355	6
1779	Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. 2016 , 46, 344-349	48
1778	Nailfold Videocapillaroscopy Alterations in Dermatomyositis and Systemic Sclerosis: Toward Identification of a Specific Pattern. 2016 , 43, 1575-80	13
1777	Symptoms of Raynaud's phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology. 2016 , 36, 1371-7	11
1776	Toward new criteria for systemic lupus erythematosus-a standpoint. 2016 , 25, 805-11	53
1775	Screening of pulmonary hypertension in a Spanish cohort of patients with systemic sclerosis. 2016 , 146, 1-7	
1774	BSR and BHPR guideline for the treatment of systemic sclerosis. 2016 , 55, 1906-10	97
1773	Difficulty with daily activities involving the lower extremities in people with systemic sclerosis. 2016 , 35, 483-8	8
1772	Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension. 2016 , 11, 941-52	3
1771	Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease. 2016 , 68, 1021-7	20
1770	Epidemiology of Mixed Connective Tissue Disease, 1985-2014: A Population-Based Study. 2016 , 68, 1843-1848	45
1769	What Should Be the Cut Point for Classification Criteria of Studies in Gout? A Conjoint Analysis. 2016 , 68, 1731-1735	2
1768	The Role of Anti-U1 RNP Positivity in Predicting Survival in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Angel or Demon? Comment on the Article by Sobanski et al. 2016 , 68, 1788-9	5
1767	Brief Report: Whole-Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis. 2016 , 68, 2257-62	28
1766	Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosis. 2016 , 43, 808-10	8

1765	A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis. 2016 , 25, 287-92	17
1764	Trial Design, Measurement, and Analysis of Clinical Investigations. 2016 , 54-77.e2	1
1763	The IL-33 gene is related to increased susceptibility to systemic sclerosis. 2016 , 36, 579-84	26
1762	Systemic sclerosis and silica exposure: a rare association in a large Brazilian cohort. 2016 , 36, 697-702	12
1761	Anterior segment parameters and eyelids in systemic sclerosis. 2016 , 36, 577-83	11
1760	Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting. 2016 , 59, 201-8	24
1759	In systemic sclerosis prolonged QTc interval is associated with reduced exercise tolerance. 2016 , 203, 570-2	3
1758	Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. 2016 , 12, 115-35	11
1757	Performance of the new American College of Rheumatology classification criteria in Turkish systemic sclerosis patients: a multicenter study. 2016 , 35, 357-61	4
1756	Diagnosis and Management of Systemic Sclerosis: A Practical Approach. 2016 , 76, 203-13	17
1755	Post-September 11, 2001, Incidence of Systemic Autoimmune Diseases in World Trade Center-Exposed Firefighters and Emergency Medical Service Workers. 2016 , 91, 23-32	28
1754	Raynaud phenomenon. 2016 , 4-5, 9-16	2
1753	The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. 2016 , 52, 43-53	20
1752	Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. 2016 , 55, 1195-201	24
1751	Systemic sclerosis: Sexual dysfunction and lower urinary tract symptoms in 73 patients. 2016 , 45, e79-89	10
1750	Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. 2016 , 46, 109-14	46
1749	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. 2016 , 46, 115-23	53
1748	Serum level of circulating syndecan-1: A possible association with proliferative vasculopathy in systemic sclerosis. 2016 , 43, 63-6	8

1747	Strategy for treatment of fibrosis in systemic sclerosis: Present and future. 2016 , 43, 46-55	28
1746	Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients. 2016 , 55, 1112-6	25
1745	Digital ischaemia during cooling is independently related to nailfold capillaroscopic pattern in patients with Raynaud's phenomenon. 2016 , 55, 1083-90	7
1744	Quantitative Alterations of Capillary Diameter Have a Predictive Value for Development of the Capillaroscopic Systemic Sclerosis Pattern. 2016 , 43, 599-606	32
1743	Assessment of nailfold capillaries with a handheld dermatoscope may discriminate the extent of organ involvement in patients with systemic sclerosis. 2016 , 35, 479-82	4
1742	Serological profile and clinical features of nucleolar antinuclear pattern in patients with systemic lupus erythematosus from southwestern Spain. 2016 , 25, 980-7	5
1741	International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. 2016 , 7, 1	86
1740	Genetic factors and systemic sclerosis. 2016 , 15, 427-32	48
1739	Advances in pathogenesis and treatment of systemic sclerosis. 2016 , 16, 55-60	32
1738	M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo. 2016 , 170, 99-111	5
1737	The Case A man with hypertension, respiratory distress, and rapidly progressive renal failure. 2016 , 89, 509-10	
1736	Can thyroid volume predict thyroid dysfunction in patients with systemic sclerosis? A prospective cross-sectional study from a tertiary care center in North West India. 2016 , 35, 765-9	3
1735	Post-occlusive reactive hyperaemia (POHR) in systemic sclerosis: very early disease (VEDOSS) represents a separate entity compared to established disease. 2016 , 45, 408-11	8
1734	Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement. 2016 , 7, 5	13
1733	Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. 2016 , 15, 690-4	50
1732	New insights into CD4(+) T cell abnormalities in systemic sclerosis. 2016 , 28, 31-6	25
1731	[Screening of pulmonary hypertension in a Spanish cohort of patients with systemic sclerosis]. 2016 , 146, 1-7	6
1730	Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension. 2016 , 13, 31-9	44

1729	Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. 2016 , 4, 31-47	16
1728	Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. 2016 , 15, 61-70	56
1727	Systemic sclerosis: New evidence re-enforces the role of B cells. 2016 , 15, 155-61	70
1726	Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease. 2016 , 11, 213-7	52
1725	Corticosteroids in Myositis and Scleroderma. 2016 , 42, 103-18, ix	9
1724	Is osteonecrosis of the lunate bone an underestimated feature of systemic sclerosis? A case series of nine patients and review of literature. 2016 , 45, 446-54	9
1723	Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: translational association with Hashimoto's thyroiditis. 2016 , 51, 291-7	6
1722	Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. 2016 , 55, 301-6	52
1721	Local skin gene expression reflects both local and systemic skin disease in patients with systemic sclerosis. 2016 , 55, 377-9	12
1720	Estimation of the symptoms for GERD by GerdQ in the patients with rheumatic diseases. 2016 , 26, 265-70	
1719	Electrocardiographic detection of pulmonary hypertension in patients with systemic sclerosis using the ventricular gradient. 2016 , 49, 60-8	6
1718	Detection of anti-U3-RNP/fibrillar IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis. 2016 , 64, 483-8	7
1717	Anticentromere antibody-positive primary Sjögren's syndrome: Epitope analysis of a subset of anticentromere antibody-positive patients. 2017 , 27, 115-121	9
1716	Digital ulcers in systemic sclerosis. 2017 , 56, 14-25	120
1715	The Clinical Relevance of Anti-DFS70 Autoantibodies. 2017 , 52, 202-216	56
1714	Therapeutic implications from the pathogenesis of Raynaud's phenomenon. 2017 , 13, 723-735	8
1713	Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease. 2017 , 53, 120-127	3
1712	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. 2017 , 20, 99-106	3

1711	Anti-angiotensin II type 1 receptor autoantibodies (ATR-AAs) in patients with systemic sclerosis: lack of association with disease manifestations. 2017 , 37, 593-598	4
1710	Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature. 2017 , 36, 583-590	22
1709	"It's Not Me, It's Not Really Me." Insights From Patients on Living With Systemic Sclerosis: An Interview Study. 2017 , 69, 1733-1742	24
1708	Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. 2017 , 69, 1272-1279	20
1707	Systemic sclerosis and exposure to heavy metals: A case control study of 100 patients and 300 controls. 2017 , 16, 223-230	34
1706	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. 2017 , 236, 432-437	48
1705	2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. 2017 , 76, 9-16	570
1704	Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function. 2017 , 46, 759-766	5
1703	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. 2017 , 44, 639-647	54
1702	Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort. 2017 , 44, 459-465	16
1701	Determining Criteria and Weights for Prioritizing Health Technologies Based on the Preferences of the General Population: A New Zealand Pilot Study. 2017 , 20, 679-686	10
1700	Nailfold capillaroscopy [An underutilised investigation in rheumatology]. 2017 , 14, 21-26	0
1699	Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. 2017 , 214, 1129-1151	58
1698	Esclerodermia. 2017 , 12, 1448-1457	
1697	The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc. 2017 , 76, 756-764	28
1696	Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma. 2017 , 69, 1306-1312	38
1695	Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis. 2017 , 20, 767-773	9
1694	Letter to editor: "Interstitial pneumonia with autoimmune features: Clinical, radiologic and histological characteristics and outcome in a series of 57 patients". 2017 , 127, 65-66	5

1693	Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. 2017 , 19, 42	37
1692	Study of urotensin-2 (T21M and S89N) gene polymorphisms in systemic sclerosis. 2017 , 12, 125-129	0
1691	Intra-and inter-observer reliability of nailfold videocapillaroscopy - A possible outcome measure for systemic sclerosis-related microangiopathy. 2017 , 112, 1-6	19
1690	Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement in systemic sclerosis. 2016 , 18, 70	26
1689	Ventilation distribution and small airway function in patients with systemic sclerosis. 2017 , 23, 132-138	4
1688	Diffuse Pulmonary Ossification in Fibrosing Interstitial Lung Diseases: Prevalence and Associations. 2017 , 284, 255-263	36
1687	Proangiogenic effects of soluble Klotho on systemic sclerosis dermal microvascular endothelial cells. 2017 , 19, 27	19
1686	Systemic sclerosis: Association between physical function, handgrip strength and pulmonary function. 2017 , 21, 972-977	5
1685	Successful long-term (22 year) treatment of limited scleroderma using therapeutic plasma exchange: Is blood rheology the key?. 2017 , 65, 131-136	4
1684	Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis. 2017 , 36, 1317-1324	8
1683	Systemic sclerosis. 2017 , 390, 1685-1699	764
1682	The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 2017 , 69, 1661-1669	53
1681	Spontaneous Chitin Accumulation in Airways and Age-Related Fibrotic Lung Disease. 2017 , 169, 497-509.e13	58
1680	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. 2017 , 56, 1302-1311	34
1679	Pathogenesis of systemic sclerosis-current concept and emerging treatments. 2017 , 65, 790-797	42
1678	Fl1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis. 2017 , 44, 1198-1205	15
1677	Pulmonary Artery Dimensions as a Prognosticator of Transplant-Free Survival in Scleroderma Interstitial Lung Disease. 2017 , 195, 403-409	6
1676	Quantitative outcome measures for systemic sclerosis-related Microangiopathy - Reliability of image acquisition in Nailfold Capillaroscopy. 2017 , 113, 56-59	11

1675	Esophagogastric junction in systemic sclerosis: A study with the functional lumen imaging probe. 2017 , 29, e13073	14
1674	Axial spondyloarthritis classification criteria: the debate continues. 2017 , 29, 317-322	16
1673	Detection of early endothelial damage in patients with Raynaud's phenomenon. 2017 , 113, 22-28	16
1672	Causes and consequences of endoplasmic reticulum stress in rheumatic disease. 2017 , 13, 25-40	59
1671	High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. 2017 , 19, 135	13
1670	Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. 2017 , 129, 1-7	13
1669	Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis. 2017 , 184, 54-62	24
1668	A To-Do List at Diagnosis of Systemic Sclerosis with Positive Anti-RNA Polymerase III Antibodies. 2017 , 44, 550-552	6
1667	Retinal nerve fiber and optic disc morphology using spectral-domain optical coherence tomography in scleroderma patients. 2017 , 27, 281-284	7
1666	Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 Deficiency. 2017 , 137, 1850-1859	26
1665	Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. 2017 , 152, 999-1007	40
1664	Long-term improvement in activities of daily living in women with systemic sclerosis attending occupational therapy. 2017 , 80, 417-422	2
1663	Muscle function in women with systemic sclerosis: Association with fatigue and general physical function. 2017 , 47, 33-39	14
1662	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. 2017 , 20, 1247-1260	10
1661	[Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Comparison of DETECT algorithm to decisions of a multidisciplinary team, in a competence centre]. 2017 , 38, 502-507	5
1660	Meta-analysis of the changes of peripheral blood regulatory T cell to CD4 T cell ratio in patients with systemic sclerosis. 2017 , 7, 43532	1
1659	Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. 2017 , 22, 1592-1597	16
1658	Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. 2017 , 69, 1891-1902	43

1657	Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. 2017 , 16, 796-802	11
1656	The role of nailfold capillaroscopy in the assessment of internal organ involvement in systemic sclerosis: A critical review. 2017 , 16, 787-795	26
1655	Identification of CD146 as a novel molecular actor involved in systemic sclerosis. 2017 , 140, 1448-1451.e6	9
1654	Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy. 2017 , 114, 41-45	10
1653	[Prevalence of macrovascular arterial involvement of the 4 limbs in systemic sclerosis: About a case series of 14 patients]. 2017 , 38, 430-435	2
1652	Intrarenal arterial stiffness is increased in systemic sclerosis patients with anti-ribonucleic acid polymerase III antibodies. 2017 , 56, 1039-1041	2
1651	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 2017 , 69, 898-910	33
1650	Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. 2017 , 36, 1261-1268	40
1649	Serum levels of genomic DNA of α (I) collagen are elevated in scleroderma patients. 2017 , 44, 927-931	1
1648	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. 2017 , 76, 792-801	65
1647	TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients. 2017 , 19, 8	52
1646	The 2016 classification criteria for primary Sjogren's syndrome: what's new?. 2017 , 15, 69	26
1645	Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis. 2017 , 37, 735-741	6
1644	CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis. 2017 , 36, 1649-1654	33
1643	Morphea and Eosinophilic Fasciitis: An Update. 2017 , 18, 491-512	63
1642	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). 2017 , 76, 942-947	122
1641	Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts. 2017 , 69, 1078-1089	36
1640	Nail involvement in systemic sclerosis. 2017 , 76, 1115-1123	16

1639	Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis. 2017 , 111, 20-24	14
1638	Prognostic Role of Exhaled Breath Condensate pH and Fraction Exhaled Nitric Oxide in Systemic Sclerosis Related Interstitial Lung Disease. 2017 , 53, 120-127	1
1637	Proteomic Investigation of Dermal Fibroblasts Isolated from Affected and Unaffected Skin Samples from Patients with Limited Cutaneous Systemic Sclerosis: 2 Distinct Entities?. 2017 , 44, 40-48	10
1636	Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. 2017 , 46, 767-774	28
1635	Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation. 2017 , 9, 3-10	10
1634	High-resolution manometry in patients with idiopathic inflammatory myopathy: Elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. 2017 , 56, 386-392	24
1633	Geographic variation as a risk factor for digital ulcers in systemic sclerosis patients: a multicentre registry. 2017 , 46, 288-295	6
1632	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. 2017 , 8, 1130	155
1631	IRF7 gene expression profile and methylation of its promoter region in patients with systemic sclerosis. 2017 , 20, 1551-1561	18
1630	Spectrum of orocutaneous disease associations: Immune-mediated conditions. 2017 , 77, 795-806	12
1629	An atypical case of scleroderma. 2017 , 78, 590-591	
1628	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. 2017 , 56, v33-v37	4
1627	Combined measurement of carbon monoxide and nitric oxide lung transfer does not improve the identification of pulmonary hypertension in systemic sclerosis. 2017 , 50,	9
1626	Points to consider in renal involvement in systemic sclerosis. 2017 , 56, v49-v52	10
1625	PTP4A1 promotes TGF β signaling and fibrosis in systemic sclerosis. 2017 , 8, 1060	26
1624	Points to consider-Raynaud's phenomenon in systemic sclerosis. 2017 , 56, v45-v48	19
1623	Points to consider for skin ulcers in systemic sclerosis. 2017 , 56, v67-v71	37
1622	Validation of the ACR/EULAR classification criteria for systemic sclerosis in patients with early scleroderma. 2017 , 37, 1825-1833	6

1621	Endothelin-1, Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients. 2017 , 37, 1651-1657	20
1620	Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum. 2017 , 69, 2359-2369	21
1619	Automated Measurement of Microvascular Function Reveals Dysfunction in Systemic Sclerosis: A Cross-sectional Study. 2017 , 44, 1603-1611	20
1618	Rituximab in early systemic sclerosis. 2017 , 3, e000384	23
1617	Progress in the clinical classification of systemic sclerosis. 2017 , 29, 568-573	6
1616	An international Survey on non-invasive techniques to assess the microcirculation in patients with Raynaud's phenomenon (SUNSHINE survey). 2017 , 37, 1879-1890	23
1615	Increased Epicardial Fat Volume Is Independently Associated with the Presence and Severity of Systemic Sclerosis. 2017 , 24, 1473-1481	11
1614	Growth Differentiation Factor-15 (GDF-15) Level and Relation to Clinical Manifestations in Egyptian Systemic Sclerosis patients: Preliminary Data. 2017 , 46, 703-713	7
1613	Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. 2017 , 7, 741-746	10
1612	Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. 2017 , 83, 95-112	81
1611	Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. 2017 , 96, e6617	13
1610	Phototherapy in systemic sclerosis: Review. 2017 , 33, 296-305	12
1609	Disease-related autoantibody profile in patients with systemic sclerosis. 2017 , 50, 414-421	46
1608	Reproducibility of the scleroderma pattern assessed by wide-field capillaroscopy in subjects suffering from Raynaud's phenomenon. 2017 , 56, 1780-1783	9
1607	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. 2017 , 56, 1874-1883	7
1606	Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. 2017 , 4, e000134	46
1605	Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systemic Sclerosis. 2017 , 26, 841-854	23
1604	Oral Complications of Multiorgan Disorders. 2017 , 25, 187-195	

1603	Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?. 2017 , 44, e42-e44	2
1602	Progression of Organ Involvement in Systemic Sclerosis Patients with Persistent "Late" Nailfold Capillaroscopic Pattern of Microangiopathy: A Prospective Study. 2017 , 44, 1941-1942	12
1601	Evidence-based management of Raynaud's phenomenon. 2017 , 9, 317-329	15
1600	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. 2017 , 26,	84
1599	Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. 2017 , 50,	25
1598	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. 2017 , 69, 2370-2379	36
1597	Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. 2017 , 7, 14874	42
1596	AVALIAÇÃO DO RISCO DE DESENVOLVIMENTO DE ÚLCERAS DIGITAIS EM PACIENTES COM ESCLEROSE SISTÊMICA. 2017 , 57, S84-S85	
1595	AVALIAÇÃO DO RISCO DE DESENVOLVIMENTO DE DOENÇA ESTABELECIDADA EM PACIENTES COM ESCLEROSE SISTÊMICA PRECOCE. 2017 , 57, S388-S389	
1594	A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis. 2017 , 309, 833-842	6
1593	Chemiluminescent immunoassay technology: what does it change in autoantibody detection?. 2017 , 8, 9	85
1592	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. 2017 , 38, 2649-2662	88
1591	Brief Report: Association of Elevated Adipsin Levels With Pulmonary Arterial Hypertension in Systemic Sclerosis. 2017 , 69, 2062-2068	15
1590	[Systemic sclerosis and occupational difficulties: Results of a prospective study]. 2017 , 38, 718-724	2
1589	State of the art on nailfold capillaroscopy in dermatomyositis and polymyositis. 2017 , 47, 432-444	32
1588	Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target. 2017 , 7, 4397	46
1587	Malnutrition is an independent risk factor for mortality in Mexican patients with systemic sclerosis: a cohort study. 2017 , 37, 1101-1109	8
1586	RNA polymerase III-positive systemic sclerosis in a patient with circumscribed morphea. 2017 , 56, 1856	

1585	Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. 2017 , 10, 21	31
1584	Increased serum levels of fractalkine and mobilisation of CD34CD45 endothelial progenitor cells in systemic sclerosis. 2017 , 19, 60	17
1583	The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score. 2017 , 19, 133	18
1582	Systemic sclerosis due to crystalline silica exposure among jewelry workers in Korea: two case reports. 2017 , 29, 18	1
1581	Immune-Mediated Heart Disease. 2017 , 1003, 145-171	9
1580	Case of anti-RuvBL1/2 antibody-positive morphea and polymyositis. 2017 , 44, 1188-1190	3
1579	Classification of Japanese patients with mild/early systemic sclerosis (SSc) by the 2013 ACR/EULAR classification criteria for SSc. 2017 , 27, 614-617	4
1578	In systemic sclerosis skin perfusion of hands is reduced and may predict the occurrence of new digital ulcers. 2017 , 110, 1-4	13
1577	Elevated serum levels of soluble CD146 in patients with systemic sclerosis. 2017 , 36, 119-124	11
1576	A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. 2017 , 46, 625-631	123
1575	Prevalence of Systemic Sclerosis in Primary Biliary Cholangitis Using the New ACR/EULAR Classification Criteria. 2017 , 44, 33-39	18
1574	2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. 2017 , 69, 35-45	517
1573	Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension. 2017 , 56, 87-94	1
1572	Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. 2017 , 52, 53-58	37
1571	Bi-ventricular interplay in patients with systemic sclerosis-associated pulmonary arterial hypertension: Detection by cardiac magnetic resonance. 2017 , 27, 481-488	4
1570	Capillary density: An important parameter in nailfold capillaroscopy. 2017 , 109, 7-18	33
1569	CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc). 2017 , 17, 411-414	5
1568	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. 2017 , 122 Suppl 1, S14-S17	24

1567	X-ray diffraction analysis of spontaneously draining calcinosis in scleroderma patients. 2017 , 46, 118-121	11
1566	Primary Raynaud's phenomenon and nailfold videocapillaroscopy: age-related changes in capillary morphology. 2017 , 36, 1637-1642	10
1565	Vascular Evaluation of the Hand by Power Doppler Ultrasonography and New Predictive Markers of Ischemic Digital Ulcers in Systemic Sclerosis: Results of a Prospective Pilot Study. 2017 , 69, 543-551	22
1564	The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren's syndrome and systemic sclerosis. 2017 , 65, 622-629	15
1563	Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis. 2017 , 36, 367-372	8
1562	Esophageal Motor Abnormalities in Patients With Scleroderma: Heterogeneity, Risk Factors, and Effects on Quality of Life. 2017 , 15, 207-213.e1	51
1561	Prevalence and risk factors for left ventricular diastolic dysfunction in a scleroderma cohort. 2017 , 46, 281-287	20
1560	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. 2017 , 56, v23-v26	6
1559	Scleroderma in children. 2017 , 31, 576-595	23
1558	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. 2017 , 56, 1884-1893	23
1557	Videocapillaroscopy in Connective Tissue Diseases. 2017 ,	1
1556	Classification criteria in Sjögren's syndrome. 2017 , 5, 313	1
1555	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. 2017 , 2, 169-182	11
1554	Systemic Sclerosis. 2017 , 301-326	
1553	Clinical Features and Treatment of Scleroderma. 2017 , 1424-1460.e5	2
1552	Phenotypic Alterations Involved in CD8+ Treg Impairment in Systemic Sclerosis. 2017 , 8, 18	15
1551	Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function. 2017 , 8, 75	16
1550	Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease. 2017 , 2017, 6736239	9

1549	Increased Whole Blood Viscosity Is Associated with the Presence of Digital Ulcers in Systemic Sclerosis: Results from a Cross-Sectional Pilot Study. 2017 , 2017, 3529214	5
1548	Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure. 2017 , 2017, 4249157	4
1547	Nailfold digital capillaroscopic findings in patients with diffuse and limited cutaneous systemic sclerosis. 2017 , 55, 15-23	6
1546	Juvenile Systemic Sclerosis: Review of 17 Portuguese Patients. 2017 , 2, 121-126	1
1545	Polymorphism of keratin 1 associates with systemic lupus erythematosus and systemic sclerosis in a south Chinese population. 2017 , 12, e0186409	2
1544	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. 2017 , 19, 156	9
1543	Do scleroderma patients look young?: Evaluation by using facial imaging system. 2017 , 11, 342-345	4
1542	Functional autoantibodies directed against cell surface receptors in systemic sclerosis. 2017 , 2, 160-168	7
1541	EUSTAR Registration Impacts Favourably on Clinical Practice. 2017 , 2, e4-e4	1
1540	Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight. 2017 ,	0
1539	Recent advances in managing systemic sclerosis. 2017 , 6, 88	3
1538	Circulating angiostatin serum level in patients with systemic sclerosis. 2017 , 34, 543-546	2
1537	Neutrophil-to-lymphocyte Ratio in Diagnosis of Systemic Sclerosis for Prediction of Interstitial Lung Disease. 2017 , 24, 138	2
1536	Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease. 2017 , 9, 362-371	28
1535	Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. 2018 , 70, 1806-1813	17
1534	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon. 2018 , 70, 903-911	39
1533	Intestinal Involvement in Systemic Sclerosis: A Clinical Review. 2018 , 63, 834-844	24
1532	Idiopathic pulmonary fibrosis: A guide for nurse practitioners. 2018 , 43, 48-54	4

1531	The safety of iloprost in systemic sclerosis in a real-life experience. 2018 , 37, 1249-1255	10
1530	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. 2018 , 70, 1373-1384	38
1529	Differences in clinical presentation and incidence of cardiopulmonary involvement in late-onset versus early-onset systemic sclerosis: inception cohort study. 2018 , 21, 1082-1092	4
1528	Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. 2018 , 77, 1179-1186	42
1527	Inhibitory Regulation of Skin Fibrosis in Systemic Sclerosis by Apelin/APJ Signaling. 2018 , 70, 1661-1672	21
1526	Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis. 2018 , 53, 1319-1327	16
1525	CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis. 2018 , 70, 1644-1653	18
1524	Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia. 2018 , 23, 1032-1040	13
1523	Venous Thromboembolism in Systemic Sclerosis: Prevalence, Risk Factors, and Effect on Survival. 2018 , 45, 942-946	3
1522	Evaluation of membrane-bound and soluble forms of human leucocyte antigen-G in systemic sclerosis. 2018 , 193, 152-159	9
1521	Erasmus syndrome: systemic sclerosis and silicosis co-occurrence. 2018 , 21, 1326-1329	1
1520	Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. 2018 , 36, 508-524	14
1519	Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. 2018 , 48, 334-342	2
1518	The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis. 2018 , 198, 17-28	6
1517	Serum level of endostatin and digital ulcers in systemic sclerosis patients. 2018 , 15, 424-428	4
1516	A 22-Year-Old Woman With Systemic Lupus Erythematosus Presents With Two Damaged Kidneys, One Seizure, No Platelets, and Many Possible Diagnoses. 2018 , 70, 1686-1693	1
1515	Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. 2018 , 17, 582-587	52
1514	Selective deletion of PPAR γ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression. 2018 , 4, 15	17

1513	Stony Hard Skin During Early Infancy. 2018 , 40, 614-616	1
1512	The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. 2018 , 14, 431-442	6
1511	Systemic sclerosis: Current concepts of skin and systemic manifestations. 2018 , 36, 459-474	17
1510	Improving life expectancy of patients with scleroderma: results from the South Australian Scleroderma Register. 2018 , 48, 951-956	4
1509	Update on outcome assessment in myositis. 2018 , 14, 303-318	55
1508	Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. 2018 , 89, 162-170	48
1507	Mosaic capillaroscopic findings in systemic sclerosis. 2018 , 168, 248-249	5
1506	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. 2018 , 70, 1646-1652	5
1505	Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2. 2018 , 70, 932-942	14
1504	Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review. 2018 , 48, 482-494	32
1503	Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: A retrospective study. 2018 , 28, 1009-1015	9
1502	Capillary abnormalities observed by nailfold video-capillaroscopy in Japanese patients with systemic sclerosis. 2018 , 28, 1066-1068	1
1501	Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. 2018 , 70, 1557-1562	11
1500	Molecular Basis for Dysregulated Activation of NKX2-5 in the Vascular Remodeling of Systemic Sclerosis. 2018 , 70, 920-931	9
1499	Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. 2018 , 77, 744-751	27
1498	Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study. 2018 , 47, 311-318	6
1497	The prognosis of pulmonary arterial hypertension associated with primary Sjögren's syndrome: a cohort study. 2018 , 27, 1072-1080	18
1496	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. 2018 , 57, 813-817	14

1495	Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort. 2018 , 57, 480-487	21
1494	The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. 2018 , 33, 197-203	10
1493	Evaluation of ITGB2 (CD18) and SELL (CD62L) genes expression and methylation of ITGB2 promoter region in patients with systemic sclerosis. 2018 , 38, 489-498	10
1492	Moving towards a molecular taxonomy of autoimmune rheumatic diseases. 2018 , 14, 75-93	47
1491	Platelet indices as markers of inflammation in systemic sclerosis patients: Relation to vascular endothelial growth factor and flow mediated dilatation. 2018 , 40, 239-242	6
1490	Resilience in women with autoimmune rheumatic diseases. 2018 , 85, 715-720	60
1489	Genome-Wide DNA Methylation Analysis in Systemic Sclerosis Reveals Hypomethylation of IFN-Associated Genes in CD4 and CD8 T Cells. 2018 , 138, 1069-1077	35
1488	Systemic sclerosis complicated with localized scleroderma-like lesions induced by K ⁺ B ⁺ ner phenomenon. 2018 , 89, 282-289	11
1487	Assessment of hand superficial oxygenation during ischemia/reperfusion in healthy subjects versus systemic sclerosis patients by 2D near infrared spectroscopic imaging. 2018 , 155, 101-108	8
1486	Impact of double positive for anti-centromere and anti-SS-a/Ro antibodies on clinicopathological characteristics of primary Sjögren's syndrome: a retrospective cohort study. 2018 , 28, 872-878	6
1485	A noninvasive surface wave technique for measuring finger's skin stiffness. 2018 , 68, 115-119	2
1484	An evaluation of two novel capillaroscopy techniques in suspected scleroderma-spectrum disorders: A single-centre cross-sectional study. 2018 , 28, 676-680	4
1483	Epigenetics and pathogenesis of systemic sclerosis; the ins and outs. 2018 , 79, 178-187	23
1482	Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. 2018 , 57, 625-630	8
1481	Screening for connective tissue disease-associated antibodies by automated immunoassay. 2018 , 56, 909-918	23
1480	Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis. 2018 , 48, 111-116	18
1479	Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer. 2018 , 70, 1517-1524	10
1478	Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. 2018 , 10,	102

1477	Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. 2018 , 38, 363-374	28
1476	Regulatory mechanisms of collagen expression by interleukin-22 signaling in scleroderma fibroblasts. 2018 , 90, 52-59	7
1475	Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. 2018 , 57, 712-717	26
1474	State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. 2018 , 27,	40
1473	Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a pragmatic non-randomized trial. 2018 , 57, 1408-1416	8
1472	Advances in nailfold capillaroscopic analysis in systemic sclerosis.. 2018 , 3, 122-131	20
1471	Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al. 2018 , 70, 973-974	13
1470	Short course of simvastatin has no effect on markers of endothelial activation in normolipidemic patients with systemic sclerosis. 2018 , 46, 1893-1901	3
1469	Ultrasound characterization of cutaneous ulcers in systemic sclerosis. 2018 , 37, 1555-1561	25
1468	The role of capillaroscopy and thermography in the assessment and management of Raynaud's phenomenon. 2018 , 17, 465-472	22
1467	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. 2018 , 40, 1997-2003	7
1466	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. 2018 , 57, 441-450	39
1465	Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial. 2018 , 24, 185-192	3
1464	Hand functions in systemic sclerosis and rheumatoid arthritis and influence on clinical variables. 2018 , 21, 249-252	10
1463	Analysis of clinical features and prognostic factors in Chinese patients with rheumatic diseases in an intensive care unit. 2018 , 40, 63-66	4
1462	Pulmonary manifestations in Egyptian patients with systemic sclerosis. 2018 , 40, 39-44	10
1461	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. 2018 , 70, 571-581	74
1460	Possible pro-inflammatory role of heparin-binding epidermal growth factor-like growth factor in the active phase of systemic sclerosis. 2018 , 45, 182-188	1

1459	Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. 2018 , 45, 405-410	17
1458	Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. 2018 , 70, 308-316	55
1457	Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study. 2018 , 18, 237-243	3
1456	There is a need for new systemic sclerosis subset criteria. A content analytic approach. 2018 , 47, 62-70	18
1455	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. 2018 , 47, 870-876	4
1454	FOXP3, ICOS and ICOSL gene polymorphisms in systemic sclerosis: FOXP3 rs2294020 is associated with disease progression in a female Italian population. 2018 , 223, 112-117	5
1453	Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. 2018 , 47, 849-857	10
1452	Detection of anti-mitochondrial antibodies by immunoprecipitation in patients with systemic sclerosis. 2018 , 452, 1-5	10
1451	[Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies]. 2018 , 145, 33-36	5
1450	Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease. 2018 , 23, 385-391	16
1449	Combination of Capillaroscopic and Ultrasonographic Evaluations in Systemic Sclerosis: Results of a Cross-Sectional Study. 2018 , 70, 938-943	19
1448	Gastrointestinal and Hepatic Disease in Systemic Sclerosis. 2018 , 44, 15-28	26
1447	Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus. 2018 , 28, 865-871	8
1446	Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis. 2018 , 70, 566-577	15
1445	Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis. 2018 , 70, 1385-1392	17
1444	Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis. 2018 , 70, 450-461	21
1443	Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature. 2018 , 17, 155-164	36
1442	Physical activity in patients with systemic sclerosis. 2018 , 38, 443-453	9

1441	Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status. 2018 , 37, 757-763	5
1440	Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. 2018 , 30, e13247	14
1439	Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. 2018 , 70, 1218-1227	4
1438	Skin biomechanical properties in patients with systemic sclerosis: what parameter should be used?. 2018 , 32, e173-e175	1
1437	Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. 2018 , 27, 399-406	39
1436	Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal. 2018 , 19, 513-515	3
1435	A normal diffusing capacity of the lungs for carbon monoxide is rare in incidental pulmonary arterial hypertension in systemic sclerosis: Data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma cohort.. 2018 , 3, 237-241	1
1434	Prevalence of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease. 2018 , 97, e11437	8
1433	A Novel Approach to Classify Nailfold Capillary Images in Indian Population Using USB Digital Microscope. 2018 , 7, 25-39	1
1432	A comparison of a fluorescence enzyme immunoassay versus indirect immunofluorescence for initial screening of connective tissue diseases: Systematic literature review and meta-analysis of diagnostic test accuracy studies. 2018 , 32, 521-534	18
1431	Transforming growth factor- β signaling in systemic sclerosis. 2018 , 32, 3-12	17
1430	The role of nailfold videocapillaroscopy in patients with systemic sclerosis. 2018 , 41, 113-119	7
1429	Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity. 2018 , 32, 541-549	2
1428	Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. 2018 , 32, 563-571	16
1427	Can Routine Use of Patient-Reported Outcomes Help Guide Systemic Sclerosis Chronic Disease Care?. 2018 , 24, 272-274	2
1426	Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association. 2018 , 13, e0210023	0
1425	Raynaud's Phenomenon. 2018 ,	
1424	Systemic sclerosis: severe pulmonary arterial hypertension and pericardial effusion at diagnosis. 2018 , 2018,	

1423	Sublingual microcirculatory alterations in patients with stable systemic sclerosis. 2018 , 25, 257-260	
1422	Differenzialdiagnose interstieller Lungenerkrankungen. 2018 , 15, 413-418	
1421	Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. 2018 , 13, e0206545	20
1420	Proposed method of histological separation between connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonias. 2018 , 13, e0206186	4
1419	Comparison of Level of Fatigue and Disease Correlates in Patients With Rheumatoid Arthritis and Systemic Sclerosis. 2018 , 33, 316-321	5
1418	GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. 2018 , 9, 5224	59
1417	Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. 2018 , 27,	168
1416	Clinical Significance of Serum Galectin-9 and Soluble CD155 Levels in Patients with Systemic Sclerosis. 2018 , 2018, 9473243	9
1415	Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis. 2018 , 9, 2835	11
1414	Fibroblast Growth Factor 23 to Alpha-Klotho Index Correlates with Systemic Sclerosis Activity: A Proposal for Novel Disease Activity Marker. 2018 , 7,	8
1413	A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement. 2018 , 19, 186	69
1412	Clinical and Immunological Features of Anti-centromere Antibody-Positive Primary Sjögren's Syndrome. 2018 , 5, 499-505	15
1411	A Paradigmatic Interplay between Human Cytomegalovirus and Host Immune System: Possible Involvement of Viral Antigen-Driven CD8+ T Cell Responses in Systemic Sclerosis. 2018 , 10,	17
1410	Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis. 2018 , 72, 1804-1813	38
1409	Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis. 2018 , 45, 1572-1576	24
1408	Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives.. 2018 , 3, 201-213	5
1407	Clinical Reasoning: A 58-year-old woman with systemic scleroderma and progressive cervical cord compression. 2018 , 91, e1262-e1264	1
1406	Systemic scleroderma and lupus panniculitis with atypical clinical features: A case report and comprehensive review. 2018 , 4, 789-793	3

1405	Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma - A review. 2018 , 17, 1186-1201	27
1404	Prospective evaluation of the capillaroscopic skin ulcer risk index in systemic sclerosis patients in clinical practice: a longitudinal, multicentre study. 2018 , 20, 239	2
1403	Regulatory T Cells in Systemic Sclerosis. 2018 , 9, 2356	35
1402	Mutations of FAM111B gene are not associated with Systemic Sclerosis. 2018 , 8, 15988	0
1401	Muscle disease in scleroderma. 2018 , 30, 576-580	7
1400	Comparison of Pain Characteristics in Patients with Rheumatoid Arthritis and Systemic Sclerosis with Particular Reference to the Neuropathic Pain Component: Cross-Sectional Study. 2018 , 27, 537-542	1
1399	Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression. 2018 , 15, 1427-1433	26
1398	Impact of micronutrient deficiency & malnutrition in systemic sclerosis: Cohort study and literature review. 2018 , 17, 1081-1089	9
1397	Uncommon patterns of antinuclear antibodies recognizing mitotic spindle apparatus antigens and clinical associations. 2018 , 97, e11727	9
1396	Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. 2018 , 4, 103-114	3
1395	Detection in whole blood of autoantibodies for the diagnosis of connective tissue diseases in near patient testing condition. 2018 , 13, e0202736	10
1394	Pulmonary Hypertension in Connective Tissue Disease is Associated with the New York Heart Association Functional Class and Forced Vital Capacity, But Not with Interstitial Lung Disease. 2018 , 25, 179	1
1393	Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. 2018 , 2, 126-141	40
1392	Prognostic Factors of Renal Involvement in Systemic Sclerosis. 2018 , 43, 682-689	17
1391	Attenuated nitric oxide bioavailability in systemic sclerosis: Evidence from the novel assessment of passive leg movement. 2018 , 103, 1412-1424	3
1390	Image analysis of fibrosis in labial salivary glands of patients with systemic autoimmune diseases. Close correlation of lobular fibrosis to seropositive rheumatoid arthritis and increased anti-CCP and RF titres in the serum. 2018 , 50, 418-425	
1389	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. 2018 , 70, 1829-1834	6
1388	Vascular complications in systemic sclerosis: a prospective cohort study. 2018 , 37, 2429-2437	10

1387	Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis. 2018 , 38, 1511-1519	17
1386	HRCT findings of collagen vascular disease-related interstitial pneumonia (CVD-IP): a comparative study among individual underlying diseases. 2018 , 73, 833.e1-833.e10	9
1385	Impact of systemic sclerosis oral manifestations on patients' health-related quality of life: A systematic review. 2018 , 47, 808-815	14
1384	Value of cardiac magnetic resonance imaging in systemic sclerosis. 2018 , 56, 92-98	3
1383	Evaluation of an Automated Screening Assay, Compared to Indirect Immunofluorescence, an Extractable Nuclear Antigen Assay, and a Line Immunoassay in a Large Cohort of Asian Patients with Antinuclear Antibody-Associated Rheumatoid Diseases: A Multicenter Retrospective Study. 2018 , 2018, 9094217	12
1382	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. 2018 , 13, e0197112	24
1381	High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes. 2018 , 48, 475-481	17
1380	Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension. 2018 , 8, 2045894018788268	18
1379	Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. 2018 , 24, 1961-1964	38
1378	Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. 2018 , 77, 1507-1515	83
1377	[What the rheumatologist can learn from the dermatologist-or: nobody can separate good friends : Interfaces of both domains]. 2018 , 77, 484-492	
1376	All-Trans Retinoic Acid Induces CD4+CD25+FOXP3+ Regulatory T Cells by Increasing FOXP3 Demethylation in Systemic Sclerosis CD4+ T Cells. 2018 , 2018, 8658156	16
1375	Significance of combined anti-CCP antibodies and rheumatoid factor in a New Zealand cohort of patients with systemic sclerosis. 2018 , 21, 1430-1435	5
1374	Soluble CD163 as a Potential Biomarker in Systemic Sclerosis. 2018 , 2018, 8509583	17
1373	Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease. 2018 , 70, 2087-2095	17
1372	Image enhancement effect on inter and intra-observer reliability of nailfold capillary assessment. 2018 , 120, 100-110	4
1371	Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study. 2018 , 2018, 8286067	5
1370	CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis. 2018 , 27, 1030-1037	27

1369	Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay. 2018 , 20, 157	9
1368	Unclassifiable interstitial lung disease: from phenotyping to possible treatments. 2018 , 24, 461-468	10
1367	Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release. 2018 , 9, 1665	11
1366	Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus in a patient with progressive systemic sclerosis. 2018 , 27, 1860-1863	1
1365	Synovial involvement assessed by power Doppler ultra-sonography in systemic sclerosis: results of a cross-sectional study. 2018 , 57, 2012-2021	15
1364	Interstitial Pneumonia With Autoimmune Features: An Emerging Challenge at the Intersection of Rheumatology and Pulmonology. 2018 , 70, 1901-1913	28
1363	The effects of upper and lower limb exercise on the microvascular reactivity in limited cutaneous systemic sclerosis patients. 2018 , 20, 112	18
1362	Paraneoplastic systemic sclerosis associated with colorectal carcinoma. 2018 , 56, 194-198	2
1361	Computed tomography trachea volumetry in patients with scleroderma: Association with clinical and functional findings. 2018 , 13, e0200754	2
1360	Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3. 2018 , 9, 428	10
1359	Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures. 2018 , 9, 449	22
1358	Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?. 2018 , 9, 541	62
1357	-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor. 2018 , 9, 574	9
1356	Anti-High-Density Lipoprotein Antibodies and Antioxidant Dysfunction in Immune-Driven Diseases. 2018 , 5, 114	6
1355	Coexistence of mucosa-associated lymphoid tissue lymphoma and systemic sclerosis showing positive for anticentromere antibody and anti-RNA polymerase III antibody: A case report and published work review. 2018 , 45, e337-e339	1
1354	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): Study protocol.. 2018 , 3, 91-97	5
1353	Clinical and Laboratory Characteristics and Mortality in Korean Patients with Systemic Sclerosis: A Nationwide Multicenter Retrospective Cohort Study. 2018 , 45, 1281-1288	8
1352	Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis. 2018 , 2, rky002	5

1351	Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. 2018 , 23, 1041-1048	14
1350	Immunotherapy of systemic sclerosis. 2018 , 14, 2559-2567	4
1349	Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients. 2018 , 17, 866-872	17
1348	Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis. 2018 , 65, 757-781	37
1347	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. 2018 , 70, 1654-1660	8
1346	Microbial and metabolic multi-omic correlations in systemic sclerosis patients. 2018 , 1421, 97-109	29
1345	Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?. 2018 , 18, 25	9
1344	PhenoDis: a comprehensive database for phenotypic characterization of rare cardiac diseases. 2018 , 13, 22	10
1343	Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts. 2018 , 20, 77	16
1342	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study. 2018 , 70, 1634-1643	49
1341	Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. 2018 , 90, e2068-e2076	4
1340	How touch glove and expertise influence the basic touch gestures performances for people with Systemic Sclerosis. 2018 ,	
1339	High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference. 2018 , 20, 181	26
1338	Possible role of adipocytokines in systemic sclerosis-associated small pericardial effusion.. 2018 , 3, 153-158	
1337	Sklerodermie-assoziierte interstitielle Lungenerkrankungen. 2018 , 15, 383-395	0
1336	Validation of the Social Interaction Anxiety Scale in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort study.. 2018 , 3, 98-105	3
1335	Systemic considerations for orofacial neuropathy. 2018 , 44, 170-185	
1334	Anticentromere Antibody-positive Scleroderma Renal Crisis Requiring Dialysis. 2018 , 57, 3479-3483	

1333	Hearing loss in patients with scleroderma: associations with clinical manifestations and capillaroscopy. 2018 , 37, 2439-2446	2
1332	Systemic sclerosis-rheumatoid arthritis overlap syndrome complicated with Sweet's syndrome. 2018 , 37, 2281-2284	
1331	Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis. 2018 , 38, 1225-1234	7
1330	Association between the -174 C/G polymorphism in the interleukin-6 (IL-6) gene and gastrointestinal involvement in patients with systemic sclerosis. 2018 , 37, 2447-2454	1
1329	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. 2018 , 57, 1623-1631	26
1328	2-Methoxyestradiol inhibits hypoxia-induced scleroderma fibroblast collagen synthesis by phosphatidylinositol 3-kinase/Akt/mTOR signalling. 2018 , 57, 1675-1684	9
1327	Systemic Sclerosis at an Intensive Care Unit: A Case Series and Literature Review. 2019 , 25, 181-185	1
1326	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. 2019 , 58, 567-579	35
1325	The microbiome in autoimmune diseases. 2019 , 195, 74-85	162
1324	Muscle endurance, strength, and active range of motion in patients with different subphenotypes in systemic sclerosis: a cross-sectional cohort study. 2019 , 48, 141-148	7
1323	Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis. 2019 , 29, 476-483	6
1322	Early sign of microangiopathy in systemic sclerosis: The significance of cold stress test in dynamic laser Doppler flowmetry. 2019 , 71, 373-378	3
1321	Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor- β 2019 , 13, e1800069	3
1320	Near-infrared spectroscopic imaging of the whole hand: A new tool to assess tissue perfusion and peripheral microcirculation in scleroderma. 2019 , 48, 867-873	8
1319	Association between Skin Thickness Measurements with Corneal Biomechanical Properties and Dry Eye Tests in Systemic Sclerosis. 2019 , 27, 1138-1143	1
1318	Evidence of macro- and micro-angiopathy in scleroderma: An integrated approach combining 22-MHz power Doppler ultrasonography and video-capillaroscopy. 2019 , 122, 125-130	14
1317	Risk Factors for Future Scleroderma Renal Crisis at Systemic Sclerosis Diagnosis. 2019 , 46, 85-92	18
1316	Corneal Manifestations of Systemic Sclerosis. 2019 , 27, 968-977	9

1315	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. 2019 , 38, 2673-2681	25
1314	Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. 2019 , 9, 2045894019859477	20
1313	[Systemic sclerosis-clinical picture, diagnosis, and treatment]. 2019 , 70, 723-741	
1312	Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case series. 2019 , 94, 1214-1226	6
1311	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSSciper inception cohort study. 2019 , 78, 1576-1582	18
1310	Nailfold capillaroscopy in rheumatology: ready for the daily use but with care in terminology. 2019 , 38, 2293-2297	11
1309	Oral features of systemic sclerosis: A case-control study. 2019 , 25, 1995-2002	13
1308	CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis. 2019 , 3, 100009	9
1307	Clinical, Imaging, and Pathologic Features of Conditions with Combined Esophageal and Cutaneous Manifestations. 2019 , 39, 1411-1434	4
1306	Patients with ANCA-Associated Glomerulonephritis and Connective Tissue Diseases: A Comparative Study from the Maine-Anjou AAV Registry. 2019 , 8,	7
1305	Increased prevalence of small airways dysfunction in patients with systemic sclerosis as determined by impulse oscillometry. 2020 , 59, 641-649	4
1304	Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features. 2019 , 39, 1767-1775	11
1303	Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. 2019 , 40, 501-518	13
1302	IL-16 expression is increased in the skin and sera of patients with systemic sclerosis. 2020 , 59, 519-523	5
1301	Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease. 2019 , 38, 3619-3626	2
1300	Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications. 2019 , 1, 258-266	5
1299	Undifferentiated connective tissue disease at risk of systemic sclerosis: A weighted score to identify patients who will evolve. 2019 , 18, 102358	5
1298	Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA-125b in Systemic Sclerosis. 2019 , 71, 2068-2080	8

1297 Giant calcinosis revealing systemic sclerosis. **2019**, 22, 1787-1788

1296 Sidestream Dark Field (SDF) imaging of oral microcirculation in the assessment of systemic sclerosis. **2019**, 126, 103890 4

1295 Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension. **2019**, 52, e8513 3

1294 Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. **2018**, 4, e000786 14

1293 Targeting very early systemic sclerosis: a case-based review. **2019**, 39, 1961-1970 9

1292 Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis. **2019**, 9, 9468 14

1291 Value of lung diffusing capacity for nitric oxide in systemic sclerosis. **2019**, 7, e14149 7

1290 Multiple External Root Resorption of Teeth as a New Manifestation of Systemic Sclerosis-A Cross-Sectional Study in Japan. **2019**, 8, 3

1289 Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody. **2019**, 20, 256 13

1288 Analysis of genetic polymorphisms of glutathione S-transferase (GSTP1, GSTM1, and GSTT1) in Polish patients with systemic sclerosis. **2019**, 22, 2119-2124 2

1287 Clinical and serological profile of systemic sclerosis in Tunisia: A retrospective observational study. **2019**, 48, e284-e291 1

1286 Increased expression of GAB1 promotes inflammation and fibrosis in systemic sclerosis. **2019**, 28, 1313-1320 2

1285 Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). **2019**, 21, 217 20

1284 Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma?. **2019**, 49, 42-58 1

1283 The association between reproductive factors and systemic sclerosis in Chinese women: A case-control study and meta-analysis. **2019**, 22, 1832-1840 2

1282 Nailfold videocapillaroscopy alterations in dermatomyositis, antisynthetase syndrome, overlap myositis, and immune-mediated necrotizing myopathy. **2019**, 38, 3451-3458 9

1281 A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. **2019**, 21, 202 10

1280 Biomarkers of skin and lung fibrosis in systemic sclerosis. **2019**, 15, 1215-1223 7

1279	Systemic sclerosis. 2019 , 80, 530-536	22
1278	Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan. 2019 , 28, 1407-1416	8
1277	Evaluation of patients with dry eye for the presence of primary or secondary Sjögren's syndrome. 2019 , 13, 1787-1797	0
1276	Suspected inflammatory rheumatic diseases in patients presenting with skin rashes. 2019 , 33, 101440	7
1275	The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. 2019 , 70, 43-49	3
1274	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. 2019 , 78, 634-640	35
1273	Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population. 2019 , 491, 121-125	4
1272	Scleroderma-related interstitial lung disease: principles of management. 2019 , 13, 357-367	5
1271	Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria. 2019 , 58, 730-732	2
1270	Interstitial lung disease associated with systemic sclerosis (SSc-ILD). 2019 , 20, 13	80
1269	Position article and guidelines 2018 recommendations of the Brazilian Society of Rheumatology for the indication, interpretation and performance of nailfold capillaroscopy. 2019 , 59, 5	7
1268	Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease. 2019 , 150, 15-20	3
1267	The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality. 2019 , 32,	5
1266	A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease. 2019 , 49, 411-419	12
1265	Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. 2019 , 11, 1621-1628	23
1264	Macrophages Guard Endothelial Lineage by Hindering Endothelial-to-Mesenchymal Transition: Implications for the Pathogenesis of Systemic Sclerosis. 2019 , 203, 247-258	7
1263	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. 2019 , 71, 1812-1823	40
1262	Clinical characteristics of sarcoidosis patients with systemic sclerosis-specific autoantibody: Possible involvement of thymus and activation-regulated chemokine and a review of the published works. 2019 , 46, 577-583	4

1261	Cardiac autonomic modulation at rest and during orthostatic stress among different systemic sclerosis subsets. 2019 , 66, 75-80	9
1260	A review of exercise pulmonary hypertension in systemic sclerosis.. 2019 , 4, 225-237	0
1259	Acroosteolysis and bone metabolism parameters distinguish female patients with limited systemic sclerosis with and without calcinosis: a case control study. 2019 , 38, 3189-3193	2
1258	Towards a new classification of systemic sclerosis. 2019 , 15, 456-457	13
1257	A comparison between two educational methods in the rehabilitation of the microstomia in systemic sclerosis: a randomized controlled trial. 2019 , 33, 1747-1756	5
1256	Construction of an ICF core set and ICF-based questionnaire assessing activities and participation in patients with systemic sclerosis. 2019 , 58, 2260-2272	6
1255	Anticorps versus ph ⁺ hotype dans la scl ⁺ lodermie syst ⁺ mique : une ⁺ tude de cas-t ⁺ moins. 2019 , 40, A81	
1254	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. 2019 , 58, 2273-2283	12
1253	Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?. 2019 , 21, 152	3
1252	Systemic Sclerosis after Bone Marrow Transplantation: A Case with Evidence of Donor-related Disease Transfer. 2019 , 46, 1246-1247	
1251	Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. 2019 , 21, 129	10
1250	Raynaud's Phenomenon Differentiating After Cold Stress Using Thermal Parameters from Fingers. 2019 , 869-874	1
1249	The extrahepatic events of Asian patients with primary biliary cholangitis: A 30-year cohort study. 2019 , 9, 7577	2
1248	Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. 2019 , 46, 1605-1613	5
1247	Autoantibodies to a novel Rpp38 (Th/To) derived B-cell epitope are specific for systemic sclerosis and associate with a distinct clinical phenotype. 2019 , 58, 1784-1793	2
1246	Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. 2019 , 11, 257-273	66
1245	[Systemic sclerosis-clinical picture, diagnosis, and treatment]. 2019 , 78, 439-457	
1244	Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis: Relationship with Disease Activity and Type of Immunosuppressive Treatment. 2019 , 8,	5

1243	Possible association of decreased serum CXCL14 levels with digital ulcers in patients with systemic sclerosis. 2019 , 46, 584-589	3
1242	Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis. 2019 , 15, 706-712	13
1241	Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis. 2019 , 71, 1711-1722	7
1240	Analysis of serum interleukin(IL)-1β,IL-1β and IL-18 in patients with systemic sclerosis. 2019 , 8, e1045	8
1239	Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment. 2019 , 21, 103	2
1238	Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern. 2019 , 21, 106	19
1237	Anti-OJ autoantibodies: Rare or underdetected?. 2019 , 18, 658-664	25
1236	Autophagy mediates 2-methoxyestradiol-inhibited scleroderma collagen synthesis and endothelial-to-mesenchymal transition induced by hypoxia. 2019 , 58, 1966-1975	10
1235	Capillaroscopy changes are associated with disease progression in patients with early systemic sclerosis: A prospective study. 2019 , 22, 1319-1326	0
1234	Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. 2019 , 8,	9
1233	Cross-cultural adaptation of the connective tissue disease screening questionnaire and development of a Chinese version in a multi-ethnic Asian population. 2019 , 38, 2383-2397	2
1232	Nailfold capillaroscopy in systemic sclerosis - state of the art: The evolving knowledge about capillaroscopic abnormalities in systemic sclerosis.. 2019 , 4, 200-211	10
1231	Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. 2019 , 19, 357-366	15
1230	Autoantibodies in Disease Criteria for Systemic Autoimmune Diseases. 2019 , 81-89	
1229	Role of autonomic dysfunction in the regulation of myocardial blood flow in systemic sclerosis evaluated by cardiac magnetic resonance. 2019 , 22, 1029-1035	2
1228	Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parameters. 2019 , 21, 95	2
1227	Guidelines and Recommendations Towards Evidence-Based Management of Systemic Sclerosis. 2019 , 5, 115-126	1
1226	An Atypical Presentation of Raynaud's Disease. 2019 , 28, 394-396	2

1225	Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study. 2019 , 21, 76	5
1224	In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis. 2019 , 8,	16
1223	Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma. 2019 , 71, 1350-1359	10
1222	Protective Effect Against Cancer of Antibodies to the Large Subunits of Both RNA Polymerases I and III in Scleroderma. 2019 , 71, 1571-1579	16
1221	Use of Elastic Registration in Pulmonary MRI for the Assessment of Pulmonary Fibrosis in Patients with Systemic Sclerosis. 2019 , 291, 487-492	10
1220	Increased Morbidity and Mortality of Scleroderma in African Americans Compared to Non-African Americans. 2019 , 71, 1154-1163	23
1219	Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. 2019 , 92, e1416-e1426	16
1218	Ethnic Variations in Systemic Sclerosis Disease Manifestations, Internal Organ Involvement, and Mortality. 2019 , 46, 1103-1108	21
1217	Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. 2019 , 9, e024010	10
1216	Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study. 2019 , 46, 405-415	7
1215	Presence of Antitopoisomerase I Antibody Alone May Not Be Sufficient for the Diagnosis of Systemic Sclerosis. 2019 , 46, 440-442	2
1214	Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis. 2019 , 46, 1326-1334	15
1213	Rapid free thiol rebound is a physiological response following cold-induced vasoconstriction in healthy humans, primary Raynaud and systemic sclerosis. 2019 , 7, e14017	7
1212	Autologous hematopoietic stem cell transplant for progressive diffuse systemic sclerosis: procedural success and clinical outcome in 5-year follow-up. 2019 , 57, 50-54	4
1211	Hearing alterations in systemic sclerosis. 2019 , 31, e20170119	3
1210	Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. 2019 , 53,	5
1209	Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis. 2019 , 5, 127-146	
1208	Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss. 2019 , 203, 37-44	11

1207	Abrupt Onset of Dysphagia, Arthritis, Joint Contractures, and Sheets of Monomorphous Waxy Papules. 2019 , 155, 737-738	
1206	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. 2019 , 71, 1553-1570	31
1205	[Very early and early systemic sclerosis: An update]. 2019 , 40, 517-522	0
1204	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. 2019 , 78, 807-816	16
1203	La r [^] silience chez les patientes atteintes de maladies auto-immunes. 2019 , 86, 294-300	
1202	Using Machine Learning to Molecularly Classify Systemic Sclerosis Patients. 2019 , 71, 1595-1598	2
1201	Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. 2019 , 150, 154-160	37
1200	Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. 2019 , 21, 86	48
1199	Risk of digital ulcers occurrence in systemic sclerosis: a cross-sectional study. 2019 , 59, 14	5
1198	Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis. 2019 , 109, 718-722	2
1197	A systematic review of design for X techniques from 1980 to 2018: concepts, applications, and perspectives. 2019 , 102, 3473-3502	25
1196	Upper Extremity Angiographic Patterns in Systemic Sclerosis: Implications for Surgical Treatment. 2019 , 44, 990.e1-990.e7	3
1195	Increased antibody levels to stage-specific Epstein-Barr virus antigens in systemic autoimmune diseases reveal a common pathology. 2019 , 79, 7-16	14
1194	Macrophage migration inhibitory factor polymorphisms are a potential susceptibility marker in systemic sclerosis from southern Mexican population: association with MIF mRNA expression and cytokine profile. 2019 , 38, 1643-1654	8
1193	A low perfusion-metabolic mismatch in Tl and I-BMIPP scintigraphy predicts poor prognosis in systemic sclerosis patients with asymptomatic cardiac involvement. 2019 , 22, 1008-1015	1
1192	A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis. 2019 , 28, 536-542	13
1191	Predictors of Hand Contracture in Early Systemic Sclerosis and the Effect on Function: A Prospective Study of the GENISOS Cohort. 2019 , 46, 1597-1604	3
1190	The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis. 2019 , 10, 100	28

1189	Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. 2019 , 21, 7	27
1188	Raynaud's phenomenon.. 2019 , 4, 89-101	8
1187	Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. 2019 , 71, 1339-1349	34
1186	Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib. 2019 , 78, 539-550	34
1185	Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients. 2019 , 20, 771-779	2
1184	Systemic Sclerosis in Childhood. 2019 , 1183-1194	
1183	Dr. Tebo, reply. 2019 , 46, 1547	
1182	Raynaud's phenomenon. 2019 , 80, 658-664	10
1181	Rule-based and machine learning algorithms identify patients with systemic sclerosis accurately in the electronic health record. 2019 , 21, 305	14
1180	The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review. 2019 , 3, rkz044	13
1179	TH17 cells expressing CD146 are significantly increased in patients with Systemic sclerosis. 2019 , 9, 17721	8
1178	[Systemic sclerosis]. 2019 , 60, 1251-1269	4
1177	The Phenotype and Secretory Activity of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Patients with Rheumatic Diseases. 2019 , 8,	14
1176	High risk of gastrointestinal hemorrhage in patients with systemic sclerosis. 2019 , 21, 301	1
1175	Colonic Manifestations and Complications Are Relatively Under-Reported in Systemic Sclerosis: A Systematic Review. 2019 , 114, 1847-1856	11
1174	Systemic sclerosis. 2019 , 291-329	
1173	Trained immunity modulates inflammation-induced fibrosis. 2019 , 10, 5670	35
1172	Expression of apoptotic and proliferation factors in gastric mucosa of patients with systemic sclerosis correlates with form of the disease. 2019 , 9, 18461	1

1171	Fat Grafting for the Treatment of Scleroderma. 2019 , 144, 1498-1507	18
1170	NEMO score in nailfold videocapillaroscopy is a good tool to assess both steady state levels and overtime changes of disease activity in patients with systemic sclerosis: a comparison with the proposed composite indices for this disease status entity. 2019 , 21, 258	8
1169	Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study. 2019 , 21, 253	8
1168	Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity. 2019 , 71, 1119-1126	15
1167	Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients. 2019 , 162, 82-90	20
1166	Association Between Exposure to Heavy Metals and Systemic Sclerosis: the Levels of Al, Cd, Hg, and Pb in Blood and Urine of Patients. 2019 , 190, 1-10	5
1165	Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor Induced Fibrosis via Binding to α 5 Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis. 2019 , 71, 302-314	9
1164	Amniotic membrane dressings: an effective therapy for SSc-related wounds. 2019 , 58, 734-736	0
1163	Abnormal Nailfold Capillaroscopy Is Common in Patients with Connective Tissue Disease and Associated with Abnormal Pulmonary Function Tests. 2019 , 46, 1109-1116	8
1162	Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. 2019 , 58, 120-130	14
1161	The Systemic Sclerosis Questionnaire (SySQ): Validation of the Translation of the Original German Version Into Spanish and Its Relationship to the Disease and to Quality of Life. 2019 , 15, 282-288	1
1160	Less severe disease in patients with early systemic sclerosis?. 2019 , 29, 977-983	0
1159	Digital Ulcerations and Classification of SSc Subsets and Overlap Syndromes. 2019 , 7-13	
1158	Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality. 2019 , 49, 98-104	19
1157	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. 2019 , 46, 603-608	12
1156	Initial presentation determines clinical entity in patients with anti-centromere antibody positivity. 2019 , 22, 103-107	2
1155	Demographic and clinical characteristics of spinal calcinosis in systemic sclerosis: Possible association with peripheral angiopathy. 2019 , 46, 33-36	6
1154	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. 2019 , 9, 2045894018816089	8

1153	Relationship Between Increased Fecal Calprotectin Levels and Interstitial Lung Disease in Systemic Sclerosis. 2019 , 46, 274-278	6
1152	Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. 2019 , 98, 24-32	15
1151	Bulgarian rheumatology: science and practice in a cost-constrained environment. 2019 , 39, 417-429	5
1150	Efferocytosis capacities of blood monocyte-derived macrophages in systemic sclerosis. 2019 , 97, 340-347	9
1149	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. 2019 , 46, 279-284	25
1148	Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.. 2019 , 4, 149-159	1
1147	Pulmonary Manifestations of Autoinflammatory Disorders. 2019 , 193-211	0
1146	Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. 2019 , 397, 123-128	15
1145	Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. 2019 , 71, 972-982	57
1144	Epigenetics of Systemic Sclerosis. 2019 , 505-528	
1143	Mechanic hands: clinical and capillaroscopy manifestations of patients with connective tissue diseases presented with and without mechanic hands. 2019 , 38, 2309-2318	5
1142	Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature. 2019 , 18, 262-269	15
1141	A randomised controlled trial of wax baths as an additive therapy to hand exercises in patients with systemic sclerosis. 2019 , 105, 370-377	4
1140	Systemic sclerosis and primary biliary cholangitis: An overlapping entity?. 2019 , 4, 111-117	2
1139	A potential contribution of trappin-2 to the development of vasculopathy in systemic sclerosis. 2019 , 33, 753-760	2
1138	Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin.. 2019 , 4, 71-76	4
1137	Ulnar Artery Occlusion and Severity Markers of Vasculopathy in Systemic Sclerosis: A Multicenter Cross-Sectional Study. 2019 , 71, 983-990	10
1136	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. 2019 , 58, 468-475	14

1135	Nailfold capillaroscopy-how many fingers should be examined to detect abnormality?. 2019 , 58, 284-288	10
1134	Anti-RNPC-3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility. 2019 , 71, 1164-1170	15
1133	[Mimetics of systemic sclerosis]. 2019 , 78, 14-23	1
1132	Abnormal esophageal motility during a solid test meal in systemic sclerosis-detection even in very early disease and association with disease progression. 2019 , 31, e13480	7
1131	The patient experience of Raynaud's phenomenon in systemic sclerosis. 2019 , 58, 18-26	26
1130	ASCA (Anti-Saccharomyces cerevisiae Antibody) in Patients With Scleroderma. 2019 , 25, 24-27	2
1129	Clinical Characteristics and Associated Systemic Diseases in Patients With Esophageal "Absent Contractility"-A Clinical Algorithm. 2019 , 53, 184-190	7
1128	Can nailfold videocapillaroscopy images be interpreted reliably by different observers? Results of an inter-reader and intra-reader exercise among rheumatologists with different experience in this field. 2019 , 38, 205-210	10
1127	Progressive systemic sclerosis in Egyptian patients: Clinical characteristics and nail fold capillaroscopy. 2019 , 41, 47-51	8
1126	The Systemic Sclerosis Questionnaire (SySQ): Validation of the translation of the original German version into Spanish and its relationship to the disease and to quality of life. 2019 , 15, 282-288	
1125	Ten Years of Interventional Research in Systemic Sclerosis: A Systematic Mapping of Trial Registries. 2020 , 72, 140-148	1
1124	Antinuclear Antibodies in Systemic Sclerosis: an Update. 2020 , 58, 40-51	36
1123	Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. 2020 , 39, 27-36	11
1122	Clinical and laboratory features of African-Brazilian patients with systemic sclerosis. 2020 , 39, 9-17	3
1121	Incidence and prevalence of systemic sclerosis in Valcamonica, Italy, during an 18-year period.. 2020 , 5, 51-56	3
1120	Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis. 2020 , 50, 135-139	6
1119	Primary biliary cholangitis in patients with systemic sclerosis: Unmasking the true face of Reynold's syndrome. 2020 , 42, 31-34	2
1118	Scleroderma in Cairns: an epidemiological study. 2020 , 50, 445-452	2

1117	Comparison of clinical presentation and incidence of cardiopulmonary complications between male and female Thai patients with early systemic sclerosis: inception cohort study. 2020 , 39, 103-112	3
1116	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. 2020 , 182, 410-417	16
1115	Prevalence and clinical characteristics of overactive bladder in systemic sclerosis. 2020 , 30, 327-331	3
1114	Serum Interleukin 35 Levels in Systemic Sclerosis and Relationship With Clinical Features. 2020 , 26, 83-86	4
1113	Skin and Lacrimal Drainage System. 2020 , 163-233.e10	
1112	Treatment of resistant Raynaud's phenomenon with single-port thoracoscopic sympathectomy: a novel minimally invasive endoscopic technique. 2020 , 59, 1021-1025	4
1111	Immunoglobulin G galactosylation levels are decreased in systemic sclerosis patients and differ according to disease subclassification. 2020 , 49, 146-153	4
1110	Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. 2020 , 59, 1315-1324	5
1109	Systemic sclerosis: Recent insight in clinical management. 2020 , 87, 293-299	18
1108	Incidence, Risk Factors, and Outcomes of Cancer in Systemic Sclerosis. 2020 , 72, 1625-1635	7
1107	Assessing recovery after cold challenge and thumb involvement can help to rule out systemic sclerosis in patients presenting with Raynaud's phenomenon. 2020 , 49, 137-140	
1106	Acute exacerbations of fibrotic interstitial lung diseases. 2020 , 25, 525-534	34
1105	Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögren's syndrome. 2020 , 50, 119-129	16
1104	Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. 2020 , 59, 398-406	8
1103	Can Patient-Reported Symptoms Be Used to Measure Disease Activity in Systemic Sclerosis?. 2020 , 72, 1459-1465	6
1102	Is there a role for laser speckle contrast analysis (LASCA) in predicting the outcome of digital ulcers in patients with systemic sclerosis?. 2020 , 39, 69-75	7
1101	The predictive role of lung ultrasound in progression of scleroderma interstitial lung disease. 2020 , 39, 119-123	13
1100	Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis. 2020 , 39, 77-83	12

1099	T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients. 2020 , 50, 128-134	9
1098	Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. 2020 , 50, 140-148	9
1097	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. 2020 , 72, 125-136	92
1096	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. 2020 , 72, 137-149	42
1095	Use of Extracorporeal Photopheresis in Scleroderma: A Review. 2020 , 236, 105-110	7
1094	Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis.. 2020 , 5, 103-129	3
1093	microRNAs are potentially regulating the survivin gene in PBMCs from systemic sclerosis patients. 2020 , 30, 862-869	5
1092	Lung disease related to connective tissue diseases. 2020 , 265-319	
1091	The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review. 2020 , 39, 149-157	6
1090	Economic Analysis of the Use of Anti-DFS70 Antibody Test in Patients with Undifferentiated Systemic Autoimmune Disease Symptoms. 2020 , 47, 1275-1284	4
1089	Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis. 2020 , 312, 453-458	13
1088	Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. 2020 , 72, 465-476	52
1087	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. 2020 , 59, 1684-1694	9
1086	The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center. 2020 , 39, 813-821	3
1085	Validation of the 2019 European League Against Rheumatism/American College of Rheumatology Criteria Compared to the 1997 American College of Rheumatology Criteria and the 2012 Systemic Lupus International Collaborating Clinics Criteria in Pediatric Systemic Lupus Erythematosus. 2020 , 72, 1597-1601	12
1084	The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. 2020 , 59, 1407-1415	11
1083	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. 2020 , 19, 102458	90
1082	Evaluation of the association between KIR polymorphisms and systemic sclerosis: a meta-analysis. 2020 , 60, 8	0

1081	The Glittre Activities of Daily Living Test in women with scleroderma and its relation to hand function and physical capacity. 2020 , 73, 71-77	6
1080	Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting. 2020 , 26, 115-118	5
1079	Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients. 2020 , 39, 1191-1197	2
1078	Anti-enolase1 antibodies from a patient with systemic lupus erythematosus accompanied by pulmonary arterial hypertension promote migration of pulmonary artery smooth muscle cells. 2020 , 218, 22-29	0
1077	Classification of IgG4-Related Disease: A Medical Marvel of Our Time. 2020 , 72, 1-3	0
1076	Promotion of Myofibroblast Differentiation and Tissue Fibrosis by the Leukotriene B -Leukotriene B Receptor Axis in Systemic Sclerosis. 2020 , 72, 1013-1025	7
1075	Extracellular SPARC cooperates with TGF- β signalling to induce pro-fibrotic activation of systemic sclerosis patient dermal fibroblasts. 2020 , 59, 2258-2263	9
1074	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. 2020 , 201, 650-660	41
1073	Autoantibodies in connective tissue disease. 2020 , 34, 101462	4
1072	Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. 2020 , 19, 102431	13
1071	Evaluation of the primary biliary cholangitis-related serologic profile in a large cohort of Belgian systemic sclerosis patients. 2020 , 58, 416-423	5
1070	Vitamin D and Cytokine Profiles in Patients With Systemic Sclerosis. 2020 , 26, 289-294	4
1069	Expression of membrane-bound human leucocyte antigen-G in systemic sclerosis and systemic lupus erythematosus. 2020 , 81, 162-167	10
1068	Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis. 2020 , 94, e910-e920	11
1067	Inhomogeneity of capillaroscopic findings in systemic sclerosis. 2020 , 23, 207-215	0
1066	Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring. 2020 , 19, 102449	8
1065	Interstitial pneumonia with autoimmune features: A single center prospective follow-up study. 2020 , 19, 102451	17
1064	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. 2020 , 19, 102452	22

1063	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. 2020 , 72, 723-733	14
1062	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. 2020 , 59, 2043-2051	2
1061	Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. 2020 , 79, 370-378	24
1060	Clinical quantification of the integrin $\alpha 8$ by [F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). 2020 , 47, 967-979	22
1059	The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. 2020 , 79, 77-87	179
1058	[Treatment of systemic sclerosis-associated interstitial lung disease]. 2020 , 79, 294-303	2
1057	Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. 2020 , 59, 1715-1724	4
1056	In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. 2020 , 59, 1957-1968	9
1055	Systemic Autoimmune Disease Among Adults Exposed to the September 11, 2001 Terrorist Attack. 2020 , 72, 849-859	17
1054	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. 2020 , 72, 7-19	113
1053	Recent advances steer the future of systemic sclerosis toward precision medicine. 2020 , 39, 1-4	13
1052	Cervical cancer screening and Pap test non-adherence risk factors in systemic sclerosis patients. 2020 , 29, 266-269	2
1051	HHV-6A Infection and Systemic Sclerosis: Clues of a Possible Association. 2019 , 8,	15
1050	Use of Neem oil and for treatment of calcinosis-related skin ulcers in systemic sclerosis. 2020 , 48, 300060519882176	
1049	Patterns of renal pathology in Chinese patients with systemic sclerosis undergoing renal biopsy at a tertiary medical center. 2020 , 48, 300060519894456	0
1048	Laser Doppler imaging evaluation of nitroglycerin patch application in systemic sclerosis patients. 2020 , 25, 559-568	2
1047	Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study. 2020 , 22, 230	2
1046	Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial. 2020 , 9,	6

1045	Semaphorin4A-Plexin D1 Axis Induces Th2 and Th17 While Represses Th1 Skewing in an Autocrine Manner. 2020 , 21,	6
1044	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. 2020 , 12,	14
1043	Esophageal Involvement and Determinants of Perception of Esophageal Symptoms Among South Koreans With Systemic Sclerosis. 2020 , 26, 477-485	4
1042	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.. 2020 , 2, e743-e753	13
1041	Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors. 2020 , 32, 463-471	5
1040	Validation of the COVID-19 Fears Questionnaires for Chronic Medical Conditions: A Scleroderma Patient-centered Intervention Network COVID-19 Cohort study. 2020 , 139, 110271	9
1039	Scleroderma-associated thrombotic microangiopathy in overlap syndrome of systemic sclerosis and systemic lupus erythematosus: A case report and literature review. 2020 , 99, e22582	2
1038	Analysis of antinuclear antibody titers and patterns by using HEp-2 and primate liver tissue substrate indirect immunofluorescence assay in patients with systemic autoimmune rheumatic diseases. 2020 , 34, e23546	1
1037	Relationship of Wnt pathway activity and organ involvement in scleroderma types. 2020 , 23, 1558-1567	0
1036	Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?. 2020 , 19, 102659	10
1035	Treatment of systemic sclerosis-associated interstitial lung disease: A systematic literature review and meta-analysis. 2020 , 27, 146-169	
1034	The potential utility of anterior upper lobe honeycomb-like lesion in interstitial lung disease associated with connective tissue disease. 2020 , 172, 106125	3
1033	Raynaud's phenomenon, capillaroscopy, and digital ulcers as sentinel events in systemic sclerosis. 2020 , 27, 170-174	
1032	Neutrophil Extracellular Traps Generation Relates with Early Stage and Vascular Complications in Systemic Sclerosis. 2020 , 9,	11
1031	Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study. 2020 , 44, 1820-1832	11
1030	Validity and reliability of the Patient Health Questionnaire-8 in Swedish for individuals with systemic sclerosis. 2020 , 40, 1675-1687	5
1029	B-lymphocyte hyperactivation and autoantibody production in the pathophysiology of cutaneous systemic sclerosis. 2020 , 27, 68-70	
1028	Coexistence of systemic and localized scleroderma: a systematic literature review and observational cohort study. 2020 , 59, 2725-2733	2

1027	Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc-related autoantibodies: A single-center retrospective study. 2020 , 23, 1219-1225	2
1026	The Challenge of Very Early Systemic Sclerosis. 2020 , 47, 1724	0
1025	Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study. 2020 , 11, 1382	5
1024	Deep Learning-based Approach for Automated Assessment of Interstitial Lung Disease in Systemic Sclerosis on CT Images. 2020 , 2, e190006	9
1023	Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report. 2020 , 21,	6
1022	The Impact of Nailfold Capillaroscopy in the Approach of Microcirculation. 2020 ,	0
1021	Mesenchymal stem cells in systemic sclerosis therapy. 2020 , 58, 324-330	2
1020	Histologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis. 2020 , 10, 21137	2
1019	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. 2021 , 73, 1490-1501	13
1018	Systemic Sclerosis. 2020 ,	
1017	Comparison between low cost USB nailfold capillaroscopy and videocapillaroscopy: a pilot study. 2021 , 60, 3862-3867	3
1016	Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study. 2020 , 60, 38	3
1015	Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. 2020 , 50, 977-987	7
1014	Clonal haematopoiesis is increased in early onset in systemic sclerosis. 2020 , 59, 3499-3504	7
1013	Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach. 2020 , 27, 1873-1875	0
1012	A study of antigen-specific anti-cytomegalovirus antibody reactivity in patients with systemic sclerosis and concomitant anti-Ro52 antibodies. 2020 , 40, 1689-1699	3
1011	Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study. 2020 , 2, 496-502	1
1010	Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation. 2020 , 22, 183	5

1009	Subclinical atherosclerosis in systemic sclerosis and rheumatoid arthritis: a comparative matched-cohort study. 2020 , 40, 1997-2004	3
1008	High NEMO score values in nailfold videocapillaroscopy are associated with the subsequent development of ischaemic digital ulcers in patients with systemic sclerosis. 2020 , 22, 237	2
1007	Metabolic Pattern of Systemic Sclerosis: Association of Changes in Plasma Concentrations of Amino Acid-Related Compounds With Disease Presentation. 2020 , 7, 585161	2
1006	Diagnostic Power of Galectin-3 in Rheumatic Diseases. 2020 , 9,	5
1005	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. 2020 , 139, 110262	9
1004	Artifactual hypoglycemia in a patient with systemic sclerosis. 2020 , 1-6	1
1003	Handheld dermatoscopy as an easy-to-use capillaroscopic instrument in rheumatoid arthritis: a cross-sectional study. 2020 , 50, 1540-1545	1
1002	Decreased activation of ataxia telangiectasia mutated (ATM) in monocytes from patients with systemic sclerosis. 2020 , 59, 3961-3970	
1001	Evaluation of lymphocytic infiltration in the bronchial glands of Sjögren's syndrome in transbronchial lung cryobiopsy. 2020 , 20, 277	
1000	A Real-World Experience of Mycophenolate Mofetil for Systemic Sclerosis: A Retrospective Multicenter Observational Study. 2020 , 35, 366-375	1
999	Circulating peroxisome proliferator-activated receptor β s elevated in systemic sclerosis. 2020 , 37, 921-926	1
998	Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation. 2020 , 217,	8
997	Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint). 2020 , 29, 1144-1153	2
996	Mycophenolate Mofetil Improves Exercise Tolerance in Systemic Sclerosis Patients with Interstitial Lung Disease: A Pilot Study. 2020 , 7, 1037-1044	1
995	Spectrum of Fibrotic Lung Diseases. 2020 , 383, 958-968	102
994	Modulation of T-Cell Activation Markers Expression by the Adipose Tissue-Derived Mesenchymal Stem Cells of Patients with Rheumatic Diseases. 2020 , 29, 963689720945682	6
993	Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. 2020 ,	4
992	Diffuse Pulmonary Ossification on High-Resolution Computed Tomography in Idiopathic Pulmonary Fibrosis, Systemic Sclerosis-Related Interstitial Lung Disease, and Chronic Hypersensitivity Pneumonitis: A Comparative Study. 2020 , 44, 667-672	

991	Left Ventricular Mass Index as Potential Surrogate of Muscularity in Patients With Systemic Sclerosis Without Cardiovascular Disease. 2021 , 45, 1302-1308	
990	Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement. 2020 , 9,	3
989	The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). 2020 , 10,	4
988	Ultrasound assessment of skin thickness and stiffness: the correlation with histology and clinical score in systemic sclerosis. 2020 , 22, 197	10
987	Occupational silica exposure in an Australian systemic sclerosis cohort. 2020 , 59, 3900-3905	6
986	Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study. 2020 , 99, e21734	3
985	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. 2020 , 6,	9
984	An Update on Systemic Sclerosis and its Perioperative Management. 2020 , 10, 1-10	4
983	Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification. 2020 , 7, 587773	3
982	Reduced salivary flow and caries status are correlated with disease activity and severity in patients with diffuse cutaneous systemic sclerosis. 2020 , 48, 300060520941375	3
981	Angiotensin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients. 2020 , 21,	2
980	Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink. 2021 , 60, 2688-2696	2
979	A case of systemic sclerosis/lupus overlap syndrome presenting with bilateral cotton wool spots. 2020 , 20, 100967	
978	The relationship between gastrointestinal transit, Medsger GI severity, and UCLA GIT 2.0 symptoms in patients with systemic sclerosis. 2020 ,	5
977	Work Productivity and Economic Burden of Systemic Sclerosis in a Multi-Ethnic Asian Population. 2020 ,	0
976	Osteitis in Systemic Sclerosis: a nationwide case-control retrospective study (SCLEROS Study). 2020 ,	
975	Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease. 2020 , 10, 21912	1
974	Tratamiento de la enfermedad pulmonar intersticial asociada con la esclerosis sistémica: revisión sistemática de la literatura y metaanálisis. 2020 , 27, 146-169	

973	Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension. 2020 , 9,	6
972	Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis. 2020 ,	0
971	[Pseudotumoral calcinosis of the wrist compressing the radial nerve in systemic sclerosis]. 2020 , 147, 366-369	0
970	Systemic Sclerosis and Vaccinations: A Register-Based Cohort Study about Seasonal Influenza and Streptococcus pneumoniae Vaccination Rate and Uptake from Liguria Regional Center, Northwest Italy. 2020 , 8,	3
969	Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. 2020 , 59, 2625-2636	12
968	Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis. 2020 , 158, 1515-1525	22
967	Cardiac Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging With T1 Mapping to Assess Myocardial Perfusion and Fibrosis in Systemic Sclerosis: Association With Cardiac Events From a Prospective Cohort Study. 2020 , 72, 1571-1580	5
966	Ultrasound Detection of Calcinosis and Association With Ulnar Artery Occlusion in Patients With Systemic Sclerosis. 2021 , 73, 1332-1337	4
965	Development and Assessment of Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Systemic Sclerosis. 2021 , 73, 1338-1342	8
964	Reduction of fat free mass index and phase angle is a risk factor for development digital ulcers in systemic sclerosis patients. 2020 , 39, 3693-3700	1
963	Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience. 2021 , 133, 1070-1075	1
962	The Role of Angiogenesis Factors in the Formation of Vascular Changes in Scleroderma by Assessment of the Concentrations of VEGF and sVEGFR2 in Blood Serum and Tear Fluid. 2020 , 2020, 7649480	3
961	Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment. 2020 , 39, 3393-3400	3
960	Hiperactivaci ³ n del linfocito B y producci ³ n de los autoanticuerpos anticentr ³ bero, antitopoisomerasa-I, anti-ARNPol-III en la fisiopatolog ³ a de la esclerosis sist ³ mica cut ³ nea. 2020 , 27, 68-70	
959	Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies. 2020 , 3, 100049	4
958	Fatty Acid and Carnitine Metabolism Are Dysregulated in Systemic Sclerosis Patients. 2020 , 11, 822	5
957	The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation. 2020 , 9,	8
956	Outcome and prognostic factors of interstitial lung disease patients with acute respiratory failure in the intensive care unit. 2020 , 14, 1753466620926956	1

955	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. 2020 , 19, 102583	13
954	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. 2020 , 78, 17-25	13
953	Risk of scleroderma according to the type of immune checkpoint inhibitors. 2020 , 19, 102596	17
952	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. 2020 , 22, 127	11
951	Validation of the suction device Nimble for the assessment of skin fibrosis in systemic sclerosis. 2020 , 22, 128	2
950	Involvement of Disabled-2 on skin fibrosis in systemic sclerosis. 2020 , 99, 44-52	0
949	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. 2020 , 156, 901-906	6
948	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. 2020 , 50, 891-896	6
947	Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis.. 2020 , 5, 210-218	1
946	Increased CD27 expression in the skins and sera of patients with systemic sclerosis. 2020 , 9, 99-103	1
945	Nutritional Status and Bone Microarchitecture in a Cohort of Systemic Sclerosis Patients. 2020 , 12,	2
944	Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease. 2020 , 47, 1027-1032	2
943	Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis. 2020 , 72, 1897-1904	2
942	T-Cell Proapoptotic and Antifibrotic Activity Against Autologous Skin Fibroblasts Is Associated With IL-17A Axis Upregulation in Systemic Sclerosis. 2020 , 11, 220	4
941	Novel instrumental markers of proximal scleroderma provided by imaging photoplethysmography. 2020 , 41, 044004	7
940	High-throughput quantitative histology in systemic sclerosis skin disease using computer vision. 2020 , 22, 48	4
939	The α Connective Tissue Diseases 2020 , 1-64	
938	Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity. 2020 , 23, 674-680	2

937	Scleroderma mimics - Clinical features and management. 2020 , 34, 101489	6
936	Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels. 2020 , 19, 102515	12
935	Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease. 2020 , 158, 350-358	6
934	Microangiopathy and forearm arterial blood flow in systemic sclerosis: a controlled study. 2020 , 39, 2671-2676	0
933	Profibrotic Activation of Human Macrophages in Systemic Sclerosis. 2020 , 72, 1160-1169	18
932	Applicability of shear wave elastography for the evaluation of skin strain in systemic sclerosis. 2020 , 40, 737-745	15
931	Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. 2020 , 19, 102507	8
930	Pathogenic Activation of Mesenchymal Stem Cells Is Induced by the Disease Microenvironment in Systemic Sclerosis. 2020 , 72, 1361-1374	11
929	Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma. 2020 , 72, 1375-1384	2
928	Phase angle in systemic sclerosis: a marker for pulmonary function and disease severity. 2020 , 39, 1699-1701	1
927	A Novel Proposal of Salivary Lymphocyte Detection and Phenotyping in Patients Affected by Sjogren's Syndrome. 2020 , 9,	
926	Crystalline Silica Impairs Efferocytosis Abilities of Human and Mouse Macrophages: Implication for Silica-Associated Systemic Sclerosis. 2020 , 11, 219	18
925	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. 2020 , 72, 1049-1058	19
924	Bioactive Plasma Mitochondrial DNA Is Associated With Disease Progression in Scleroderma-Associated Interstitial Lung Disease. 2020 , 72, 1905-1915	8
923	Cardiovascular Risk in Systemic Sclerosis. 2020 , 6, 282-298	
922	Nailfold capillaroscopy in common non-rheumatic conditions: A systematic review and applications for clinical practice. 2020 , 131, 104036	14
921	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. 2020 , 72, 1892-1896	12
920	Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis. 2020 , 12,	11

919	A case report, a case who developed limited cutaneous scleroderma and pulmonary hypertension 8 years after diagnosis of anti-centromere antibody-positive Sjögren syndrome. 2020 , 4, 248-252	1
918	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. 2020 , 23, 532-539	7
917	Experiences of physical activity and exercise in individuals with systemic sclerosis: A qualitative study. 2020 , 18, 150-160	4
916	Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. 2020 , 50, 1489-1493	16
915	Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies. 2020 , 22, 32	5
914	Autoantibody Biomarkers in Rheumatic Diseases. 2020 , 21,	5
913	Computed tomography assessment of evolution of interstitial lung disease in systemic sclerosis: Comparison of two scoring systems. 2020 , 76, 71-75	3
912	Late Gadolinium Enhancement in Cardiac Magnetic Resonance Imaging Is Associated with High Renal Resistive Index in Patients with Systemic Sclerosis. 2020 , 45, 350-356	3
911	Investigation and analysis of HEp 2 indirect immunofluorescence titers and patterns in various liver diseases. 2020 , 39, 2425-2432	6
910	Illness perceptions, risk perceptions and worries in patients with early systemic sclerosis: A focus group study. 2020 , 18, 177-186	3
909	Systemische Sklerose. 2020 , 19, 69-76	
908	A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn's disease. 2020 , 10, 1862	11
907	Prospective serial diagnostic study: the effects of position and provocative tests on the diagnosis of oesophageal motility disorders by high-resolution manometry. 2020 , 51, 706-718	20
906	Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. 2020 , 22, 30	7
905	Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease. 2020 , 38, 581-588	3
904	The risk of circulating angiogenic T cells and subsets in patients with systemic sclerosis. 2020 , 81, 106282	5
903	Systemic sclerosis-associated interstitial lung disease. 2020 , 8, 304-320	73
902	The perspective on standardisation and harmonisation: the viewpoint of the EASI president. 2020 , 11, 4	10

901	Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis. 2020 , 39, 1543-1549	3
900	Systemic sclerosis in mother and daughter with susceptible HLA haplotype and anti-topoisomerase I autoantibodies. 2020 , 40, 1001-1009	1
899	Systemic sclerosis: Advances towards stratified medicine. 2020 , 34, 101469	3
898	Decreased CCN3 in Systemic Sclerosis Endothelial Cells Contributes to Impaired Angiogenesis. 2020 , 140, 1427-1434.e5	7
897	Impact and associates of digital pitting in patients with systemic sclerosis: a pilot study. 2020 , 49, 239-243	2
896	The relationship of serum SCUBE-1, -2 and -3 levels with clinical findings and ultrasonographic skin thickness in systemic sclerosis patients. 2020 , 23, 526-531	1
895	Phase angle could be a marker of microvascular damage in systemic sclerosis. 2020 , 73, 110730	5
894	Flare of IGA glomerulonephritis under G-CSF stimulation regimen for autologous stem cell transplantation in systemic sclerosis. 2020 , 59, e33-e34	1
893	Exploring the feasibility of an exercise programme including aerobic and resistance training in people with limited cutaneous systemic sclerosis. 2020 , 39, 1889-1898	8
892	Raynaud's phenomenon. 2020 , 34, 101474	20
891	Increased Mortality in Asians With Systemic Sclerosis in Northern California. 2020 , 2, 197-206	6
890	Nailfold Videocapillaroscopy is a Useful Tool to Recognize Definite Forms of Systemic Sclerosis and Idiopathic Inflammatory Myositis in Interstitial Lung Disease Patients. 2020 , 10,	5
889	Effect of a tailored home-based exercise program in patients with systemic sclerosis: A randomized controlled trial. 2020 , 30, 1675-1684	9
888	Fractional exhaled breath temperature in patients with asthma, chronic obstructive pulmonary disease, or systemic sclerosis compared to healthy controls. 2020 , 7, 1747014	3
887	'Narrow-sense' and 'broad-sense' vascular abnormalities of systemic sclerosis. 2020 , 43, 107-114	4
886	[Illnesses unrelated to systemic sclerosis (IUSS) diagnosed throughout the patient's follow-up in a referral center: A cohort of 200 patients]. 2020 , 41, 517-522	0
885	One-Year Outcome of Critically Ill Patients With Systemic Rheumatic Disease: A Multicenter Cohort Study. 2020 , 158, 1017-1026	5
884	Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. 2020 , 50, 1406-1413	1

883	Prognostic factors of pulmonary hypertension associated with connective tissue disease: pulmonary artery size measured by chest CT. 2020 , 59, 3221-3228	5
882	Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?. 2020 , 10,	9
881	Quantification of Ground Glass Opacities Can Be Useful to Describe Disease Activity in Systemic Sclerosis. 2020 , 10,	1
880	Thrombospondin-1 mediates muscle damage in brachio-cervical inflammatory myopathy and systemic sclerosis. 2020 , 7,	8
879	Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets. 2020 , 59, 3380-3389	2
878	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. 2020 , 72, 1350-1360	30
877	Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. 2020 , 13, 15-29	13
876	Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis. 2020 , 37, 2460-2476	3
875	Profile of common inflammatory markers in treatment-naïve patients with systemic rheumatic diseases. 2020 , 39, 2899-2906	5
874	Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. 2020 , 56,	14
873	Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity. 2020 , 29, 686-696	0
872	Biphasic Temporal Relationship between Cancers and Systemic Sclerosis: A Clinical Series from Montpellier University Hospital and Review of the Literature. 2020 , 9,	4
871	The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis. 2021 , 48, 241-246	4
870	The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?. 2021 , 48, 82-86	8
869	Assessing Malnutrition in Systemic Sclerosis With Global Leadership Initiative on Malnutrition and European Society of Clinical Nutrition and Metabolism Criteria. 2021 , 45, 618-624	10
868	A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. 2021 , 43, 65-86	7
867	Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis. 2021 , 48, 402-409	1
866	Raynaud Phenomenon in Systemic Sclerosis: Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?. 2021 , 48, 247-250	2

865	Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature. 2021 , 73, 722-731	0
864	Wnt antagonist DKK-1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a-3p. 2021 , 30, 162-168	2
863	Clinical Features of Systemic Sclerosis-Mixed Connective Tissue Disease and Systemic Sclerosis Overlap Syndromes. 2021 , 73, 732-741	8
862	Unmet Workplace Support Needs and Lost Productivity of Workers With Systemic Sclerosis: A Path Analysis Study. 2021 , 73, 423-431	4
861	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. 2021 , 73, 671-676	8
860	Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis. 2021 , 60, 87-94	4
859	Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study. 2021 , 38, 521-540	2
858	Laser speckle contrast analysis predicts major vascular complications and mortality of patients with systemic sclerosis. 2021 , 60, 1850-1857	7
857	Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. 2021 , 40, 1903-1912	3
856	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. 2021 , 75, e13819	0
855	Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. 2021 , 60, 557-567	24
854	Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study.. 2021 , 6, 87-95	
853	The importance of skin manifestations, serology and nailfold (video)capillaroscopy in morphea and systemic sclerosis: current understanding and new insights. 2021 , 35, 597-606	
852	Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma. 2021 , 73, 520-529	9
851	Donn�es r�centes sur la prise en charge clinique de la scl�dermie syst�mique. 2021 , 88, 24-31	
850	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. 2021 , 6, 66-76	2
849	Integrated bulk and single-cell RNA-sequencing identified disease-relevant monocytes and a gene network module underlying systemic sclerosis. 2021 , 116, 102547	7
848	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. 2021 , 80, 219-227	33

- 847 Cultural adaptation, translation and validation of Cochin Hand Function Scale and evaluation of hand dysfunction in systemic sclerosis. **2021**, 40, 1913-1922 1
- 846 Generalized morphea with extensive telangiectasia on the palms. **2021**, 48, e22-e23
- 845 Elastic Registration-driven Deep Learning for Longitudinal Assessment of Systemic Sclerosis Interstitial Lung Disease at CT. **2021**, 298, 189-198 5
- 844 Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients. **2021**, 30, 146-153 3
- 843 Exome-Wide Association Analysis Suggests LRP2BP as a Susceptibility Gene for Endothelial Injury in Systemic Sclerosis in the Han Chinese Population. **2021**, 141, 1254-1263.e6 0
- 842 Pulse Wave Velocity in Systemic Sclerosis: Potential Beneficial Effects of Bosentan on Forearm Arterial Stiffness? An Exploratory Study. **2021**, 48, 154-156 0
- 841 Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data. **2021**, 41, 129-137 3
- 840 COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort. **2021**, 40, 1393-1397 4
- 839 Increased Prevalence of Moderate to Severe Mitral and Aortic Valve Dysfunction in Systemic Sclerosis: A Case-control Study. **2021**, 48, 394-401 0
- 838 Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts. **2021**, 40, 2277-2284 3
- 837 Prevalence and clinical associations with premature ovarian insufficiency, early menopause, and low ovarian reserve in systemic sclerosis. **2021**, 40, 2267-2275 4
- 836 Skin Histology in Systemic Sclerosis: a Relevant Clinical Biomarker. **2020**, 23, 3
- 835 Systemic Sclerosis: A Comprehensive Approach to Diagnosis and Management. **2021**, 6, 159-175
- 834 Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSICIS trial. **2021**, 59, 252-259 5
- 833 Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. **2021**, 15, 336-344 5
- 832 High-frequency Ultrasound Assessment of Systemic Sclerosis Skin Involvement: Intraobserver Repeatability and Relationship With Clinician Assessment and Dermal Collagen Content. **2021**, 48, 867-876 6
- 831 Cement Factory Worker Presenting With Raynaud Phenomenon, Breathlessness, and Digital Ulcers. **2021**, 159, e93-e96 0
- 830 High prevalence of salivary gland ultrasound abnormalities in systemic sclerosis. **2021**, 88, 105113 2

829	Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments. 2021 , 51, 36-42	3
828	Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. 2021 , 26, 461-468	10
827	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. 2021 , 140, 110314	3
826	Bioelectrical Impedance Vector Analysis for Nutritional Status Assessment in Systemic Sclerosis and Association With Disease Characteristics. 2021 , 48, 728-734	0
825	Myocardial T1 mapping and extracellular volume quantification as novel biomarkers in risk stratification of patients with systemic sclerosis. 2021 , 76, 162.e1-162.e8	5
824	[Monocentric study on pharmaceuticals taken by patients to treat systemic sclerosis]. 2021 , 42, 86-92	
823	Renal resistive index in IgA nephropathy and renal scleroderma vasculopathy. 2021 , 133, 104095	3
822	Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. 2021 , 73, 315-323	7
821	Worsening of esophageal dilatation is associated with increase in a high-resolution computed tomography (HRCT) score in early systemic sclerosis-associated interstitial lung disease (SSc-ILD). 2021 , 40, 955-963	1
820	Is exposure to environmental factors associated with a characteristic clinical and laboratory profile in systemic sclerosis? A retrospective analysis. 2021 , 41, 1143-1150	1
819	Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests. 2021 , 40, 213-219	2
818	Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Health-Related Quality of Life. 2021 , 73, 305-314	2
817	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. 2021 , 73, 295-304	10
816	Nailfold videocapillaroscopy: a novel possible surrogate marker for the evaluation of peripheral microangiopathy in pulmonary arterial hypertension. 2021 , 50, 85-94	4
815	Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis. 2021 , 159, 781-790	3
814	Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis. 2021 , 60, 929-939	0
813	The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). 2021 , 60, 872-880	0
812	Cultural adaptation and validation of the Systemic Sclerosis Quality of Life questionnaire into Arabic language. 2021 , 40, 1409-1416	0

811	Scleroderma-associated cutaneous calcinosis: a remarkable regression post stem cell transplantation. 2021 , 40, 789-790	1
810	A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis. 2021 , 29, 81-89	10
809	Reliability, Validity, and Sensitivity to Change of the Cochin Hand Functional Disability Scale and Testing the New 6-Item Cochin Hand Functional Disability Scale in Systemic Sclerosis. 2021 , 27, 102-106	1
808	A case of pulmonary arterial hypertension complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis and systemic sclerosis. 2021 , 1-7	1
807	Non-Invasive Assessment of Endothelial Dysfunction in Pulmonary Arterial Hypertension. 2021 , 32, 6-14	1
806	Does sublingual microscopy correlate with nailfold videocapillaroscopy in systemic sclerosis?. 2021 , 40, 2263-2266	2
805	Quantitative nailfold capillaroscopy-update and possible next steps. 2021 , 60, 2054-2065	4
804	Interstitial lung disease pathology in systemic sclerosis. 2021 , 13, 1759720X211032437	1
803	Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiology in patients with systemic sclerosis. 2021 ,	0
802	Nailfold capillaroscopy in systemic diseases: short overview for internal medicine. 2021 , 59, 201-217	0
801	Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases. 2021 , 10,	
800	TGFB1 Induced Cross-Linking of the Extracellular Matrix of Primary Human Dermal Fibroblasts. 2021 , 22,	2
799	Autologous fat grafting in the treatment of a scleroderma stump-skin ulcer: a case report. 2021 , 8, 18-22	1
798	Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts. 2021 , 15, 71-80	7
797	Scleroderma epidemiology update. 2021 , 33, 122-127	5
796	Helicobacter pylori and Upper Endoscopy in Systemic Sclerosis: A Cross-sectional Study in the Real World. 2021 , 27, 40-41	
795	Essential Hypertension Worsens Left Ventricular Contractility in Systemic Sclerosis. 2021 , 48, 1299-1306	1
794	Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications. 2021 , 313, 783-791	2

793	Systemic sclerosis sine scleroderma in children. 2021 ,	2
792	Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506. 2021 , 35, 2058738421998086	0
791	A mixed method study exploring patient satisfaction and feasibility of two exercise programmes in systemic sclerosis-associated microstomia. 2021 , 5, rkab017	1
790	Practical screening tools for sarcopenia in patients with systemic sclerosis. 2021 , 16, e0245683	5
789	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. 2021 , 11, 1	2785
788	. 2021 , 9, 80275-80287	
787	Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. 2021 , 40, 2779-2789	2
786	Prevalence of retinal changes in patients with systemic sclerosis: the association between retinal vascular changes and nailfold capillaroscopic findings. 2021 , 59, 27-34	0
785	Evaluation of the optic nerve head vessel density in patients with limited scleroderma. 2021 , 13, 2515841421995387	
784	Association between core stability and physical function, functional performance in patients with systemic sclerosis. 2021 , 24, 548-554	
783	Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. 2021 , 60, 3646-3655	3
782	Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR). 2021 , 5, rkab027	1
781	Gastrointestinal Manifestations of Non-GI Disorders. 2021 , 2117-2166	
780	Acute exacerbation in interstitial lung disease. 2021 , 16, 178-187	1
779	Postural balance and fall risk in patients with systemic sclerosis: A cross-sectional study. 2021 , 36, 167-175	0
778	Distinct MR features in scleroderma associated myopathy. 2021 , 126, 707-716	1
777	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. 2021 , 60, 5028-5041	8
776	Identification of Autoimmunity to Peptides of Collagen V α 1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis. 2020 , 11, 604602	3

775	Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis. 2021 , 36, 1504-1514	1
774	Prevalence and clinical association with calcinosis cutis in early systemic sclerosis. 2021 , 31, 1113-1119	1
773	Evaluation of limited hand mobility in systemic sclerosis patients by using "prayer sign" and "tabletop sign". 2021 , 40, 2771-2777	0
772	Comparison of Clinical Characteristics and Outcomes between Idiopathic and Secondary Pleuroparenchymal Fibroelastosis. 2021 , 10,	1
771	Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens. 2021 , 50, 307-313	3
770	Durometry in SSc: The hard facts. A systematic literature review and additional pilot study. 2021 , 60, 2099-2108	0
769	Barriers and facilitators to physical activity for people with scleroderma: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. 2021 ,	0
768	Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. 2021 , 61, 15	7
767	Capillaroscopy as a diagnostic tool in the diagnosis of mixed connective tissue disease (MCTD): a case report. 2021 , 5, 9	1
766	Interstitial lung disease in systemic sclerosis (systemic scleroderma). 2021 , 15, 1-62	2
765	Immunosuppression use in early systemic sclerosis may be increasing over time.. 2022 , 7, 33-41	
764	Circulating Plasma microRNAs In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. 2021 ,	2
763	Anti-RNPC-3 antibody predicts poor prognosis in patients with Interstitial Lung Disease associated to Systemic Sclerosis. 2021 ,	3
762	Novel case of a scleroderma-mimicking syndrome associated with gastrointestinal stromal tumour. 2021 , 14,	1
761	B cells in systemic sclerosis: from pathophysiology to treatment. 2021 , 40, 2621-2631	1
760	Increased malignancies in our Waikato cohort of patients with systemic sclerosis. 2021 , 24, 555-561	1
759	Successful Pregnancy Outcome With Connective Tissue Disease-Associated Interstitial Lung Disease: A Case Series. 2021 , 28,	1
758	Poor maternal and foetal outcomes in women with systemic sclerosis: an interview-based study at a tertiary centre. 2021 , 41, 1133-1142	3

757	Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis. 2021 , 24, 711-718	4
756	Surgical Debulking for Symptomatic Management of Calcinosis Cutis of the Hand and Upper Extremity in Systemic Sclerosis. 2021 , 46, 928.e1-928.e9	1
755	F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. 2021 , 23, 76	9
754	Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in expanded international cohort. www.juvenile-scleroderma.com . 2021 ,	4
753	Systemic sclerosis is associated with lower limb vascular stiffness and microvascular impairment: results from a prospective study. 2021 , 40, 3679-3686	1
752	Retinal microcirculation abnormalities in patients with systemic sclerosis: an explorative optical coherence tomography angiography study. 2021 , 60, 5827-5832	10
751	Anti-tRNA synthetase syndrome interstitial lung disease: A single center experience.	
750	Interstitial Lung Disease Worsens Short- and Long-Term Outcomes of Systemic Rheumatic Disease Patients Admitted to the ICU: A Multicenter Study. 2021 , 10,	0
749	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. 2021 , 3, e175-e184	3
748	C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. 2021 , 1-8	
747	Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients. 2021 , 50, 469-474	3
746	Esclerosis sist^ mica. 2021 , 13, 1769-1778	
745	Nail is Systemic Disorders: Main Signs and Clues. 2021 , 39, 153-173	2
744	Review of the Current Medical and Surgical Treatment Options for Microstomia in Patients With Scleroderma. 2021 , 47, 780-784	0
743	Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis. 2021 , 23, 100	1
742	Autologous stem cell transplantation in scleroderma. 2021 , 50, 104065	2
741	Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A.	
740	Esophagus involvement in systemic sclerosis: ultrasound parameters and association with clinical manifestations. 2021 , 23, 122	0

739	Fatigue and its relationship with disease-related factors in patients with systemic sclerosis: A cross-sectional study. 2021 , 51, 530-539	2
738	Breathomics to diagnose systemic sclerosis using thermal desorption and comprehensive two-dimensional gas chromatography high-resolution time-of-flight mass spectrometry. 2021 , 413, 3813-3822 ¹	
737	Systemic sclerosis in a patient with turner syndrome: A case report and a review of associated autoimmune diseases. 2021 ,	
736	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. 2021 , 10,	6
735	Molecular mapping of interstitial lung disease reveals a phenotypically distinct senescent basal epithelial cell population. 2021 , 6,	11
734	Digital Ulcers in Systemic Sclerosis. 2021 , 50, 104064	7
733	[Polyarthritis - From symptoms to diagnosis]. 2021 , 146, 582-590	1
732	Anti-PM/Scl Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement. 2021 , 60, 1101-1107	0
731	Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis. 2021 , 37, 2137-2147	3
730	Identification of key genes and immune profile in limited cutaneous systemic sclerosis-associated pulmonary arterial hypertension by bioinformatics analysis. 2021 , 271, 119151	1
729	Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis. 2021 , 21, 174	2
728	Metabolic syndrome and adipokine levels in systemic lupus erythematosus and systemic sclerosis. 2021 , 40, 4253-4258	1
727	Convolutional Neural Networks for Differential Diagnosis of Raynaud's Phenomenon Based on Hands Thermal Patterns. 2021 , 11, 3614	6
726	Fibrosing arthropathy in juvenile scleroderma. 2021 , 15, 64-68	
725	Pregnancy-associated risk factors and incidence of systemic sclerosis in primiparous women: A nationwide population-based cohort study. 2021 , 1-6	1
724	Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests. 2021 , 54, 148-155	6
723	Flow cytometry evaluation of CD14/CD16 monocyte subpopulations in systemic sclerosis patients: a cross sectional controlled study. 2021 , 61, 27	2
722	Dysfunctional Keratinocytes Increase Dermal Inflammation in Systemic Sclerosis: Results From Studies Using Tissue-Engineered Scleroderma Epidermis. 2021 , 73, 1311-1317	6

721	Expression Quantitative Trait Locus Analysis in Systemic Sclerosis Identifies New Candidate Genes Associated With Multiple Aspects of Disease Pathology. 2021 , 73, 1288-1300	3
720	Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination. 2021 , 11, 10431	0
719	Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers. 2021 , 11, 10679	1
718	Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond. 2021 , 12, 679613	5
717	Identifying the most influential gene expression profile in distinguishing ANCA-associated vasculitis from healthy controls. 2021 , 119, 102617	1
716	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. 2021 , 73, 2338-2347	0
715	Nailfold videocapillaroscopic changes in patients with pulmonary arterial hypertension associated with connective tissue diseases. 2021 , 41, 1289-1298	1
714	Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists. 2021 , 36, 515-526	0
713	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. 2021 , 48, 1698-1717	2
712	Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. 2021 ,	1
711	Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. 2021 , 73, 1301-1310	37
710	Anti-tRNA synthetase syndrome interstitial lung disease: A single center experience. 2021 , 106432	0
709	HIGH FREQUENCY ULTRASONOGRAPHY: RELIABLE TOOL TO MEASURE SKIN FIBROSIS IN SSC? A systematic literature review and additional pilot study. 2021 ,	0
708	Identifying potential classification criteria for calcium pyrophosphate deposition disease (CPPD): Item generation and item reduction. 2021 ,	5
707	The Efficacy of a Home-Based, Self-Administered Hand Exercise Program for Patients With Systemic Sclerosis: A Randomized Controlled, Evaluator-Blind, Clinical Trial. 2021 ,	0
706	Prediction and primary prevention of major vascular complications in systemic sclerosis. 2021 , 87, 51-58	2
705	The Autoantigen Repertoire and the Microbial RNP World. 2021 , 27, 422-435	0
704	At one's fingertips: can you nail the diagnosis?. 2021 ,	

703	An in vivo confocal microscopy study of corneal changes in patients with systemic sclerosis. 2021 , 11, 11111	1
702	Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. 2021 , 184, 3006-3021.e17	28
701	Genetic variants in are related to lower galectin-3 serum levels and clinical outcomes in systemic sclerosis patients: A case-control study. 2021 , 54, 187-194	0
700	A preliminary study of possible fibrotic role of meprin metalloproteases in scleroderma patients.. 2021 , 36, 510-517	
699	Study the Relationship of MDCT Staging in Disease Extent with the Systemic Sclerosis Disease Parameters. 2021 ,	
698	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. 2021 , 23, 170	4
697	Human mesenchymal stem cells for the management of systemic sclerosis. Systematic review. 2021 , 20, 102831	4
696	Clinical characteristics and survival of patients with three major connective tissue diseases associated with pulmonary hypertension: A study from China. 2021 , 22, 925	2
695	Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients.. 2021 , 6, 256-263	
694	Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. 2021 , 51, 495-512	3
693	Quantification of Antifibrillar (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis. 2021 , 11,	1
692	Increased risk of end-stage renal disease in patients with systemic sclerosis. 2021 , 1-8	1
691	Gut Microbiota And Inflammatory Disorders. 2021 ,	
690	Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings. 2021 , 23, 175	1
689	Rheumatological evaluation of patients with interstitial lung disease. 2021 , 1-8	2
688	Comparison of antinuclear antibody profiles obtained using line immunoassay and fluorescence enzyme immunoassay. 2021 , 49, 3000605211014390	
687	Transfer of PBMC From SSc Patients Induces Autoantibodies and Systemic Inflammation in Rag2-/-/IL2rg-/- Mice. 2021 , 12, 677970	1
686	Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.. 2022 , 7, 57-61	0

685	Interstitial pneumonia with autoimmune features: from research classification to diagnosis. 2021 , 27, 374-387	0
684	H FPEF score predicts atherosclerosis presence in patients with systemic connective tissue disease. 2021 , 44, 946-954	2
683	Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. 2021 , 11,	0
682	Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis. 2021 , 2021, 5523582	0
681	Esophageal Dilatation as a Predictor of Systemic Sclerosis in Patients with Interstitial Lung Disease.. 2021 , 22, 231-236	0
680	Successful Prepectoral Breast Reconstruction in a Patient With Systemic Sclerosis. 2021 , 13, e15996	
679	Prevalence and prognostic significance of heart failure with preserved ejection fraction in systemic sclerosis. 2022 , 18, 17-25	0
678	Comparison of hyaluronic acid in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. 2021 , 31, 020701	
677	The emerging challenge of pain in systemic sclerosis: Similarity to the pain experience reported by Sjögren's syndrome patients. 2021 , 2, 113-119	
676	Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. 2021 , 31, 020502	0
675	Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France.. 2022 , 7, 49-56	0
674	Intravenous prostanoids in systemic sclerosis-associated pulmonary arterial hypertension: a single centre experience. 2021 ,	1
673	French recommendations for the management of systemic sclerosis. 2021 , 16, 322	3
672	Wound Image Quality From a Mobile Health Tool for Home-Based Chronic Wound Management With Real-Time Quality Feedback: Randomized Feasibility Study. 2021 , 9, e26149	4
671	Physical therapy in systemic sclerosis: the patient perspective. 2021 ,	
670	Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis. 2021 , 48, 1830-1838	0
669	The prevalence and clinical features associated of hypothyroidism among Thai systemic sclerosis patients. 2021 , 11, 14902	0
668	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. 2021 , 40, 1251-1266	1

667	Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in Systemic Sclerosis. 2021 , 104, 63-73	1
666	Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients. 2021 , 9,	1
665	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. 2021 , 11, 20458940211029899	
664	Validity and reliability of the Swedish version of the Self-Efficacy for Managing Chronic Disease scale for individuals with systemic sclerosis. 2021 , 1-10	0
663	Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial. 2021 ,	0
662	Evaluation of the direct effects on retinal and choroidal microvasculature of systemic scleroderma. 2021 , 136, 104166	2
661	THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. 2021 ,	15
660	Management and support of patients with fibrosing interstitial lung diseases. 2021 , 46, 39-44	
659	Preliminary results on long-term follow-up of systemic sclerosis patients under extracorporeal photopheresis. 2021 , 1-4	2
658	Higher Ventricular-Arterial Coupling Derived from Three-Dimensional Echocardiography Is Associated with a Worse Clinical Outcome in Systemic Sclerosis. 2021 , 14,	0
657	Is axillary botulinum toxin efficient in controlling secondary Raynaud's phenomenon? A case report.. 2021 , 6, 327-329	
656	Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis. 2021 , 73, 1720-1730	3
655	Platelet phagocytosis via PSGL1 and accumulation of microparticles in systemic sclerosis. 2021 ,	2
654	Interval between symptom onset and diagnosis among patients with autoimmune rheumatic diseases in a multi-ethnic Asian population. 2021 , 24, 1061-1070	1
653	Role and effectiveness of complex and supervised rehabilitation on overall and hand function in systemic sclerosis patients-one-year follow-up study. 2021 , 11, 15174	3
652	A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases. 2021 , 73, 1550-1561	8
651	Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia. 2021 ,	2
650	Circulating CTRP9 is Associated with Severity of Systemic Sclerosis-associated Interstitial Lung Disease. 2021 ,	1

649	Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. 2021 , 73, 1731-1737	5
648	Evaluation of Prognostic Factors in Anti-MDA5 Antibody-Positive Patients in Chongqing, China: A Retrospective Study. 2021 , 14, 4775-4781	0
647	Brachio-cervical inflammatory myopathy associated with systemic sclerosis. Case series and review of literature. 2021 , 73, 122-130	0
646	[Characteristics of patients with connective tissue disease-associated pulmonary arterial hypertension treated with prostanoids: A multicenter retrospective study]. 2021 , 42, 825-831	
645	Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening. 2021 , 13, e17291	
644	Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience. 2021 ,	1
643	Early-stage symptomatic osteoarthritis of the knee - time for action. 2021 , 17, 621-632	11
642	Polyautoimmunity Clusters as a New Taxonomy of Autoimmune Diseases.	0
641	Scleroderma specific autoantibodies and MS-like manifestations: A novel association?. 2021 , 20, 102871	
640	Development and validation of a patient-reported outcome in systemic sclerosis: the Hand scleroDerma lived Experience (HANDE) scale. 2021 ,	2
639	Bone morphogenetic protein-7 inhibits endothelial-to-mesenchymal transition in primary human umbilical vein endothelial cells and mouse model of systemic sclerosis via Akt/mTOR/p70S6K pathway. 2021 , 103, 82-92	
638	Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis. 2021 , 1-7	3
637	Usefulness of high-frequency ultrasonography in the evaluation and monitoring of sclerosing dermatoses: a cohort study. 2021 ,	1
636	CD19 + CD21 cells are increased in systemic sclerosis-associated interstitial lung disease. 2021 , 1	1
635	Serum resistin is predictive marker of development of new digital ulcers in systemic sclerosis. 2021 , 1	1
634	Body mass index and adipokines/cytokines dysregulation in systemic sclerosis. 2021 , 206, 153-160	2
633	Nailfold Capillaroscopy With USB Digital Microscopy in Connective Tissue Diseases: A Comparative Study of 245 Patients and Healthy Controls. 2021 , 8, 683900	3
632	Pulmonary function tests in systemic sclerosis-associated interstitial lung disease: new directions and future prospects. 2021 , 22, 100442	0

- 631 Slow colonic transit in systemic sclerosis: an objective assessment of risk factors and clinical phenotype. **2021**, 0
- 630 Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A. **2021**, 218, 8
- 629 Systemic Sclerosis and the Liver. **2021**, 18, 76-80 1
- 628 Ulcerative Lupus Erythematosus Profundus in a Patient With Limited Cutaneous Systemic Sclerosis. **2021**, 112, 767-767
- 627 A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. **2021**, 1 1
- 626 Thymic Carcinoma With Multiple Paraneoplastic Disorders. **2021**, 362, 324-330 1
- 625 Botulinum toxin in the management of primary and secondary Raynaud's phenomenon. **2021**, 35, 101684 0
- 624 Cardiac calcium score in systemic sclerosis. **2021**, 1 0
- 623 Factors associated with the antinuclear antibody (ANA) titer of systemic autoimmune rheumatic diseases in ANA-positive patients after treatment: a retrospective study. **2021**, 1 0
- 622 Short- and long-term prognosis of acute critically ill patients with systemic rheumatic diseases: A retrospective multicentre study. **2021**, 100, e26164 0
- 621 Renal Function in Patients With Systemic Sclerosis: Do We Estimate It Correctly?. **2021**,
- 620 B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. **2021**, 73, 2086-2095 2
- 619 The prognostic value of the COPD Assessment Test in fibrotic interstitial lung disease. **2021**,
- 618 Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients. **2021**, 11, 18011
- 617 Skin manifestations associated with systemic diseases - Part I. **2021**, 96, 655-671 2
- 616 Association of cytochrome P2D6 gene polymorphism with the susceptibility of Egyptian patients to systemic sclerosis disease. **2021**, 29, 100926
- 615 Ulcerative Lupus Erythematosus Profundus in a Patient With Limited Cutaneous Systemic Sclerosis. **2021**, 112, 767-767
- 614 Pain and Self-Efficacy Among Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. **2021**, 70, 334-343 2

613	Multimodality imaging of the gastrointestinal manifestations of scleroderma. 2021 , 76, 640-649	1
612	Adult onset Still's disease in a patient with scleroderma: case report. 2021 , 5, 44	1
611	Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2 α . 2021 ,	1
610	Association between clinical phenotypes of dermatomyositis and polymyositis with myositis-specific antibodies and overlap systemic autoimmune diseases. 2021 , 100, e27230	0
609	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. 2021 , 1	2
608	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score. 2021 ,	5
607	Interstitial Lung Disease in Systemic Sclerosis: A Single-Center Retrospective Analysis. 2021 ,	
606	Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements. 2021 , 11, 20458940211032529	1
605	Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. 2021 , 11,	0
604	Development of Lupus Erythematosus Tumidus During the Course of Systemic Sclerosis. 2021 , 13, e18064	
603	Value of nail fold video capillaroscopy and carotid intima media thickness in assessment of micro and macro-vascular disease in systemic sclerosis patients. 2021 , 43, 275-280	1
602	Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. 2021 , 187, 106579	2
601	Bone mineral density and trabecular bone score assessment in systemic sclerosis: A cross-sectional study. 2021 , 88, 105214	2
600	SCLERODERMA AND MALIGNANCY.	
599	Systemic Sclerosis and Pulmonary Disease. 2021 , 1303, 173-182	0
598	Disease progression in systemic sclerosis. 2021 , 60, 1565-1567	1
597	The aetiopathogenic significance, clinical relevance and therapeutic implications of vasculopathy in idiopathic inflammatory myopathy. 2021 , 60, 1593-1607	2
596	Peripheral microangiopathy in precapillary pulmonary hypertension: a nailfold video capillaroscopy prospective study. 2021 , 22, 27	8

595	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. 2021 , 23, 10	4
594	Implication of miR-126 and miR-139-5p in Plasmacytoid Dendritic Cell Dysregulation in Systemic Sclerosis. 2021 , 10,	9
593	Serum Calponin 3 Levels in Patients with Systemic Sclerosis: Possible Association with Skin Sclerosis and Arthralgia. 2021 , 10,	0
592	Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort. 2021 , 41, 551-563	4
591	Photoacoustic and high-frequency ultrasound imaging of systemic sclerosis patients. 2021 , 23, 22	4
590	Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. 2021 , 13, 1759720X211032457	4
589	Wound Image Quality From a Mobile Health Tool for Home-Based Chronic Wound Management With Real-Time Quality Feedback: Randomized Feasibility Study (Preprint).	
588	Funktionsstörungen des Ösophagus bei Sklerodermie und neuromuskulären Erkrankungen. 2021 , 15-17	
587	CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. 2017 , 69, 1871-1878	43
586	Pathology of Systemic Sclerosis. 2017 , 141-159	1
585	Disease Subsets in Clinical Practice. 2017 , 39-48	4
584	Evolving Concepts of Diagnosis and Classification. 2017 , 49-64	1
583	Nailfold videocapillaroscopy results in patients with rheumatoid arthritis. 2017 , 36, 1969-1974	12
582	Body composition and bone status in relation to microvascular damage in systemic sclerosis patients. 2021 , 44, 255-264	3
581	The profiles of miRNAs and lncRNAs in peripheral blood neutrophils exosomes of diffuse cutaneous systemic sclerosis. 2020 , 98, 88-97	10
580	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. 2020 , 135, 110132	13
579	State-of-the-art technologies provide new insights linking skin and blood vessel abnormalities in SSc-related disorders. 2020 , 130, 104006	5
578	Increased expression of the transforming growth factor Inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target. 2020 , 59, 3092-3098	5

577	Role of placental inflammatory mediators and growth factors in patients with rheumatic diseases with a focus on systemic sclerosis. 2021 , 60, 3307-3316	3
576	Association between gene expression profiling of skin lesion and autoantibody in patients with systemic sclerosis.	1
575	Inflammatory profile of induced sputum composition in systemic sclerosis: a comparison with healthy volunteers.	1
574	Machine Learning of the Cardiac Phenome and Skin Transcriptome to Categorize Heart Disease in Systemic Sclerosis.	1
573	Mortality in the Waikato Hospital Systemic Sclerosis Cohort. 2018 , 21, 253-260	6
572	The impact of skin calcinosis on digital ulcers in patients with SSc: clinical and prognostic stratification using the "wound bed score". 2020 , 17, 1783-1790	2
571	Systemic sclerosis in sub-Saharan Africa: a systematic review. 2020 , 37, 176	2
570	TGF- β -induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. 2020 , 130, 2347-2363	24
569	Improving sensitivity of the connective tissue disease screening questionnaire: A comparative study of various scoring methods. 2021 , 30, 35-44	1
568	Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease. 2020 , 6,	3
567	Relation of Warrick Score and Polysomnographic Parameters in Patients with Interstitial Lung Disease. 2019 , 25, 2087-2095	2
566	Acute Heart Failure in Scleroderma Renal Crisis: A Case Study for Review of Cardiac Disease in Systemic Sclerosis. 2020 , 8, 1-7	3
565	Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. 2014 , 9, e93812	50
564	An assessment of the measurement equivalence of English and French versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in systemic sclerosis. 2014 , 9, e102897	9
563	Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. 2015 , 10, e0126707	66
562	Evaluation of Peripheral Blood Circulation Disorder in Scleroderma Patients Using an Optical Sensor with a Pressurization Mechanism. 2016 , 11, e0159611	2
561	Evaluation of an automated connective tissue disease screening assay in Korean patients with systemic rheumatic diseases. 2017 , 12, e0173597	6
560	Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial. 2020 , 15, e0232739	18

559	CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features. 2020 , 15, e0241719	9
558	Early myocardial damage and microvascular dysfunction in asymptomatic patients with systemic sclerosis: A cardiovascular magnetic resonance study with cold pressor test. 2020 , 15, e0244282	5
557	PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC CONNECTIVE TISSUE DISEASES: THE CURRENT STATE OF THE PROBLEM. 2018 , 56, 474-485	3
556	The role of autoantibodies in the early diagnosis of systemic immunoinflammatory rheumatic diseases. 2019 , 13, 5-10	4
555	A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases. 2021 , 59, 547-561	7
554	B-type Natriuretic Peptide as a Marker of Different Forms of Systemic Sclerosis. 2018 , 37, 406-414	4
553	Esophageal manometry in systemic sclerosis: findings and association with clinical manifestations. 2020 , 66, 48-54	3
552	[Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis]. 2015 , 87, 49-56	1
551	SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. 2016 , 7, 69321-69336	66
550	Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova). 2019 , 86-91	7
549	Effects of N-acetylcysteine on Pulmonary Functions in Patients with Systemic Sclerosis: A Randomized Double Blind, Placebo Controlled Study. 2020 , 16, 149-157	2
548	Evaluation of Autoantibodies in Patients with Primary and Secondary Sjogren's Syndrome. 2017 , 11, 10-15	14
547	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. 2020 , 9, e16799	3
546	Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort Study. 2020 , 9, e23532	4
545	Biomicroscopy of the bulbar conjunctiva: the possibilities of the method in assessing microcirculatory disorders in systemic sclerosis. 2020 , 19, 43-50	1
544	Demographic and clinical differences between idiopathic and scleroderma-related pulmonary arterial hypertension: Russian National Registry analysis. 2016 , 13, 65-72	1
543	Peripheral Microangiopathy in Patients with Precapillary Pulmonary Hypertension: Correlation with Cardiac Function and Patients' Functional Capacity. Study Design and Rationale. 2020 , 31, 369-373	5
542	Quantitative dynamic contrast-enhanced ultrasound for the functional evaluation of the skeletal muscle microcirculation in systemic sclerosis. 2016 , 62, 35-44	8

541	Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. 2020 , 9,	7
540	BIOMARKERS OF DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS. 2020 , 73, 2300-2305	0
539	Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis. 2020 , 47, 1668-1677	4
538	Methods for the morphological and functional evaluation of microvascular damage in systemic sclerosis. 2015 , 30, 1-5	11
537	Updated Classification Criteria for Systemic Sclerosis: the Concept of Early Diagnosis. 2014 , 87, 395	3
536	Systemic Sclerosis and Pleural Effusion in a Patient with Ankylosing Spondylitis. 2018 , 93, 492-496	1
535	Changes in peripheral CD19(+)Foxp3(+) and CD19(+)TGFβ(+) regulatory B cell populations in rheumatoid arthritis patients with interstitial lung disease. 2015 , 7, 471-7	29
534	Short-Term Lung Function Changes and Predictors of Progressive Systemic Sclerosis-Related Interstitial Lung Disease. 2020 , 83, 312-320	2
533	Active subcutaneous calcinosis demonstrated by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in a case of limited cutaneous systemic sclerosis. 2016 , 31, 154-5	3
532	Rituximab treatment in patients with systemic sclerosis and interstitial lung disease. 2017 , 12, 294-297	10
531	Predictors of mortality in interstitial lung disease patients without pulmonary hypertension. 2020 , 15, 238-243	2
530	Systemic Diseases in Dakar (Senegal): Spectrum, Epidemiological Aspect and Diagnostic Time-Limit. 2018 , 08, 196-206	5
529	Anti-RNA Polymerase III Antibodies in Systemic Sclerosis. 2015 , 05, 81-86	1
528	Pattern of Nailfold Capillaroscopy in Patients With Systemic Lupus Erythematosus. 2020 , 35, 568-574	2
527	Rheumatological Findings in Patients with Breast Cancer. 2020 , 16, 55-60	3
526	Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. 2016 , 3, 95-100	10
525	New perspectives in the imaging of Raynaud's phenomenon. 2020 , 7, S212-S221	9
524	Paul Klee's illness as a series of historical and clinical vignettes. 2017 , 2, 135-136	3

523	Treg/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients. 2017 , 7, 84-96	17
522	The Prevalence of Autoimmune Disorders in Women: A Narrative Review. 2020 , 12, e8094	38
521	Pulmonary Manifestations in Systemic Sclerosis: Hospital-Based Descriptive Study. 2020 , 12, e8649	1
520	Interstitial Lung Disease in Systemic Scleroderma, Complicated with Bilateral Pulmonary Aspergilloma: An Unusual Association. 2015 , 9, OD11-3	1
519	Systemic Sclerosis with Multiple Pulmonary Manifestations. 2016 , 10, OD16-7	3
518	Expression of macrophage migration inhibitory factor and its receptor CD74 in systemic sclerosis. 2021 , 46, 375-383	0
517	Significant U1snRNP Positivity in 3 Cases of Overlap Syndrome: A Diagnostic Dilemma.. 2022 , 7, 342-349	
516	Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease in Brazil: A Real-Life, Long-Term Follow-up Observational Study. 2021 , 28,	0
515	Detection of microvascular changes in systemic sclerosis and other rheumatic diseases. 2021 , 17, 665-677	9
514	Comparison study of bead-based and line-blot multiplex ANA immunoassays in the diagnosis of systemic autoimmune rheumatic diseases. 2021 , 1	0
513	Spontaneous improvement of interstitial pneumonia with autoimmune features: A case report. 2021 , 9, e0867	
512	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. 2022 , 7, 24-32	5
511	Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis. 2021 ,	2
510	Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?. 2021 , 23, 259	0
509	Lymphocyte subsets in the peripheral blood are disturbed in systemic sclerosis patients and can be changed by immunosuppressive medication. 2021 , 1	0
508	Infections of scleroderma digital ulcers: A single center cohort retrospective study.. 2021 , 13, 9075	0
507	ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases. 2021 , 8,	2
506	Prognostic impact of HNF4B expression in interstitial lung disease. 2021 ,	0

505	Cardiovascular Manifestations of Systemic Sclerosis: An Overview of Pathophysiology, Screening Modalities, and Treatment Options. 2021 ,	0
504	Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. 2021 ,	3
503	A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. 2021 ,	0
502	Identification of a Novel Serological Marker in Seronegative Rheumatoid Arthritis Using the Peptide Library Approach. 2021 , 12, 753400	1
501	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. 2021 , 61, 60	4
500	Management of patients with fibrosing interstitial lung diseases. 2021 ,	0
499	Raynaud Phenomenon and Other Vasospastic Disorders. 2021 , 39, 583-599	2
498	Evaluation of keratin 1 gene expression and its single nucleotide polymorphism (rs14024) in systemic sclerosis patients. 2021 , 25, 101404	
497	Primary Raynaud's Phenomenon. 2015 , 81-93	
496	Systemic Sclerosis. 2015 , 949-955	
495	[A case report of bilateral trigeminal sensory neuropathy as one of the initial manifestation of systemic scleroderma (the difficulties of early diagnosis of the primary disease)]. 2015 , 115, 59-63	1
494	[Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux]. 2015 , 87, 42-47	1
493	Rheumatoid Arthritis and Related Disorders. 2015 , 1-20	
492	Scleroderma: Not an orphan disease any more. 2015 , 5, 131	
491	Characteristics and Therapy for Peripheral Vasculopathy in Systemic Sclerosis. 2016 , 78, 343-346	
490	Immunodiagnosis of Scleroderma. 888-896	
489	The Clinical Efficacy of Nailfold Capillaroscopy in Rheumatic Diseases. 2016 , 90, 494-500	2
488	Rheumatoid Arthritis and Related Disorders. 2017 , 1525-1543	

- 487 Critical Ischemia in Patients with Raynaud's Phenomenon. **2017**, 257-266
- 486 Historical Perspective of Scleroderma. **2017**, 3-7
- 485 Overlap Syndromes. **2017**, 65-74
- 484 Innovative Approaches to Clinical Trials in Systemic Sclerosis. **2017**, 649-656
- 483 Raynaud's Phenomenon, Digital Ulcers and Nailfold Capillaroscopy. **2017**, 297-316
- 482 Clinical Trial Design in Systemic Sclerosis. **2017**, 623-635
- 481 Vascular Lung Diseases. **2017**, 251-273
- 480 Evaluation of Left Ventricular Diastolic Function by Echocardiography with Tissue Doppler in Systemic Sclerosis. **2017**, 109, 410-415 3
- 479 Kollagenosen. **2017**, 75-96
- 478 A case of limited cutaneous systemic sclerosis (sine scleroderma) combined with scleroderma renal crisis that necessitated the initiation of maintenance hemodialysis. **2017**, 50, 207-212 1
- 477 Interstitial Lung Disease-Associated Pulmonary Hypertension in the Connective Tissue Disorders. **2017**, 165-180
- 476 Epigenetics of Systemic Sclerosis. **2017**, 1-24
- 475 Personality and Psychopathology in Patients with Systemic Sclerosis. **2017**, 10, 41-48
- 474 Semi-quantification image methods for assessing severity of scleroderma-associated interstitial lung disease according to computed tomography data. **2017**, 27, 41-50 4
- 473 Rheumatology and Neurology. **2017**, 23, 691-721
- 472 Systemic Sclerosis. **2018**, 367-370
- 471 Literatur. **2018**, 159-162 1
- 470 Femoral cartilage thickness in patients with systemic sclerosis: Its relation to vitamin D. 006-012

- 469 Sistemik Skleroderma Hastalarında Periferik Kan T Regulatoruvar H⁺ İreleri Ve T Helper 17 H⁺ İrelerinin Değerlendirilmesi. **2018**, 40, 28-33
- 468 7. Practical Use of Autoantibody Testing in Connective Tissue Diseases. **2018**, 107, 470-475
- 467 A STUDY OF PLEURO-PULMONARY MANIFESTATIONS IN SYSTEMIC SCLEROSIS - HOSPITAL BASED OBSERVATIONAL STUDY. **2018**, 5, 1719-1723
- 466 Sublingual microcirculatory alterations in patients with stable systemic sclerosis. **2018**, 25, 257-260 1
- 465 Tumoral Calcinosis of the Neck in a Patient with Systemic Sclerosis. **2018**, 10, e3585 1
- 464 Electrocardiographic Findings in Systemic Sclerosis. **2018**,
- 463 Subclinical biventricular systolic dysfunction in patients with systemic sclerosis. **2019**, 6, 89-93 0
- 462 Clinical significance of interleukin 27 serum concentration in patients with systemic sclerosis: relation to clinical, laboratory and radiological parameters. **2019**, 46, 101-107 0
- 461 CLINICAL AND LABORATORY FEATURES OF ANTICENTROMERE ANTIBODY-POSITIVE SJ⁺ GREN^B SYNDROME. **2019**, 57, 431-439 1
- 460 The relationship between global longitudinal strain and pulmonary function tests in patients with scleroderma and normal ejection fraction and pulmonary artery pressure: a case-control study. **2020**, 36, 883-888 2
- 459 T⁺ İkiye Tersiyer bir merkezde sistemik skleroz hastalarında pulmoner hipertansiyon taraması kesitsel orjinal İlişki.
- 458 Resolving phenotypic and prognostic differences in interstitial lung disease related to systemic sclerosis by computed tomography-based radiomics.
- 457 Sleep Disturbance in Scleroderma. **2021**, 27, S242-S245 1
- 456 Systemic sclerosis: correlation between lung abnormalities on high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs). **2020**, 51, 1
- 455 Comparison of Mental Health Symptoms Prior to and During COVID-19 among Patients with Systemic Sclerosis from Four Countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study.
- 454 Association between coronary artery disease severity and videocapillaroscopic findings of nail fold capillary circulation.
- 453 Serum immunoglobulin a deficiency and autoimmune comorbidities: a cross-sectional study in 281 patients with systemic lupus erythematosus. **2020**, 66, 752-756
- 452 Concomitance of Elephantiasis Nostras Verrucosa and Systemic Sclerosis. **2020**, 27,

- 451 Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. **2021**, 11, 0
- 450 Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. **2021**, 23, 1
- 449 Nail-fold capillaroscopy for the dermatologists. **2021**, 1-14 0
- 448 Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. **2021**, 22, 282 1
- 447 The Connective Tissue Diseases **2022**, 357-420
- 446 Systemic sclerosis (scleroderma). **2020**, 4513-4532
- 445 Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. **2020**, 26, 1539-1547 3
- 444 Premature Onset Aortic Stenosis in Systemic Sclerosis: A Report of a Series of Cases. **2020**, 59, 3177-3181 0
- 443 Fenômeno de Raynaud, capilaroscopia y úlceras digitales como eventos centinela en la esclerosis sistémica. **2020**, 27, 170-174
- 442 A Patient with Finger Gangrene. **2020**, 20, 86-89
- 441 A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory Diseases Infected by SARS-CoV-2 (ReumaCoV-Brasil Registry): Protocol for a Prospective, Observational Study. **2020**, 9, e24357 4
- 440 Diagnosis of pulmonary arterial hypertension preceding the confirmation of systemic sclerosis in a patient with Raynaud's phenomenon. **2022**, 139, 104267
- 439 Gut microbiome in systemic sclerosis: a potential therapeutic target.. **2022**, 39, 101-109 1
- 438 Rheumatoid Arthritis and Related Disorders. **2020**, 1-20
- 437 Diffuse Systemic Sclerosis in a Patient with Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome: A Case Report. **2020**, 32, 69-73
- 436 Myocarditis in Systemic Immune-Mediated Diseases. **2020**, 195-221
- 435 Rheumatic Diseases. **2020**, 222-260
- 434 Auto-antibody evaluation in idiopathic interstitial pneumonia and worse survival of patients with Ro52/TRIM21 auto-antibody. **2020**, 67, 199-205 0

- 433 Sacroiliitis Detected by Magnetic Resonance Imaging in Patients With Systemic Sclerosis. **2020**, 35, 515-520
- 432 Damage index changes in patients with systemic sclerosis: a retrospective analysis over a five-year period. **2020**, 58, 42-47
- 431 Adult Hemophagocytic Lymphohistiocytosis in Sub-Saharan Area: A Retrospective Study of 26 cases. **2020**, 12, e7258 3
- 430 Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study. **2021**, 52, 151926-151926 1
- 429 Ultrasonographic characteristics of major salivary glands in anti-centromere antibody-positive primary Sjögren's syndrome. **2021**, 16, e0259519 0
- 428 Association of Race and Risk of Future Scleroderma Renal Crisis at Systemic Sclerosis Diagnosis. **2021**, 0
- 427 How do systemic sclerosis manifestations influence patients' lives? Results from a survey on patients and caregivers. **2021**, 37, 5-15 1
- 426 Scleroderma. **2022**, 311-337
- 425 Is There a Link Between Nailfold Videocapillaroscopy and Pulmonary Function Tests in Systemic Sclerosis Patients?: A 24-Month Follow-up Monocentric Study. **2021**, 28, 0
- 424 Capillary loss reflects disease activity and prognosis in patients with systemic sclerosis. **2020**, 20, 3438-3443 3
- 423 Effects of Bosentan in the Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: A Longitudinal, Multicenter, Uncontrolled Trial. **2021**, 27, e599-e601 0
- 422 Validity of endocan as a biomarker in systemic sclerosis: relation to pathogenesis and disease activity. **2020**, 47, 0
- 421 Raynaud-Phénomènes. **2020**, 07, 215-232 1
- 420 Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis. **2021**, 24, 260-267 1
- 419 Auto-antibody profile and clinical presentation of Vietnamese with systemic sclerosis. **2021**, 62, e301-e303 0
- 418 Treatment of Systemic Sclerosis Associated Interstitial Lung Disease. **2020**, 20, 56-64
- 417 Gastrointestinal Manifestations of Non-GI Disorders. **2021**, 1-51
- 416 Characteristics of clinical, laboratory, and immunological manifestations in patients with anticentromere antibody-associated Sjögren's disease. **2020**, 14, 50-59 0

415 Nailfold Capillaroscopy in Rheumatic Diseases.

414 Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis. **2016**, 6, 50-6 9

413 The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders. **2016**, 27, 122-9 6

412 Acute oral tetrahydrobiopterin administration ameliorates endothelial dysfunction in systemic sclerosis. **2017**, 35 Suppl 106, 167-172 5

411 Chronic Multiorgan Rare Disease: The Role of the Nurse Practitioner as a Leader of the Healthcare Team. **2017**, 32, 413-416 1

410 Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment. **2018**, 36 Suppl 113, 175-182 3

409 Bundle Branch Blocks and Fragmented QRS Complex in Iranian Patients with Systemic Sclerosis. **2019**, 14, 6-11

408 Non-invasive digital thermal monitoring and flow-mediated dilation in systemic sclerosis. **2019**, 37 Suppl 119, 97-101 5

407 Nailfold Capillaroscopy and Retinal Findings in Patients with Systemic Sclerosis: Is There An Association?. **2020**, 11, 382-386 1

406 Molecular "omic" signatures in systemic sclerosis. **2020**, 7, S173-S180 0

405 Imaging photoplethysmography and its applications. **2022**, 439-468

404 Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease. **2021**, 191, 106689

403 Structural abnormalities associated with glaucoma using swept-source optical coherence tomography in patients with systemic sclerosis. **2021**, 1

402 Diet in Scleroderma: Is There a Need for Intervention?. **2021**, 11, 0

401 Independent association between occupational exposure and decline of forced vital capacity in systemic sclerosis (SSc): a multicenter recruitment retrospective cohort study. **2021**, 0

400 Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. **2021**, 11, 4

399 Nuclear receptor subfamily 4A signaling as a key disease pathway of CD1c+ dendritic cell dysregulation in systemic sclerosis.

398 Autoimmune conditions in the World Trade Center general responder cohort: A nested case-control and standardized incidence ratio analysis. **2021**, 1

- 397 The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. **2021**, 22, 856 1
- 396 Gender-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study from the National Registry of the Italian Society Of Rheumatology. **2021**, 3
- 395 Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis. **2021**, 11, 0
- 394 Clinical application of mesenchymal stem cells in rheumatic diseases. **2021**, 12, 567 1
- 393 Functional Disability Among Systemic Sclerosis Patients: Relation to Disease Characteristics and Quality of Life Parameters. **2021**, 0
- 392 Audiological Involvement in Patients with Systemic Sclerosis. **2021**,
- 391 RNA-Seq analysis identifies novel roles for the primary cilia gene SPAG17 and the SOX9 locus non-coding RNAs in systemic sclerosis.
- 390 The contribution of LIGHT to the development of systemic sclerosis by modulating IL-6 and Th1 chemokine expression in dermal fibroblasts. **2021**, 1
- 389 Systemic sclerosis: what's in a name?. **2021**, 3, e820-e821
- 388 Is it really post-irradiation morphea or oleoma of the breast?-A case report and literature review.. **2021**, 10, 3424-3430
- 387 Nailfold capillaroscopy and retinal findings in patients with systemic sclerosis: Is there an association?. **2020**, 11, 382 3
- 386 Systemic Sclerosis. **2021**, 263-271
- 385 Female Sexual Dysfunction and Pelvic Floor Muscle Function Associated with Systemic Sclerosis: A Cross-Sectional Study.. **2022**, 19, 0
- 384 Tetrahydrobiopterin Administration Augments Exercise-Induced Hyperemia and Endothelial Function in Patients With Systemic Sclerosis.. **2021**, 8, 791689
- 383 Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.. **2022**, 24, 19 1
- 382 Osteopetrosis in a Patient of Systemic Sclerosis Sine Scleroderma: A Rare Association.. **2021**, 31, 1019-1022
- 381 Predictors of progression to systemic sclerosis: Analysis of Very Early Disease of Systemic Sclerosis (VEDOSS) in a large single cohort.. **2022**, 0
- 380 Definition and application of proximal-distal gradient finger perfusion in systemic sclerosis by laser speckle contrast analysis.. **2021**, 104307 0

- 379 Early Diagnosis of Systemic Sclerosis by Skin Ultrasonography. **2020**, 27,
- 378 Interstitial pneumonia with autoimmune features. **2020**, 50, 247-255
- 377 Molecular Biomarkers Signatures in systemic sclerosis. **2020**, 7, 173-180 1
- 376 Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis.. **2021**, 32, 345-349 1
- 375 Clinical Impact of the ABO Blood Type in Patients with Rheumatic Diseases: Is there a Link to the ABO and Rhesus?. **2021**, 32, 237-242 1
- 374 Juvenile systemic sclerosis - observations of one clinical centre.. **2021**, 59, 367-372 1
- 373 Epidemiological characteristics and outcomes of SARS-CoV-2 infection in patients with rheumatic diseases: first report from the Argentine SAR-COVID registry. **2021**, 7-15
- 372 The Correlation between Helicobacter Pylori Infection and Disease Severity in Patients with Systemic Sclerosis. **2021**, 13, 253-258
- 371 Capillaroscopic findings and clinical characteristics in patients with primary and secondary Raynaud's phenomenon. **2021**, 3-8
- 370 Cardiovascular burden in systemic sclerosis: QRISK3 versus Framingham for risk estimation. **2021**, 1 1
- 369 Clinical and serological characteristics of systemic sclerosis: Experience of a tertiary care center in Pakistan.. **2021**, 36, 587-594
- 368 Fibrillar antibodies in systemic sclerosis.
- 367 The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis.. **2022**, 2
- 366 Rheumatoid Arthritis and Related Disorders. **2022**, 1615-1634
- 365 Common mental disorders in South Asian patients with systemic sclerosis: a CIS-R-based cross-sectional study.. **2022**, 1 0
- 364 Impact and Possible Mechanism(s) of Adipose Tissue-Derived Mesenchymal Stem Cells on T-Cell Proliferation in Patients With Rheumatic Disease.. **2021**, 12, 749481 3
- 363 The Levels of Serum Serotonin Can Be Related to Skin and Pulmonary Manifestations of Systemic Sclerosis.. **2022**, 58,
- 362 Multimodal repertoire analysis unveils B cell biology in health and immune-mediated diseases. 0

361	Systemic Sclerosis. 2022 , 107-135	
360	Dysregulation of the gene signature of effector regulatory T cells in the early phase of systemic sclerosis.. 2022 ,	0
359	Thoracic lymphadenopathies in diffuse systemic sclerosis: an observational study on 48 patients using computed tomography.. 2022 , 22, 44	0
358	Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.. 2022 , 1	1
357	Utility of the breath-holding test in patients with systemic sclerosis.. 2022 ,	
356	Myositis-Specific Autoantibodies and QTc Changes by ECG in Idiopathic Inflammatory Myopathies.. 2022 ,	0
355	Monoclonal gammopathy in autoimmune diseases: Analysis and follow-up of 160 cases in a tertiary center in China.. 2021 , 234, 108909	
354	Mindin is essential for cutaneous fibrogenesis in a new mouse model of systemic sclerosis.	0
353	New insights into the taxonomy of autoimmune diseases based on polyautoimmunity.. 2021 , 126, 102780	1
352	Interkit Reproducibility of the Indirect Immunofluorescence Assay on HEp-2 Cells Depends on the Immunofluorescence Reactivity Intensity and Pattern.. 2021 , 12, 798322	2
351	Microangiopathy in Inflammatory Diseases-Strategies in Surgery of the Lower Extremity.. 2022 , 12,	0
350	Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.. 2022 , 53, 151973	0
349	Role of shear wave elastography ultrasound in patients with systemic sclerosis.. 2022 , 1	
348	The 1-minute sit-to-stand test to detect desaturation during 6-minute walk test in interstitial lung disease.. 2022 , 32, 5	0
347	Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases.. 2022 , 5, 100145	2
346	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.. 2022 ,	1
345	Erosive arthritis autoantibodies in systemic sclerosis.. 2021 ,	0
344	Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.. 2022 ,	1

- 343 Involvement of the Nervous System in Systemic Sclerosis. **2022**, 16,
- 342 Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis.. **2022**, 1
- 341 Involvement of the Nervous System in Systemic Sclerosis. **2022**, 16,
- 340 Ultrasonographic detection of enthesitis and its relation to clinical manifestations among Egyptian systemic sclerosis patients. **2022**, 49,
- 339 Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSICIS trial.. **2022**, 0
- 338 Red and white lesion of the tongue in a patient with cutaneous findings.. **2022**,
- 337 Does early systemic sclerosis really exist?. **2021**, 1
- 336 Outcomes in patients with systemic sclerosis undergoing early versus delayed intervention with potential disease-modifying therapies.. **2021**, 1
- 335 The Immunogenetics of Systemic Sclerosis.. **2022**, 1367, 259-298
- 334 NADPH-derived ROS generation drives fibrosis and endothelial-to-mesenchymal transition in systemic sclerosis: Potential cross talk with circulating miRNAs.. **2022**, 13, 11-24 0
- 333 Lung involvement in systemic sclerosis. **2022**, 73-103
- 332 Anti-topoisomerase 1 antibody level changes after B cell depletion therapy in systemic sclerosis. **2022**, 60, 57-63
- 331 Diagnosis of Simultaneous Atrial and Ventricular Mechanical Performance in Patients with Systemic Sclerosis.. **2022**, 11, 0
- 330 Prolonged Capillary Refill Time Highlights Early Performing of Nailfold Capillaroscopy in Patients with Systemic Sclerosis.
- 329 Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.. **2022**, 0
- 328 Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox.. **2022**, 10, 1
- 327 Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program.. **2022**, 8, 45 0
- 326 Microvascular Imaging as a Novel Tool for the Assessment of Blood Flow Velocity in Patients with Systemic Sclerosis: A Single-Center Feasibility Study. **2022**, 12, 2306 2

325	Serum markers of cardiac complications in a systemic sclerosis cohort.. 2022 , 12, 4661	0
324	Gastrointestinal symptom severity and progression in systemic sclerosis.. 2022 ,	0
323	Prevalence of peripheral eosinophilia and clinical associations in systemic sclerosis patients.. 2022 ,	0
322	Systemic Sclerosis (SSc) After COVID-19: A Case Report.. 2022 , 14, e23179	0
321	Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality.. 2021 ,	2
320	The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis.. 2022 , 9, 845359	0
319	Capillaroscopy and Immunological Profile in Systemic Sclerosis.. 2022 , 12,	1
318	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.. 2022 , 12, 5289	0
317	Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers.. 2022 ,	3
316	Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis.. 2022 , 10,	0
315	Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review.. 2022 , 1	0
314	Sistemik Skleroz Hastalarında Anksiyete, Depresyon ve Yaşam Kalitesinin Değerlendirilmesi: Diff^ ĩ ya da Limitli Tutulum ^ ĩ emli mi?.	
313	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.. 2022 , 1	0
312	Blood neutrophil count and neutrophil-to-lymphocyte ratio predict disease progression and mortality in two independent systemic sclerosis cohorts.. 2022 ,	0
311	Adipose-Derived Regenerative Cell Transplantation in Systemic Sclerosis: Scleroderma Treatment with Celution Processed Adipose Derived Regenerative Cells- a Randomized Clinical Trial.. 2022 ,	0
310	Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.. 2022 ,	0
309	Global hypomethylation pattern in systemic sclerosis: An application for absolute quantification of epigenetic DNA modification products by 2D-UPLC-MS/MS.. 2022 , 108997	0
308	Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?. 2022 , 10,	0

- 307 Prognostic Significance of Small Pulmonary Vessel Alteration Measured by Chest Computed Tomography in Connective Tissue Diseases With Pulmonary Arterial Hypertension. **5**, Publish Ahead of Print,
- 306 Correlation of nailfold capillaroscopy findings with history of digital ulcer on same finger: Results of SCLEROCAP study.. **2022**, 104365 0
- 305 Capillaroscopic analysis of the microvascular status in mixed versus undifferentiated connective tissue disease.. **2022**, 142, 104367 0
- 304 Interleukin-1-Activated Microvascular Endothelial Cells Promote DC-SIGN+ Alternative Macrophages Associated with Skin Fibrosis in Systemic Sclerosis.. **2021**, 0
- 303 Therapeutic effect of cyclin-dependent kinase 4/6 inhibitor on dermal fibrosis in murine models of systemic sclerosis. **2021**, 0
- 302 Reciprocal effects of scleroderma and temporomandibular dysfunction between patient cohorts.. **2021**, 1-8 0
- 301 Interstitial pneumonia with autoimmune features: challenges and controversies.. **2021**, 30, 1
- 300 Dental implants in patients suffering from systemic sclerosis: a retrospective analysis of clinical outcomes in a case series with 24 patients.. **2021**, 7, 118 1
- 299 Salivary gland ultrasonography in patients with connective tissue diseases: a multi-center observational study. **2021**, 1
- 298 Genetic associations of non-MHC susceptibility loci with systemic sclerosis in a Han Chinese population.. **2021**, 0
- 297 Anti-Ro/SS-A Antibody is Associated with Worse Pulmonary Outcome and Reduced Overall Survival in Systemic Sclerosis.. **2021**, 1
- 296 25-hydroxyvitamin D3 Levels and Their Clinical Associations in a Polish Cohort of Systemic Sclerosis Patients: A Cross-Sectional Study. **2022**, 12, 265 0
- 295 Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA.. **2021**, 12, 786039 0
- 294 Autonomic nervous system activity in primary Raynaud's phenomenon: Heart rate variability, plasma catecholamines and [¹²⁵I]MIBG heart scintigraphy.. **2021**, 0
- 293 The economic burden of systemic sclerosis-A systematic review.. **2021**, 0
- 292 Impaired LAIR-1-mediated immune control due to collagen degradation in fibrosis. 0
- 291 Screening rates and prevalence of osteoporosis in a real-world, Australian systemic sclerosis cohort. **2021**, 1
- 290 Antinuclear antibody pattern and autoantibody profiling of systemic sclerosis patients in a tertiary referral center in North India.. **2022**, 0

289 Health Care Utilization Is Increased In Systemic Sclerosis Patients Who Have Digital Ulcers.. **2022,**

288 Is it Still 'Idiopathic?': Features of Autoimmunity in IPAH.. **2022,**

287 Systemic sclerosis manifestations and clinical outcomes in Hispanics/Latinos of the American Southwest.. **2022, 7, 135-143**

286 Study Protocol: A Randomized Controlled Prospective Single-Center Feasibility Study of Rheopheresis for Raynaud's Syndrome and Digital Ulcers in Systemic Sclerosis (RHEACT Study).. **2022, 9, 871744** ○

285 The validity of systemic sclerosis diagnoses in two university hospitals in Finland.. **2022, 1-4**

284 Iguratimod Inhibits Skin Fibrosis by regulating TGF- β /Smad Signaling Pathway in Systemic Sclerosis.. **2022, e13791** ○

283 The Relevance of Skin Biopsies in General Internal Medicine: Facts and Myths.. **2022, 1**

282 Extracorporeal photopheresis for systemic sclerosis. A meta-analysis of randomized clinical trials.. **2022, e15530** ○

281 Image_1.TIF. **2020,**

280 Image_2.TIF. **2020,**

279 Image_3.tif. **2020,**

278 Data_Sheet_1.doc. **2020,**

277 Image_1.JPEG. **2018,**

276 Table_1.DOCX. **2018,**

275 data_sheet_1.docx. **2018,**

274 data_sheet_2.xlsx. **2018,**

273 image_1.PDF. **2018,**

272 image_2.PDF. **2018,**

271 image_3.PDF. **2018,**

270 image_4.PDF. **2018,**

269 table_1.xlsx. **2018,**

268 table_2.xlsx. **2018,**

267 table_3.xlsx. **2018,**

266 table_4.xlsx. **2018,**

265 Data_Sheet_1.PDF. **2020,**

264 table_1.docx. **2018,**

263 Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States.. **2022,**

262 Over one-third of Th/To antibody positive scleroderma patients develop pulmonary hypertension in long-term follow-up.. **2022,**

1

261 [Nailfold capillaroscopy-Principles and clinical application].. **2022,** 81, 313

0

260 Oxidative stress promotes fibrosis in systemic sclerosis through stabilization of a kinase-phosphatase complex.. **2022,** 7,

0

259 [Clinical and immunological characteristics of 88 cases of overlap myositis].. **2021,** 53, 1088-1093

258 Diagnostic Value of Anti-Nuclear Antibodies: Results From Korean University-Affiliated Hospitals.. **2022,** 37, e159

1

257 Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center.. **2022,** 24, 91

0

256 American College of Rheumatology and the European League Against Rheumatism classification criteria for IgG4-related disease: an update for radiologists.. **2022,** 1

0

255 Autoantibodies versus Skin Fibrosis Extent in Systemic Sclerosis: A Case-Control Study of Inverted Phenotypes. **2022,** 12, 1067

3

254 Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease.. **2022,** 11,

0

- 253 Raynaud's Phenomenon with Focus on Systemic Sclerosis.. **2022**, 11, 0
- 252 Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.. **2022**, 24, 166 1
- 251 Criteria for the pathogenicity of anticentromere (anti-CENP-B) autoantibodies in systemic sclerosis: Comment on the article of van Leeuwen et al.. **2022**, 0
- 250 Phenotyping exercise limitation of patients with Interstitial Fibrosing Lung Disease: the importance of exercise hemodynamics.. **2022**,
- 249 Severe digital ischemia as an unrecognized manifestation in patients with antisynthetase autoantibodies: Case series and systematic literature review. 239719832210908
- 248 Impact of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Rheumatic Disease Patients on T Helper Cell Differentiation. **2022**, 23, 5317
- 247 A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies. **2022**, 12, 1139 3
- 246 Collagen Vascular Diseases in Pregnancy. **2017**, 981-997
- 245 Treatment of Scleroderma with Fat Grafting, PRP, and Adipose-Derived Stem Cells. **2022**, 431-445
- 244 Mental Health Care Use and Associated Factors in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study.
- 243 [18F]Sodium Fluoride PET has the potential to identify active formation of calcinosis cutis in limited cutaneous systemic sclerosis. **2022**, 152027 0
- 242 Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease.
- 241 Machine learning identifies a common signature for anti-SSA/Ro60 antibody expression across autoimmune diseases. 0
- 240 Increased levels of sirtuin-1 in systemic lupus erythematosus.
- 239 Angiographic characteristics of vasculopathy in patients with idiopathic inflammatory myopathies and systemic sclerosis. **2022**, 12,
- 238 Peripheral blood IL -6 levels in systemic sclerosis patients: correlation between IL -6 levels and clinical phenotypes. 1
- 237 Assessment of pulmonary arterial stiffness in patients with systemic sclerosis without overt pulmonary hypertension.
- 236 Prevalence and characteristics of inflammatory rheumatic diseases in patients with thalassemia. 0

- 235 Potential of Photon-Counting Detector CT for Radiation Dose Reduction for the Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis. **30**, Publish Ahead of Print, 0
- 234 Transforming growth factor beta isoforms and TGF-**B**1 and TGF-**B**2 expression in systemic sclerosis patients. 0
- 233 Patient acceptable symptom state for burden from appearance changes in people with systemic sclerosis: a cross-sectional survey. *jrheum*.210889
- 232 Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development. **13**, 2
- 231 Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis. **2022**, **6**,
- 230 Rheumatological Disorders. **2022**, 259-275
- 229 Nailfold capillaroscopy: a survey of current UK practice and next steps to increase uptake amongst rheumatologists. 0
- 228 Effect of pregnancy on scleroderma progression. 239719832211013
- 227 Identification and Prognosis of Patients With Interstitial Pneumonia With Autoimmune Features. Publish Ahead of Print, 1
- 226 The Impaired Elasticity of Large Arteries in Systemic Sclerosis Patients. **2022**, **11**, 3256 0
- 225 Cytokine-producing B-cell balance associates with skin fibrosis in patients with systemic sclerosis. 0
- 224 Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis. **2022**, **24**, 0
- 223 Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. 2
- 222 Systemic sclerosis in Native Americans of the American Southwest. 1
- 221 Analytical and clinical performance of different platforms simultaneously detecting 15 antinuclear antibodies.
- 220 Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study. **2022**, **4**, e507-e516 0
- 219 Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?. **13**, 0
- 218 Dehydroepiandrosterone in fibrotic interstitial lung disease: a translational study. **2022**, **23**, 1

217	Altered ocular microvasculature in patients with systemic sclerosis and very early disease of systemic sclerosis using optical coherence tomography angiography. 2022 , 12,	
216	Renal Crisis as the Initial Manifestation of Scleroderma. 2022 ,	
215	RNA-Seq analysis identifies alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis.	0
214	Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay. 2022 , 13,	0
213	Clinical significance of serum ferritin in patients with systemic sclerosis.	0
212	Systemic Sclerosis, Reversible Cerebral Vasoconstriction Syndrome, and NeuroMyelitis Optica in a Patient. 2022 , 2022, 1-5	0
211	Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis. 2022 , 13,	1
210	Influence of CT Image Matrix Size and Kernel Type on the Assessment of HRCT in Patients with SSC-ILD. 2022 , 12, 1662	
209	Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes. 2022 , 12,	2
208	Clinical Assessment for Pulmonary Hypertension in Interstitial Lung Disease.	
207	Role of B-Cell in the Pathogenesis of Systemic Sclerosis. 13,	1
206	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study.	1
205	The Systolic Pulmonary Arterial Pressure Liaises Impaired Cardiac Autonomic Control to Pro-inflammatory Status in Systemic Sclerosis Patients. 9,	0
204	Nailfold video capillaroscopy as a useful diagnostic tool in systemic vasculitis. 2022 , 143, 104406	
203	Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial.	0
202	Autologous stem cell transplantation improves cardiopulmonary exercise testing outcomes in systemic sclerosis patients.	0
201	Kidney transplantation in systemic sclerosis: Advances in graft, disease, and patient outcome. 13,	0
200	Iloprost Duration for Digital Ulcers in Systemic Sclerosis: French Retrospective Study at Two Centers and Literature Review. 9,	0

- 199 Kinetics of response to iloprost evaluated by laser speckle contrast analysis in systemic sclerosis. 1-4 ○
- 198 PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH A SYSTEMIC SCLEROSIS: REVIEW OF LITERATURE. **2015**, 32-39 1
- 197 Nuclear receptor subfamily 4A signaling as a key disease pathway of CD1c + dendritic cell dysregulation in systemic sclerosis.
- 196 A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's.
- 195 Systemic sclerosis patients with negative antinuclear antibodies have distinctive clinical manifestations: a multicenter CRDC cohort in China. ○
- 194 Stem cell transplantation for systemic sclerosis. **2022**, 2022, ○
- 193 Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells. ○
- 192 Both T and B cells are indispensable for the development of a PBMC transfer-induced humanized mouse model for SSc. **2022**, 24, ○
- 191 Tofacitinib blocks interferon-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial. ○
- 190 Skin thickness affects the result of tuberculin skin test in systemic sclerosis. **2022**, 6, ○
- 189 New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. **2022**, 11, 4631 ○
- 188 Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study. **2022**, 101, e29993 ○
- 187 Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND). 10, e13471 ○
- 186 The Preventive Role of Physical Activity in Systemic Sclerosis: A Cross-Sectional Study on the Correlation with Clinical Parameters and Disease Progression. **2022**, 19, 10303 ○
- 185 Urinary incontinence in systemic sclerosis: a prospective multicentre cohort study.
- 184 Imaging techniques for assessment of vascular involvement in systemic sclerosis. Publish Ahead of Print, ○
- 183 Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSICIS-ON. annrheumdis-2022-222564 ○
- 182 Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in Skin. ○

- 181 Physical frailty in patients with systemic sclerosis. **2022**, 56, 152077
- 180 Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature. **2022**, 21, 103159 ○
- 179 Scleroderma cardiac crisis: A-life-threatening but reversible complication of systemic sclerosis. **2022**, 21, 103162 ○
- 178 Epidemiology and Treatment of Systemic Sclerosis in Korea. **2022**, 29, 200-214 ○
- 177 T cell abnormalities in systemic sclerosis. **2022**, 21, 103185 ○
- 176 Clinical Study of Tofacitinib in the Treatment of Systemic Sclerosis Complicated with Interstitial Lung Disease. ○
- 175 Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study. **2022**, 19, 147997312211255 ○
- 174 Nail Folds Capillaries Abnormalities Associated With Type 2 Diabetes Mellitus Progression and Correlation With Diabetic Retinopathy. **2022**, 15, 117955142211228 ○
- 173 Association between Routine Laboratory Parameters and the Severity and Progression of Systemic Sclerosis. **2022**, 11, 5087 ○
- 172 PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease. e20210329 3
- 171 Longitudinal global transcriptomic profiling of preclinical systemic sclerosis reveals molecular changes associated with disease progression. ○
- 170 Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study. **2022**, 11, 5013 ○
- 169 A diagnostic score for eosinophilic granulomatosis with polyangiitis among eosinophilic disorders. **2022**, ○
- 168 Functional disability and health-related quality of life among systemic sclerosis patients in Bangladesh. **2022**, 6, ○
- 167 Anti-PM-Scl antibodies positive patients encompass three different groups with distinct prognoses. ○
- 166 Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis. ○
- 165 Direct and indirect health-related costs of systemic sclerosis in New Zealand. ○
- 164 Exome sequencing link mutation in RGPD4 with systemic sclerosis-associated interstitial lung disease and the low level of testosterone in exploration study. 12, ○

- 163 Comparison of the effect of reporting cytoplasmic patterns as anti-nuclear antibody positive and anti-nuclear antibody negative on reflex test ordering. 0
- 162 Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSICIS trial. 1
- 161 Cyclophosphamide-induced melanonychia striata. **2022**, 15, e251441 0
- 160 Dynamic prediction of pulmonary hypertension in systemic sclerosis using landmark analysis. 0
- 159 Predicting the response to pulmonary vasodilator therapy in systemic sclerosis with pulmonary hypertension by using quantitative chest CT. 0
- 158 Juvenile diabetes and systemic sclerosis: just a coincidence?. **2022**, 20, 0
- 157 Validation of the Swedish version of PROMIS-29v2 and FACIT-Dyspnea Index in patients with systemic sclerosis. 1-9 0
- 156 Serum metabolite differences detected by HILIC UHPLC-Q-TOF MS in systemic sclerosis. 0
- 155 Thy-1 plays a pathogenic role and is a potential biomarker for skin fibrosis in scleroderma. 0
- 154 Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study. 0
- 153 Understanding the value of non-specific abnormal capillary dilations in presence of Raynaud's phenomenon: a detailed capillaroscopic analysis. **2022**, 8, e002449 0
- 152 Increased Expression of LMCD1 in Scleroderma-Associated Interstitial Lung Disease is Critical for Profibrotic Characteristics of Lung Myofibroblasts. 0
- 151 Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension. 13, 2
- 150 Detection of Epstein-Barr virus in systemic sclerosis patients: A molecular and serological based study. 0
- 149 Evaluation of hypertension in systemic sclerosis and systemic lupus erythematosus overlap. 239719832211226 0
- 148 Exposure to silica and systemic sclerosis: A retrospective cohort study based on the Canadian Scleroderma Research Group. 9, 0
- 147 Forte prevalence d'anomalies échographiques des glandes salivaires dans la sclérodémie systémique. **2022**, 0
- 146 Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin. **2022**, 54, 1577-1585 0

- 145 The role of PET/CT in connective tissue disorders: systemic sclerosis, Sjögren's syndrome and systemic lupus erythematosus. **2022**, 66, ○
- 144 Returned in my man card A qualitative study of the experiences, coping styles and support needs of men with systemic sclerosis. ○
- 143 Pulmoner Tutulumu Olan Sistemik Skleroz Hastalarında Hematolojik Parametrelerin Rolü **2022**, 12, 608-616 ○
- 142 Functional genomics in primary T cells and monocytes identifies mechanisms by which genetic susceptibility loci influence systemic sclerosis risk. ○
- 141 Very Early Diagnosis of Systemic Sclerosis: Deciphering the heterogeneity of systemic sclerosis in the very early stages of the disease. 239719832211292 ○
- 140 Nailfold video-capillaroscopy in the study of cardiovascular disease: a systematic review. Publish Ahead of Print, ○
- 139 Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis. 239719832211301 ○
- 138 Stress Echocardiographic Prediction of Emerging Pulmonary Vascular Disease in Systemic Sclerosis. **2022**, ○
- 137 Mild pulmonary hemodynamic alterations in patients with systemic sclerosis: relevance of the new 2022 ESC/ERS definition of pulmonary hypertension and impact on mortality. **2022**, 23, ○
- 136 The Assessment of Systemic sclerosis-associated Raynaud's Phenomenon (ASRAP) questionnaire: Item Bank and Short Form Development. ○
- 135 High-throughput 3D microvessel-on-a-chip model to study defective angiogenesis in systemic sclerosis. **2022**, 12, ○
- 134 Profibrotic Effects of Endothelin-1 on Fibroblasts Are Mediated by Aldosterone in Vitro: Relevance to the Pathogenesis and Therapy of Systemic Sclerosis and Pulmonary Arterial Hypertension. **2022**, 10, 2765 2
- 133 Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome. ○
- 132 Serum Adiponectin, a Novel Biomarker Correlates with Skin Thickness in Systemic Sclerosis. **2022**, 12, 1737 ○
- 131 Assessing scleroderma patterns with superb microvascular imaging: is it possible? New prospects for ultrasound. ○
- 130 Prevalence and clinical association of sarcopenia among Thai patients with systemic sclerosis. **2022**, 12, ○
- 129 Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR. **2022**, ○
- 128 Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. 1

- 127 Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases. Volume 15, 2285-2312 ○
- 126 Erasmus Syndrome. **2022**, 4, ○
- 125 Asymmetric dimethylarginine correlates with worsening peripheral microangiopathy in systemic sclerosis. **2022**, 104448 ○
- 124 Increased QT dispersion and related factors in patients with systemic sclerosis. **2022**, 4, 368-373 ○
- 123 Interstitial Pneumonia with Autoimmune Features: Implications for Clinical Practice. ○
- 122 Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease. ○
- 121 CEACAM 1, 3, 5 and 6 -positive classical monocytes correlate with interstitial lung disease in early systemic sclerosis. 13, ○
- 120 Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. **2022**, 8, e002477 2
- 119 Cutaneous Features, Autoantibody Profile, and Nailfold Capillaroscopy of Systemic Sclerosis: A Study of 60 Cases. **2022**, 70, 24-31 ○
- 118 Evaluating the threshold score for classification of systemic lupus erythematosus using the EULAR/ACR criteria. jrheum.220100 ○
- 117 Cirrhosis of the Liver: A Case Report and Literature Review of a Rare Case Presentation of Autoimmune Hepatitis With Systemic Sclerosis. **2022**, ○
- 116 Small airways dysfunction in patients with systemic sclerosis and interstitial lung disease. 9, ○
- 115 The clinical characteristics and outcomes of patients with systemic sclerosis with myocardial involvement. ○
- 114 Comparison of pulmonary function, respiratory symptoms, functional level, and health-related quality of life in patients with systemic sclerosis according to smoking status. 1-10 ○
- 113 Association between anti-SSSCA1 antibodies and cancer in systemic sclerosis. ○
- 112 Treatment of Severe Swallowing Dysfunction in Systemic Sclerosis with IVIG: Role of Antimuscarinic Antibodies. **2022**, 11, 6665 ○
- 111 Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. **2022**, 24, ○
- 110 Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: implications for disease pathogenesis. **2022**, 152136 ○

109	Lung CCR6 ^{hi} CXCR3 ^{hi} Type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases. 2022 , 12,	0
108	Transferability of radiomic signatures from experimental to human interstitial lung disease. 9,	0
107	Improving outcomes in scleroderma: recent progress of cell-based therapies.	0
106	MiR-27a as a diagnostic biomarker and potential therapeutic target in systemic sclerosis. 2022 , 12,	1
105	Centromere defects, chromosome instability, and cGAS-STING activation in systemic sclerosis. 2022 , 13,	0
104	Arthritis. 2023 , 818-840.e1	0
103	Pleuropulmonary involvement in patients with collagen vascular diseases: A cross-sectional study in a cohort of Egyptian population. 2022 , 71, 531	0
102	Appropriate immunoassay systems are needed to evaluate various anticentromere antibodies as biomarkers for disease progression in systemic sclerosis. 2023 , 512, 113400	0
101	Immune complexome analysis of a rich variety of serum immune complexes identifies disease-characteristic immune complex antigens in systemic sclerosis. 2023 , 134, 102954	0
100	Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study. 2023 , 90, 105495	0
99	Favorable long term effects of intensified immunosuppression combined with therapeutic plasma exchange in patients with early-onset progressive systemic sclerosis-related interstitial lung disease. 2022 , 5, 100174	0
98	Dermatologic Concepts and Terminology. 2022 , 21-72	0
97	Efficacy and safety of oral pulmonary vasodilators in pulmonary veno-occlusive disease. 2022 , 12,	0
96	Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis.	0
95	Autologous hematopoietic stem cell transplantation improves long-term survival—data from a national registry. 2022 , 24,	0
94	Different chest HRCT scan protocols change the extent of ground glass opacities. 2022 , 22,	0
93	Multispectral imaging of nailfold capillaries using light-emitting diode illumination. 2022 , 27,	0
92	Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial. 2022 , 23,	0

- 91 Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study. **2022**, 12, 2007 ○
- 90 Study the Relationship of MDCT Staging in Disease Extent with the Systemic Sclerosis Disease Parameters. **2022**, 18, 597-602 ○
- 89 Assessing dyspnea-related kinesiophobia in patients with systemic sclerosis (SSc): validity and reliability of Turkish Breathlessness Beliefs Questionnaire for SSc. ○
- 88 Cumulative disease damage and anti-PM/Scl antibodies are associated with a heavy burden of calcinosis in systemic sclerosis. ○
- 87 The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review. **2022**, 15, 1584 ○
- 86 Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis. ○
- 85 Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. ard-2022-223237 2
- 84 Mouth opening in systemic sclerosis: its course over time, determinants and impact on mouth handicap. 239719832211381 ○
- 83 Perception of aesthetic impairment in patients with systemic sclerosis using a semi-quantitative scale and association with disease characteristics.. ○
- 82 MINDIN (SPONDIN-2) IS ESSENTIAL FOR CUTANEOUS FIBROGENESIS IN A MOUSE MODEL OF SYSTEMIC SCLEROSIS. **2022**, ○
- 81 Enhanced Activity of NLRP3 Inflammasome in the Lung of Patients with Anti-Synthetase Syndrome. **2023**, 12, 60 ○
- 80 Kapillarmikroskopie [Grundlagen und klinische Anwendung. **2023**, 74, 55-64 ○
- 79 Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases. **2023**, 24, 1275 ○
- 78 Subclinical Systemic Sclerosis Primary Heart Involvement by Cardiovascular Magnetic Resonance Shows No Significant Interval Change. ○
- 77 Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling. ○
- 76 Comparison of predictive value of FRAX, trabecular bone score, and bone mineral density for vertebral fractures in systemic sclerosis: A cross-sectional study. **2023**, 102, e32580 ○
- 75 Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study. **2023**, 12, 657 ○
- 74 Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. **2023**, 20, 1553 ○

73	Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study.	0
72	Systemic sclerosis. Part I: epidemiology, diagnosis and therapy. 2023 , 23, 66-75	0
71	Identification of new telomere- and telomerase-associated autoantigens in systemic sclerosis. 2023 , 135, 102988	2
70	Phase angle, nutritional status, and mortality in systemic sclerosis: An exploratory pilot study. 2023 , 107, 111946	0
69	Correlation between Microvascular Damage and Internal Organ Involvement in Scleroderma: Focus on Lung Damage and Endothelial Dysfunction. 2023 , 13, 55	2
68	Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study. 2022 , 8, e002673	0
67	Beneficial effects of Helicobacter pylori eradication in systemic sclerosis patients.	0
66	Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. 2022 , 60, 392-398	0
65	Diagnostic criteria in dermatology. 1-10	0
64	Clinical significance of anti-rheumatoid arthritis 33 antibody in patients with systemic lupus erythematosus. 108155892211506	0
63	Additional value of T1 and T2 mapping techniques for early detection of myocardial involvement in scleroderma. 2023 ,	0
62	Effects of faecal microbiota transplantation on the small intestinal mucosa in systemic sclerosis.	1
61	Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon. 2023 , 25,	0
60	Inflammatory arthritis in systemic sclerosis is associated with elevated C-reactive protein and requires musculoskeletal ultrasound for reliable detection. 9,	0
59	Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation. annrheumdis-2021-221926	0
58	Autoimmune diseases. 2023 , 123-244	0
57	Prevalence of erectile dysfunction in Thai scleroderma patients and associated factors. 2023 , 18, e0279087	0
56	Phenomic Studies on Diseases: Potential and Challenges.	0

- 55 Evaluation of choroidal vascularity index in systemic sclerosis patients. **2023**, 41, 103297 ○
- 54 Patients with inflammatory myopathies overlapping with systemic sclerosis: A Brazilian-Japanese bicentric study. **2023**, 38, 138-147 ○
- 53 Rheumatic diseases: The microbiota-immunity axis in development and treatment. **2023**, 83-111 ○
- 52 Fine-tuning characterization of patients with interstitial pneumonia and an underlying autoimmune disease in real-world practice: We get closer with Nailfold videocapillaroscopy. 10, ○
- 51 Can transbronchial lung cryobiopsy benefit adaptive treatment strategies in connective tissue disease-associated interstitial lung disease?. ○
- 50 Incidence and prevalence of systemic sclerosis in Thailand in year 2017-2020: a database from the Ministry of Public Health. ○
- 49 Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes. 239719832311559
- 48 Juvenile and adult-onset scleroderma: Different clinical phenotypes. **2023**, 60, 152197 ○
- 47 Circulating Calprotectin (cCLP) in autoimmune diseases. **2023**, 22, 103295 ○
- 46 Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome. **2023**, 60, 152185 ○
- 45 Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases. **2023**, 212, 107224 ○
- 44 Long-term home parenteral nutrition in systemic sclerosis-related intestinal failure is feasible but unveils occult cardiac disease. **2023**, 110, 112009 ○
- 43 Approach to Systemic Sclerosis Patient Assessment. **2023**, 49, 193-210 ○
- 42 Identifying subsets of patients with undifferentiated connective tissue disease: Results from a prospective, real-world experience using particle-based multi-analyte technology. **2023**, 22, 103298 ○
- 41 Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease. **2023**, 212, 107242 ○
- 40 Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. ○
- 39 Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc. **2023**, 25, 1
- 38 Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension. **2023**, 13, ○

- 37 The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort. **2023**, 22, 103290 ○
- 36 Quality Measures in Systemic Sclerosis. **2023**, 13, 579 ○
- 35 Myositis-Specific and Myositis-Associated Antibodies in Fibromyalgia Patients: A Prospective Study. **2023**, 11, 658 ○
- 34 Systemic sclerosis in a patient with Turner syndrome: A case report and a review of associated autoimmune diseases. **2022**, 29, 325-330 ○
- 33 Systemic autoimmune rheumatic diseases as paraneoplastic phenomena: 3 illustrative case reports and narrative review of the literature. 1-8 ○
- 32 T cells in the pathogenesis of systemic sclerosis. **2023**, 447-474 ○
- 31 The diagnostic laboratory tests in rheumatic diseases. **2023**, 113-148 ○
- 30 Attitudes and factors affecting decision-making regarding COVID -19 vaccination among autoimmune rheumatic disease patients. **2023**, 26, 751-758 ○
- 29 Serum IgG Glycan Hallmarks of Systemic Lupus Erythematosus. **2023**, ○
- 28 Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension. **2023**, 25, ○
- 27 Mortality and prognostic factors in connective tissue disease-associated pulmonary arterial hypertension patients complicated with right heart failure. ○
- 26 Salivary Flow Rate and Oral Status in Patients with Primary Sjögren Syndrome and Diffuse Cutaneous Systemic Sclerosis: A Cross-Sectional Study. **2023**, 13, 1057 ○
- 25 A composite serum biomarker index for the diagnosis of systemic sclerosis interstitial lung disease: a multicentre, observational, cohort study. ○
- 24 Complete resolution of gastric antral vascular ectasia after autologous haematopoietic stem cell transplantation in systemic sclerosis. ard-2023-224011 ○
- 23 Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry SPRING of the Italian Society for Rheumatology. **2023**, 9, e002890 ○
- 22 Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis. **2023**, 24, 5629 ○
- 21 Overlap syndrome with antibodies against multiple transfer-RNA components presenting antisynthetase syndrome. **2023**, 33, 405-409 ○
- 20 Cutaneous Manifestations of Scleroderma. **2023**, 15, 86-96 ○

- 19 Systemic sclerosis following COVID-19 infection with recurrent corticosteroid-induced scleroderma renal crisis. **2023**, 16, e253735 ○
- 18 Release of High-Mobility Group Box-1 after a Raynaud's Attack Leads to Fibroblast Activation and Interferon- γ -Induced Protein-10 Production: Role in Systemic Sclerosis Pathogenesis. **2023**, 12, 794 ○
- 17 Advances in biological and targeted therapies for systemic sclerosis. ○
- 16 Monitoring small airway dysfunction in connective tissue disease-related interstitial lung disease: a retrospective and prospective study. **2023**, 23, ○
- 15 Dermatoskopie von granulomatösen und Autoimmunerkrankungen der Haut. **2023**, 74, 243-249 ○
- 14 Whole body insulin sensitivity is increased in systemic sclerosis. **2023**, 18, e0283283 ○
- 13 Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease. 1-14 ○
- 12 Assessment of diaphragmatic function by ultrasonography in patients with systemic sclerosis and its relation to clinical parameters. ○
- 11 GWAS for Systemic Sclerosis Identified six novel susceptibility loci including penetrating Fc γ Receptor Region. ○
- 10 Cardiac magnetic resonance imaging T1 mapping and late gadolinium enhancement entropy: Prognostic value in patients with systemic sclerosis. **2023**, ○
- 9 Description of a single centre cohort of patients with systemic sclerosis from the University Hospital of Buenos Aires and factors associated with lung function deterioration. A retrospective study. **2023**, ○
- 8 The clinical characteristics and outcomes of patients with systemic sclerosis with myocardial involvement. **2023**, 18, ○
- 7 Pulmonary hypertension in systemic sclerosis with usual interstitial pneumonia. ○
- 6 Can transbronchial lung cryobiopsy benefit adaptive treatment strategies in connective tissue disease-associated interstitial lung disease?. **2023**, 23, ○
- 5 Assessment of cardiopulmonary manifestations and its correlation with semi-quantitative scoring of high-resolution computed tomography in patients with autoimmune rheumatic diseases. **2023**, 23, ○
- 4 Classification of pulmonary sounds through deep learning for the diagnosis of interstitial lung diseases secondary to connective tissue diseases. **2023**, 106928 ○
- 3 Description of Peripheral Blood Perfusion by Laser Speckle Contrast Analysis (LASCA) in Early versus Clinically Overt Systemic Sclerosis in Routine Clinics. **2023**, 13, 1566 ○
- 2 Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort. **2023**, 11, ○

- 1 Interstitial Pneumonia with Autoimmune Features: 8 Years after Nomenclature and Classification Where are We Not and Where Are We Headed?

o